background
teratoma
commonli
ccur
gonad
around
known
extragonad
intrathorac
intrathorac
teratoma
usual
occur
mediastinum
rare
may
origin
lung
sinc
report
mohr
first
time
case
report
clinic
patient
intrathorac
teratoma
got
symptom
chest
pain
haemoptysi
cough
expector
pathognomon
symptom
spesif
intrapulmonari
teratoma
ipt
trichoptysi
expector
hair
casea
woman
admit
cough
expector
hair
accompani
hemoptysi
expector
chees
like
materi
complain
sinc
year
old
symptom
came
period
everi
six
month
unclear
precipit
factor
base
physic
examin
dull
percuss
decreas
vesicular
sound
lower
right
hemithorax
radiolog
find
suggest
mediastin
mass
lack
data
whether
transthorac
biopsi
brush
bronchoscopi
bronchoscopi
perform
hair
inferior
right
bronchu
serum
germ
cell
tumor
marker
normal
patient
toracotomi
mass
right
lung
medial
lobe
histopatolog
find
reveal
matur
intrapulmon
teratoma
conclus
trichoptysi
pathognomon
symptom
intrapulmonari
teratoma
diagnosi
depend
care
clinic
consider
imag
surgeri
main
treatment
intrapulmonari
teratoma
also
could
diagnost
tool
pre
oper
diagnosi
unclear
backgroundaim
studi
evalu
whether
correl
passiv
smoke
lung
cancer
studi
indic
correl
passiv
smoke
increas
risk
develop
lung
cancer
use
evid
encourag
public
educ
antismok
campaign
method
patient
evalu
base
occup
exposur
passiv
smoke
famili
histori
cancer
comorbid
studi
sampl
consist
men
women
late
stage
lung
cancer
admit
bangkok
hospit
patient
previous
undergon
chemotherapi
radiat
therapi
diagnosi
proven
lung
patholog
patient
evalu
retrospect
research
measur
collat
data
indic
signific
amount
lung
cancer
occurr
within
group
femal
expos
passiv
smoke
rate
chosen
indic
signific
occurr
result
male
patient
smoker
nonsmok
age
rang
year
mean
age
male
patient
mean
age
femal
patient
mean
age
patient
particip
patient
studi
thai
among
nonsmok
male
passiv
smoker
work
chemic
factori
femal
smoker
nonsmok
among
nonsmok
femal
passiv
smoker
p
work
chemic
factori
occurr
lung
cancer
femal
passiv
smoker
found
significantli
high
conclus
need
improv
health
educ
campaign
increas
public
awar
health
risk
associ
passiv
smoke
well
reevalu
current
lung
cancer
screen
practic
current
accept
medic
establish
thailand
case
cytolog
examin
pleural
fluid
allow
detect
malign
find
method
retrospect
review
cytolog
histolog
find
patient
underw
medic
thoracoscopi
local
anesthesia
institut
result
patient
diagnos
malign
pleuriti
malign
mesothelioma
histolog
diagnosi
pleural
biopsi
cytolog
find
consist
histolog
diagnosi
patient
sensit
cytolog
examin
pleural
fluid
sensit
includ
case
diagnos
suspect
malign
case
diagnos
definit
includ
case
adenocarcinoma
case
malign
mesothelioma
case
metastat
carcinoma
case
small
cell
carcinoma
two
case
find
differ
cytolog
histolog
cytolog
find
show
adenocarcinoma
case
diagnos
small
cell
carcinoma
histolog
case
diagnos
adenocarcinoma
obtain
find
malign
cell
cytolog
examin
conclus
abil
cytolog
examin
pleural
fluid
limit
thoracoscop
pleural
biopsi
recommend
diagnosi
malign
pleuriti
somat
mutat
epiderm
growth
factor
receptor
egfr
gene
associ
clinic
respons
egfr
tyrosin
kinas
inhibitor
tki
gefitinib
patient
non
small
cell
lung
cancer
nsclc
howev
distribut
biolog
signific
egfr
antibodi
nsclc
patient
yet
investig
studi
investig
whether
igg
respons
egfr
deriv
peptid
nsclc
patient
report
igg
egfr
deriv
peptid
detect
nsclc
patient
treat
gefitinib
could
possibl
prognost
factor
progress
free
pf
overal
surviv
os
nsclc
patient
receiv
gefitinib
treatment
luminex
system
use
measur
immunoglobulin
ig
differ
peptid
nsclc
patient
treat
gefitinib
kind
antipeptid
igg
detect
nsclc
patient
associ
pf
os
detect
egfrderiv
peptid
antibodi
sera
may
promis
method
predict
prognosi
nsclc
patient
treat
gefitinib
result
could
provid
new
insight
better
understand
humor
respons
egfrderiv
peptid
nsclc
patient
introduct
case
rb
year
old
femal
present
month
histori
anorexia
weight
loss
associ
short
breath
ct
scan
reveal
specul
nodular
lesion
left
upper
lobe
ct
guid
biopsi
show
squamou
cell
carcinoma
poorli
differenti
patient
underw
exploratori
thoracotomi
left
lobectomi
metastat
work
bone
scan
ct
scan
abdomen
neg
metastat
spread
histopatholog
tumor
specimen
reveal
combin
tumor
larg
cell
carcinoma
focal
neuroendocrin
differenti
cea
neg
nse
posit
adenocarcinoma
moder
differenti
cea
posit
nse
neg
mucicarmin
posit
discuss
larg
cell
neuroendocrin
carcinoma
lnec
rare
aggress
neoplasm
lung
poor
prognosi
account
approxim
lung
cancer
overal
incid
larg
cell
neuroendocrin
carcinoma
lnec
rang
report
case
seri
even
present
smaller
percentag
mix
combin
type
chest
pain
common
present
local
data
true
incid
unknown
sinc
exist
registri
tumor
immunohistochemistri
seldom
routin
perform
institut
thu
intens
search
prior
studi
found
conclus
diagnosi
lcnec
often
difficult
requir
histolog
analysi
cytolog
evalu
immunohistochemistri
prognosi
lcnec
poor
year
overal
surviv
rate
lcnec
treatment
similar
small
cell
carcinoma
howev
standard
adjuv
therapi
regimen
develop
inflammatori
mediat
involv
pathogenesi
airway
inflamm
howev
fulli
discuss
role
prostaglandin
cough
common
symptom
bronchial
asthma
effect
limaprost
anlogu
cough
respons
inhal
capsaicin
examin
patient
stabl
bronchial
asthma
random
placebocontrol
crossov
studi
capsaicin
cough
threshold
defin
lowest
concentr
capsaicin
elicit
five
cough
measur
index
airway
cough
reflex
sensit
cough
threshold
chang
twoweek
treatment
limaprost
time
day
oral
compar
placebo
find
indic
affect
airway
cough
reflex
sensit
asthmat
airway
characterist
hrct
find
six
patient
multiplc
cystic
lung
diseas
mcld
present
presenc
support
investig
help
establish
diagnosi
may
obviat
need
lung
biopsi
case
lymphangioleiomyomatosi
year
old
non
smoker
hous
wife
hrct
chest
multipl
variabl
size
thin
wall
cyst
distribut
uniformli
throughout
lung
field
apic
base
interven
normal
lung
parenchyma
right
side
locul
pneumothorax
case
idiopath
pulmonari
fibrosi
year
old
male
ipf
hrct
chest
tempor
heterogen
linear
infiltr
fibrot
foci
honey
comb
cyst
variabl
size
locat
predominantli
peripher
lung
region
especi
lower
lobe
case
antitrypsin
defici
emphysema
year
old
non
smoker
male
hrct
show
widespread
hypoattenu
space
thinbar
visibl
wall
especi
lower
lobe
due
loss
lung
parenchyma
decreas
vascular
appar
preserv
upper
lobe
attenu
case
emphysema
due
tobacco
smoke
year
old
copd
patient
hrct
chest
reveal
centrilobular
lesion
low
attenu
variabl
size
thin
wall
predomin
locat
upper
lobe
consist
centrilobular
emphysema
case
lymphoid
interstiti
pneumonia
year
old
male
sjogren
syndrom
hrct
chest
show
cyst
well
defin
wall
random
distribut
predomin
involv
central
portion
lung
mostli
involv
upper
lobe
especi
right
side
interspers
normal
lung
parenchyma
case
advanc
cystic
bronchiectasi
year
old
never
smoker
male
advanc
bronchiectasi
hrct
chest
extens
cylindr
varicos
cystic
bronchiectasi
involv
lobe
magic
syndrom
mouth
genit
ulcer
inflam
cartilag
first
describ
firestein
thought
combin
relaps
polychondr
behcet
diseas
sinc
case
publish
describ
young
femal
present
sever
diseas
necessit
tracheotomi
pregnanc
discuss
manag
follow
review
literatur
year
old
jordanian
femal
attend
ent
clinic
assess
hoars
voic
cough
repeat
attack
hoars
voic
difficulti
breath
past
respond
oral
steroid
definit
diagnosi
given
patient
although
asthma
suggest
ent
clinic
examin
show
airway
inflamm
crust
impress
rhinoscleroma
made
found
pregnant
steroid
stop
present
week
upper
airway
obstruct
necessit
emerg
tracheotomi
review
histori
reveal
recurr
mouth
genit
ulcer
difficult
intub
past
lsc
blood
investig
reveal
esr
crp
neg
ana
rf
anca
analysi
hla
hla
neg
radiolog
bronchoscopi
show
signific
subglott
stenosi
bronchoscopi
tissu
biopsi
confirm
presenc
inflam
cartilag
patient
manag
steroid
azathioprin
deliveri
child
reassess
tracheostomi
cap
undergon
dilat
stenos
segment
magic
syndrom
rare
diseas
even
challeng
present
pregnanc
despit
report
abort
prematur
birth
patient
critic
given
azathioprin
without
complic
long
term
outcom
clear
due
pauciti
data
patient
improv
steadili
first
case
magic
syndrom
diagnos
manag
pregnanc
metastat
pulmonari
calcif
rare
diseas
character
diffus
calcium
deposit
lung
known
occur
patient
chronic
renal
failur
howev
diseas
uncommon
detect
patient
sever
disord
man
chronic
kidney
diseas
progress
dyspnea
chest
radiograph
show
poorli
defin
bilater
multipl
nodular
opac
superior
middl
lung
field
axial
comput
tomographi
chest
show
groundglass
nodular
opac
alveolar
pattern
focal
consolid
rel
preserv
peripher
lower
area
radiolog
imag
suggest
infect
diffus
alveolar
hemorrhag
bronchoscop
bronchoalveolar
lavag
bal
fluid
bloodi
color
fluid
hemosiderin
laden
macrophag
shown
confirm
lung
biopsi
treat
iv
steroid
therapi
diffus
alveolar
hemorrhag
patient
improv
symptom
lung
biopsi
show
calcium
deposit
alveolar
septa
addit
mtc
bone
scintigraphi
spectct
find
show
intens
uptak
lung
final
diagnos
metastat
pulmonari
calcif
calcium
disord
patient
contrast
benign
cours
pulmonari
calcif
patient
fulmin
pulmonari
calcif
complic
chronic
kidney
diseas
hypercalcemia
describ
chronic
kidney
diseas
patient
metastat
pulmonari
calcif
consid
differenti
diagnosi
patient
present
respiratori
symptom
pulmonari
lesion
chronic
kidney
diseas
especi
combin
calcium
disord
background
aim
studi
epiderm
growth
factor
receptor
egfr
tyrosin
kinas
inhibitor
tki
erlotinib
benefit
nonsmal
cell
lung
cancer
nsclc
patient
respond
primari
resist
vascular
endotheli
growth
factor
vegf
target
recombin
human
monoclon
antibodi
bevacizumab
use
mani
type
cancer
nsclc
egfr
tki
resist
complet
understood
studi
aim
investig
whether
dual
inhibit
vegf
efgr
pathway
overcom
egfr
inhibitor
resist
method
three
egfr
wild
type
nsclc
cell
line
use
establish
xenograft
nude
mous
model
primari
resist
erlotinib
agent
alon
combin
erlotinib
bevacizumab
use
treat
mice
vivo
vegf
level
cell
line
human
bronchial
epitheli
cell
control
cell
line
assay
cell
supernat
use
elisa
erlotinib
concentr
sera
tumor
lysat
xenograft
model
determin
high
perform
liquid
chromatographi
hplc
result
vegf
level
higher
lowest
vivo
bevacizumab
inhibit
tumor
growth
model
tgi
tumor
growth
inhibit
rel
lower
two
model
model
combin
treatment
effect
either
agent
alon
erlotinib
concentr
serum
tumor
sampl
combin
group
higher
variou
degre
erlotinib
alon
group
depend
model
conclus
combin
egfr
vegfr
blockad
might
enhanc
antitumor
activ
angiogenesi
inhibitor
may
modul
tumor
vasculatur
result
enhanc
deliveri
target
agent
cancer
cell
depend
vegf
level
cell
line
nsclc
ikumi
matsushita
minako
hijikata
hideyuki
ito
naoto
keicho
depart
pathophysiolog
host
defens
research
institut
tuberculosi
jata
japan
nation
center
global
health
medicin
hospit
japan
background
aim
studi
human
beta
antimicrobi
peptid
express
airway
epithelium
without
help
induc
although
mani
studi
shown
major
polymorph
encod
peptid
conserv
significantli
associ
infecti
immunerel
disord
role
pathogenesi
mostli
unclear
method
express
level
mrna
measur
realtim
rtpcr
protein
concentr
determin
use
elisa
transcript
activ
clone
segment
contain
repres
promot
haplotyp
determin
airway
epitheli
cell
line
use
dualluciferas
report
assay
system
airway
epitheli
cell
stimul
without
analog
viral
doublestrand
rna
polyinosinicpolycytidyl
acid
poli
ic
four
extend
haplotyp
carri
three
common
polymorph
region
carri
haplotyp
show
overexpress
baselin
mrna
level
cell
primari
cultur
cell
polyic
stimul
significantli
enhanc
mrna
express
increas
protein
concentr
overrod
transcriptionpromot
effect
haplotyp
gener
thought
constitut
express
human
epitheli
cell
immun
cell
studi
demonstr
promot
genotyp
associ
cellular
gene
express
express
sensit
exogen
stimuli
polyic
irrespect
genotyp
data
might
provid
insight
inconsist
result
previou
diseas
associ
studi
role
genet
polymorph
airway
mucosa
background
aim
studi
accumul
evid
indic
cancer
stem
cell
csc
involv
intrins
resist
cancer
treatment
hand
hypox
microenviron
import
stem
cell
nich
promot
persist
csc
tumor
aim
studi
elucid
role
hypoxia
csc
resist
gefitinib
nonsmal
cell
lung
cancer
nsclc
activ
epiderm
growth
factor
receptor
egfr
mutat
method
nsclc
cell
line
express
egfr
exon
delet
mutat
expos
high
concentr
gefitinib
normox
hypox
condit
seven
day
gefitinb
exposur
small
fraction
viabl
cell
could
surviv
cell
refer
gefitinibresist
persist
grp
perform
quantit
real
time
polymeras
chain
reaction
immunofluores
evalu
express
stem
gene
insulinlik
growth
factor
receptor
relat
factor
result
grp
highli
express
stem
cell
gene
includ
show
sphereform
capac
vitro
high
tumorigen
potenti
vivo
express
factor
upregul
also
phosphoryl
grp
importantli
hypoxia
promot
activ
grp
increas
sphereform
popul
grp
furthermor
knockdown
hypoxia
induc
reduc
number
grp
activ
final
inhibit
decreas
grp
hypox
condit
conclus
hypoxia
increas
popul
lung
csc
resist
gefitinib
egfr
mutationposit
nsclc
activ
background
transform
growth
factor
induc
transloc
cytoplasm
involv
epithelialmesenchym
transit
emt
congress
also
show
modul
phosphoryl
site
pten
cterminu
inhibit
emt
via
blockad
transloc
nevertheless
could
exert
inhibitori
effect
transloc
remain
elus
aim
studi
aim
illumin
underli
mechan
use
sever
pten
construct
delet
mutant
method
prepar
four
delet
mutant
includ
pten
cterminu
delet
c
domain
delet
phosphatas
domain
delet
c
domain
phosphatas
domain
delet
thu
establish
lung
cancer
cell
doxdepend
gene
express
system
mutant
induc
dox
ad
evalu
local
immunofluoresc
confoc
laser
scan
microscopi
perform
result
immunofluoresc
imag
suggest
pten
cterminu
appear
directli
inhibit
transloc
cytoplasm
show
c
domain
phosphatas
domain
might
essenti
block
transloc
conclus
inhibit
phosphoryl
pten
cterminu
c
domain
phosphatas
domain
could
retain
pten
phosphatas
activ
might
blunt
transloc
well
emt
inhal
corticosteroid
potent
antiinflammatori
medic
treatment
asthma
report
corticosteroid
antiinflammatori
effect
also
enhanc
effect
airway
epitheli
barrier
howev
mechan
corticosteroid
enhanc
airway
epitheli
barrier
function
well
understood
therefor
investig
global
gene
express
analysi
identifi
candid
gene
signal
pathway
involv
enhanc
airway
epitheli
barrier
human
airway
epitheli
cell
cultur
transwel
insert
expos
dexamethason
dex
day
enhanc
barrier
function
measur
barrier
function
use
tran
electr
resist
ter
extract
total
rna
epitheli
cell
perform
microarray
analysi
gene
network
gener
use
ingenu
pathway
analysi
identifi
signal
pathway
involv
airway
epitheli
barrier
function
determin
steroidinduc
gene
identifi
involv
airway
epitheli
barrier
function
transfect
cell
small
interf
rna
sirna
target
gene
follow
ter
measur
identifi
sever
steroidinduc
gene
involv
process
associ
antiapoptosi
wound
heal
airway
epitheli
cell
airway
epitheli
barrier
function
reduc
knockdown
gene
result
indic
steroidinduc
gene
identifi
regul
airway
epitheli
barrier
function
gene
signal
pathway
might
new
therapeut
target
vulner
airway
epithelium
asthmat
acut
lung
injuri
ali
alveolar
macrophag
one
main
sourc
inflammatori
cytokin
macrophag
highli
versatil
cell
local
environ
factor
could
shape
phenotyp
function
properti
necessari
understand
mechan
involv
progress
system
inflamm
design
treatment
reduc
impact
ali
activ
macrophag
classifi
two
group
classic
activ
macrophag
altern
activ
macrophag
macrophag
express
mannos
receptor
studi
gener
line
transgen
mice
express
human
diphtheria
toxin
dt
receptor
control
gene
promot
transgen
mous
dt
induc
system
ablat
ali
model
lp
inflammatori
cytokin
level
higher
tg
wt
histolog
ali
exacerb
ablat
altern
activ
macrophag
may
play
protect
role
develop
ali
background
aim
studi
pulmonari
surfact
surfac
activ
lipoprotein
form
alveolar
type
ii
cell
involv
prevent
high
altitud
pulmonari
edema
induct
nuclear
factor
erythroid
factor
shown
decreas
oxid
stress
regul
specif
gene
pathway
associ
surfact
protein
sp
hypoxia
well
elucid
henc
present
studi
aim
determin
role
phase
ii
antioxid
enzym
enabl
pulmonari
surfact
homeostasi
hypoxia
method
cell
cultur
hypox
environ
differ
time
durat
h
h
h
h
h
h
male
sd
rat
expos
hypobar
hypoxia
h
result
cell
expos
differ
hour
hypoxia
show
decreas
spa
transcript
express
h
remain
constant
though
hypox
exposur
wherea
spb
express
decreas
h
nearli
abolish
upon
exposur
spc
spd
express
increas
within
h
hypox
exposur
remain
constant
till
h
hypox
stress
control
hypoxia
exposur
cell
h
show
signific
increas
protein
lipid
oxid
along
reduc
level
gsh
control
curcumin
supplement
increas
express
might
enabl
cell
balanc
express
sp
along
reduc
level
oxid
vivo
data
also
show
increas
lipid
peroxid
p
protein
oxid
p
bronchoalveolar
lavag
fluid
balf
significantli
attenu
curcumin
administr
mgkg
bw
h
prior
hypoxia
exposur
curcumin
administr
also
result
decreas
lung
nfkb
increas
express
follow
stabilis
express
hif
conclus
result
indic
curcumin
facilit
induct
phase
ii
antioxid
enzym
promot
pulmonari
surfact
homeostasi
hypoxia
motohiro
kimura
naozumi
hashimoto
yoshinori
hasegawa
depart
respiratori
medicin
nagoya
univers
graduat
school
medicin
nagoya
japan
background
aim
studi
although
persist
tgf
stimul
induc
epithelialmesenchym
transit
emt
signific
increas
phosphoryl
level
pten
cterminu
involv
well
result
loss
pten
activ
although
recent
demonstr
gene
modul
pten
phosphoryl
site
could
inhibit
phenotyp
chang
emt
lung
epitheli
cell
use
doxycyclin
dox
induc
gene
express
system
vitro
whether
exogen
induct
could
exert
inhibitori
effect
emt
remain
elus
method
evalu
whether
exogen
induct
could
effect
emt
vitro
establish
adenoviru
deliveri
system
carri
result
naiv
cell
cell
transfect
adenoviru
express
gfp
control
treat
show
decreas
express
ecadherin
de
novo
express
fibronectin
emt
contrast
cell
infect
adenoviru
express
kept
express
ecadherin
inhibit
de
novo
express
fibronectin
treatment
conclus
data
might
propos
therapeut
strategi
local
deliv
gene
diseas
model
emt
tumor
fibrosi
background
aim
studi
well
known
abnorm
growth
pulmonari
vascular
smooth
muscl
cell
pasmc
caus
pulmonari
hypertens
investig
effect
mtor
sirna
load
nanomateri
pasmc
prolifer
apoptosi
induc
hypoxia
method
intracellular
uptak
studi
perform
confoc
laser
scan
microscop
cell
transfect
effici
evalu
flow
cytometri
pasmc
viabil
analys
mtt
method
cell
apoptosi
analysi
conduct
use
annexin
vfitc
propidiumiodid
detect
kit
accord
manufactur
protocol
mrna
express
bclxl
test
twostep
rtpcr
level
bclxl
protein
determin
western
blot
result
mtor
sirna
load
acacdpei
nanoaystem
could
effici
transfect
rat
pasmc
dosedepend
manner
take
inhibit
effect
seruminduc
cell
prolifer
could
significantli
suppress
express
mtor
mrnaprotein
enhanc
pasmc
apoptosi
hypoxia
condit
importantli
data
show
acacd
load
mtor
sirna
could
inhibit
hypoxiainduc
prolifer
pasmc
hypoxia
serum
obvious
effect
cellular
uptak
nanomateri
conclus
phrespons
hybrid
nanosystem
acacd
effect
load
mtor
sirna
induc
hypox
pasmc
apoptosi
suppress
cell
prolifer
background
disrupt
alveolarvascular
barrier
earli
patholog
chang
ali
betaadrenerg
receptor
betaar
play
critic
role
regul
vascular
endotheli
barrier
function
normal
patholog
condit
known
thatbetaadrenerg
receptor
intern
regul
gtpase
mani
cell
type
howev
effect
traffick
betaar
pulmonari
microvascular
endotheli
cell
poorli
understood
aim
studi
investig
effect
endocytosi
cellsurfac
express
betaar
pulmonari
microvascular
endotheli
cell
materi
method
rat
pulmonari
microvascular
endotheli
cell
rpmvec
achiev
primari
cultur
technolog
knockdown
sirna
overexpress
transfect
wildtyp
perform
rpmvec
cellsurfac
express
betaar
rpmvec
measur
intact
cell
ligand
bind
intern
betaar
measur
ligand
intern
assay
downregul
betaar
measur
receptor
downregul
assay
subcellular
distribut
imag
fluoresc
microscopi
result
found
sirna
strongli
inhibit
agonistinduc
intern
upregul
amount
betaar
cell
surfac
rpmvec
wherea
wildtyp
promot
agonistinduc
intern
downregul
similar
effect
express
betaar
cell
surfac
conclus
propos
essenti
endocytosi
cellsurfac
express
ofbetaar
pmvec
back
ground
aim
studi
airway
viral
infect
exacerb
asthma
chronic
pulumonari
obstruct
diseas
copd
coinhibitori
molecul
implic
escap
mechan
virus
host
immun
system
escap
may
induc
viral
persist
lead
exacerb
underli
diseas
previous
show
analog
viral
doublestrand
rna
polyinosinicpolycytidyl
acid
poli
ic
upregul
express
airway
epitheli
cell
resist
corticosteroid
treatment
investig
effect
corticosteroid
plu
longact
laba
express
investig
addit
effect
longact
muscarin
agonist
lama
use
standard
therapi
copd
method
airway
epitheli
cell
line
stimul
poli
ic
express
assess
flow
cytometri
result
poli
icinduc
upregul
suppress
highconcentr
ciclesonid
indacaterol
upregul
suppress
lowconcentr
ciclesonid
use
combin
indacaterol
addit
effect
glycopyrrol
observ
express
conclus
corticosteroid
plu
laba
attenu
virusassoci
upregul
airway
epitheli
cell
result
may
partli
explain
therapi
inhal
corticosteroid
plu
laba
prevent
exacerb
asthma
copd
background
aim
studi
chronic
obstruct
pulmonari
diseas
copd
character
airflow
limit
result
environment
factor
genet
factor
although
cigarett
smoke
major
risk
factor
environment
exposur
influenc
copd
purpos
studi
investig
clinic
characterist
copd
accord
histori
environment
exposur
method
studi
popul
compris
subject
copd
recruit
pulmonari
clinic
hospit
belong
korean
obstruct
lung
diseas
studi
group
classifi
environment
exposur
accord
histori
live
near
factori
direct
exposur
histori
firewood
briquett
accord
live
environment
exposur
compar
frequenc
respiratori
symptom
pulmonari
function
qualiti
life
questionnair
exercis
capac
ct
phenotyp
result
thirtyon
subject
histori
live
near
factori
exposur
histori
briquett
exposur
histori
firewood
signific
differ
clinic
characterist
accord
histori
live
near
factori
exposur
briquett
howev
subject
histori
firewood
exposur
significantli
longer
durat
cough
sputum
firewood
exposur
group
show
higher
l
vs
l
better
exercis
capac
minut
walk
distanc
vs
conclus
clinic
characterist
differ
accord
histori
live
near
factori
exposur
briquett
copd
subject
exposur
histori
firewood
frequent
respiratori
symptom
cough
sputum
pulmonari
function
exercis
capac
preserv
data
suggest
environment
exposur
may
influenc
clinic
phenotyp
copd
global
warm
due
human
activ
lead
abnorm
climat
chang
particularli
strong
impact
climat
chang
becom
evid
last
decad
industri
develop
citi
world
fix
long
period
smoke
air
ex
moscow
beij
caus
air
pollut
differ
factor
respons
respiratori
system
impact
public
health
similar
air
contamin
natur
industri
pollut
caus
patholog
respons
respiratori
tract
aim
studi
investig
influenc
air
pollut
due
forest
fire
amid
high
air
temperatur
morbid
respiratori
di
epidemiolog
studi
demonstr
atmospher
contamin
caus
asian
sand
dust
asd
storm
aggrav
asthma
human
adult
children
present
studi
two
timecours
studi
week
week
perform
investig
advers
effect
caus
asd
experiment
mice
mice
instil
asd
sampl
intratrach
four
eight
time
interv
without
ovalbumin
ova
case
group
expos
eight
time
asd
alon
alveol
bronchiti
exacerb
variou
inflammatori
cytokin
chemokin
bronchoalveolar
lavag
fluid
balf
increas
case
group
coexpos
asd
ova
four
time
allerg
airway
inflamm
aggrav
prolifer
goblet
cell
airway
epithelium
along
eosinophilrelev
cytokin
chemokin
eotaxin
balf
also
observ
moder
fibrou
thicken
subepitheli
layer
airway
also
observ
patholog
group
howev
eighttim
coexposur
attenu
chang
hand
neutrophil
number
increas
balf
eighttim
coexposur
group
compar
fourtim
coexposur
group
adjuv
effect
asd
toward
ige
product
recogn
two
timecours
studi
howev
eighttim
coexposur
reduc
product
result
indic
shortterm
sensit
ova
asd
aggrav
allerg
inflamm
along
fibrou
thicken
subepitheli
layer
airway
wherea
longterm
sensit
attenu
chang
suggest
suppress
immun
respons
caus
immun
toler
background
nontubercul
mycobacteri
ntm
lung
diseas
gener
manag
mycobacterium
avium
complex
mac
howev
littl
known
clinic
radiograph
differ
avium
intracellular
studi
examin
clinic
characterist
radiograph
featur
ntm
lung
diseas
method
medic
record
patient
given
new
diagnosi
ntm
lung
diseas
retrospect
review
result
patient
avium
lung
diseas
patient
intracellular
lung
diseas
patient
other
patient
lung
diseas
multipl
speci
avium
intracellular
differ
follow
clinic
characterist
age
p
gender
f
f
p
receiv
quinolon
p
underli
diseas
p
radiograph
featur
caviti
p
spread
multipl
lung
lobe
p
patient
lung
diseas
multipl
speci
clinic
radiograph
featur
compar
patient
lung
diseas
singl
speci
mac
conclus
avium
intracellular
differ
clinic
radiograph
featur
differ
may
implic
diagnosi
treatment
prognost
yasuaki
uehara
shigeru
ariki
motoko
takahashi
rina
takamiya
yoshihiro
hasegawa
hiroki
takahashi
yoshio
kuroki
depart
biochemistri
sapporo
medic
univers
school
medicin
sapporo
japan
human
cation
antimicrobi
peptid
broad
spectrum
microbicid
activ
bacteria
fungi
howev
also
exhibit
cytotox
host
cell
higher
concentr
previou
studi
found
cytotox
lung
epitheli
cell
attenu
pulmonari
surfact
protein
spa
collectin
implic
host
defens
regul
inflammatori
respons
lung
moreov
identifi
function
region
spa
lie
within
tent
call
spaderiv
peptid
studi
character
effect
spaderiv
peptid
cytotox
antimicrobi
activ
spaderiv
peptid
significantli
decreas
membran
permeabl
cell
treat
mice
model
intratrach
instil
result
elev
ldh
activ
number
leukocyt
bronchoalveolar
lavag
fluid
balf
moreov
interstiti
edema
alveolar
septal
thicken
seen
histolog
examin
instil
mice
spaderiv
peptid
decreas
ldh
activ
number
leukocyt
balf
compar
level
balf
control
mice
tissu
damag
also
dramat
improv
presenc
spaderiv
peptid
examin
effect
spaderiv
peptid
antimicrobi
activ
staphylococcu
aureu
pseudomona
aeruginosa
incub
presenc
spaderiv
peptid
antimicrobi
activ
microb
affect
presenc
spaderiv
peptid
concentr
suffici
decreas
cytotox
result
suggest
spaderiv
peptid
decreas
cytotox
activ
without
affect
antimicrobi
activ
background
aim
studi
chronic
necrot
pulmonari
aspergillosi
cnpa
also
call
semiinvas
pulmonari
aspergillosi
indol
cavitari
infecti
process
lung
secondari
local
invas
aspergillu
speci
sometim
experi
cnpa
patient
demonstr
acut
progress
infiltr
shadow
although
case
report
studi
report
two
case
acut
exacerb
cnpa
examin
patholog
pneumonectomi
method
retrospect
review
medic
record
two
case
cnpa
demonstr
acut
progress
filtrat
prior
pneumonectomi
result
man
medic
histori
left
upper
lobectomi
due
pulmonari
tuberculosi
year
previous
diagnos
pulmonari
aspergillosi
year
admiss
base
pulmonari
caviti
posit
aspergillu
antigen
despit
administr
antifung
drug
predonisolon
filtrat
left
lower
lung
field
emerg
deterior
acut
exacerb
cnpa
suspect
residu
left
pneumonectomi
perform
patholog
reveal
organ
pneumonia
without
evid
fungu
bodi
man
medic
histori
pulmonari
tuberculosi
long
time
diagnos
cnpa
base
imag
find
posit
aspergillu
antibodi
although
antifung
agent
administ
intraven
local
cnpa
uncontrol
radiolog
deterior
left
pneumonectomi
perform
patholog
find
resect
lung
includ
bronchocentr
granulomatosi
without
evid
invas
fungi
area
infiltr
shadow
conclus
cnpa
case
acut
exacerb
spread
infiltr
shadow
occasion
observ
suspect
organ
pneumonia
granuloma
detect
area
infiltr
shadow
may
caus
fungal
invas
allerg
reaction
substanc
produc
aspergillu
yumi
tanaka
shinji
maebeya
shinya
tamaki
takeshi
shono
hitommi
tatsuta
takanobu
hoso
michiko
arako
depart
thorac
surgeri
wakayama
rosai
hospit
wakayama
japan
depart
respiratori
medicin
wakayama
rosai
hospit
wakayama
japan
depart
intern
medicin
saiseikai
wakayama
hospit
japan
background
surgic
resect
alway
regard
standard
treatment
pulmonari
aspergilloma
howev
surgeri
feasibl
mani
case
due
underli
diseas
low
pulmonari
function
host
report
case
effect
treat
transbronchi
intracavitari
amphotericin
b
whose
caviti
observ
year
ultrathin
bronchoscop
case
approxim
year
man
diagnos
pulmonari
aspergilloma
first
treat
oral
itraconazol
two
month
sinc
refus
surgic
resect
howev
littl
effect
hemosputum
persist
therefor
weekli
infus
amphb
caviti
transbronchi
rout
perform
time
moreov
use
fibrin
glue
mix
amphb
time
six
year
result
possibl
observ
chronolog
reduct
disappear
fungu
ball
ultrathin
bronchoscop
approxim
three
year
pass
disappear
fungu
ball
remain
aliv
without
evid
recurr
conclus
transbronchoscop
infus
amphb
caviti
thought
safe
effect
patient
pulmonari
aspergilloma
best
knowledg
rare
case
pulmonari
aspergilloma
follow
long
term
ultrathin
bronchoscop
pulmonari
mycobacterium
avium
complex
mac
diseas
prolong
cours
infect
often
associ
bronchiectasi
cavitari
diseas
variou
pathogen
microorgan
often
infect
colon
patient
bronchiectasi
studi
aim
identifi
preval
coinfect
pathogen
mac
risk
factor
coinfect
patient
pulmonari
mac
diseas
method
retrospect
analyz
pulmonari
mac
patient
fulfil
at
diagnost
criteria
visit
kyoto
univers
hospit
januari
januari
decemb
review
patient
characterist
microbiolog
result
chest
comput
tomographi
find
medic
record
defin
chronic
pathogen
coinfect
potenti
pathogen
mac
isol
consecut
sputum
sampl
taken
two
visit
month
apart
introduct
treatment
pulmonari
aspergillosi
challeng
issu
despit
introduct
use
recent
approv
antifung
treatment
treatment
pulmonari
aspergillosi
remain
difficult
sometim
surgic
treatment
requir
studi
pulmonari
aspergillosi
case
surgic
treatment
survey
institut
method
pulmonari
aspergillosi
patient
receiv
surgic
treatment
analyz
retrospect
data
collect
medic
record
result
total
case
nine
five
femal
four
male
median
age
year
old
symptom
pulmonari
aspergillosi
four
patient
hemoptysishemosputa
one
cough
one
sputum
four
asymptomat
underli
diseas
two
patient
bulla
one
diabet
mellitu
one
copd
one
lung
transplant
four
without
underli
diseas
serum
betadglucan
neg
case
aspergillu
antigen
test
show
posit
result
four
patient
antifung
agent
use
surgic
treatment
wherea
antifung
drug
use
surgic
resect
five
case
two
vrcz
one
lamb
one
mcfg
one
itcz
sever
complic
accompani
surgic
treatment
experienc
patient
well
one
month
surgeri
conclus
surgic
treatment
pulmonari
aspergillosi
could
carri
without
seriou
complic
demonstr
good
postop
cours
select
case
background
transmembran
heparan
sulfat
proteoglycan
express
varieti
cell
epitheli
cell
neutrophil
heparan
sulfat
glycosaminoglycan
side
chain
report
bind
sever
protein
growth
factor
cytokin
suggest
variou
biolog
role
report
limit
extent
pulmonari
inflamm
lung
injuri
murin
lpsinduc
lung
inflamm
model
tanino
et
al
j
respir
cell
mol
biol
goal
studi
clarifi
role
acut
pneumonia
method
serum
first
measur
patient
acut
pneumonia
compar
healthi
volunt
next
relationship
serum
clinic
paramet
analyz
last
surviv
rate
compar
wildtyp
defici
mice
intranas
instil
pneumonia
result
patient
acut
pneumonia
serum
significantli
higher
compar
healthi
volunt
neg
correl
pneumonia
sever
score
addit
serum
admiss
higher
patient
improv
short
term
antibiot
therapi
compar
requir
long
term
antibiot
therapi
moreov
serum
gradual
increas
therapi
patient
improv
short
term
antibiot
therapi
contrast
stabl
level
serum
patient
requir
long
term
antibiot
therapi
furthermor
surviv
rate
defici
mice
signific
wors
compar
wildtyp
mice
conclus
regul
pulmonari
inflamm
could
use
biomark
patient
acut
pneumonia
lysophosphatidylcholin
lpc
novel
inflammatori
lipid
mediat
suggest
import
biomark
predict
sepsi
relat
mortal
previou
studi
show
decreas
lpc
concentr
associ
sepsi
relat
mortal
investig
serum
lpc
level
commun
acquir
pneumonia
predict
outcom
analyz
correl
serum
concentr
clinic
paramet
prospect
collect
blood
sampl
patient
diagnos
commun
acquir
pneumonia
pusan
nation
univers
yangsan
hospit
august
februari
blood
sampl
obtain
initi
day
obtain
sampl
immedi
centrifug
plasma
store
degre
celciu
within
hour
check
plasma
lpc
level
use
anzwel
lpc
assay
kit
alfresa
pharma
corpor
japan
commerci
enzymat
assay
kit
retrospect
review
medic
record
patient
analyz
correl
plasma
lpc
level
clinic
paramet
pneumonia
sever
index
psi
simplifi
acut
physiolog
score
ii
sap
ii
forti
five
patient
commun
acquir
pneumonia
includ
studi
mean
psi
sap
ii
respect
mean
serum
lpc
concentr
day
day
umol
umol
respect
serum
lpc
concentr
significantli
lower
nonsurvivor
group
umol
vs
umol
p
even
though
concentr
differ
survivor
nonsurvivor
serum
lpc
concentr
significantli
correl
psi
r
p
curb
r
p
sap
ii
r
p
respect
lpc
concentr
correl
clinic
paramet
commun
acquir
pneumonia
persist
decreas
concentr
lpc
significantli
associ
mortal
commun
acquir
pneumonia
background
aim
studi
signific
human
pathogen
bacterium
streptococcu
pneumonia
recogn
major
caus
pneumonia
subject
mani
humor
immun
studi
diagnosi
gener
made
base
clinic
suspicion
along
posit
cultur
sampl
virtual
place
bodi
test
time
long
studi
establish
rapid
diagnosi
method
identif
streptococcu
pneumonia
method
laboratori
recent
develop
new
platform
call
realamp
combin
loopmedi
isotherm
amplif
lamp
portabl
tube
scanner
realtim
isotherm
instrument
rapid
detect
streptococcu
pneumonia
three
pair
amplif
primer
requir
method
deriv
conserv
dna
sequenc
uniqu
streptococcu
pneumonia
amplif
carri
degre
celsiu
use
sybr
green
minut
tube
scanner
set
collect
fluoresc
signal
interv
clinic
sampl
streptococcu
pneumonia
bacteria
use
determin
sensit
specif
primer
compar
ribosom
rnabas
nest
pcr
gold
standard
new
set
primer
consist
detect
laboratorymaintain
isol
streptococcu
pneumonia
hospit
new
primer
also
prove
sensit
publish
speciesspecif
primer
specif
develop
lamp
phosphat
japanes
phase
studi
toshiaki
tanaka
yuko
hayashi
kazuhito
okumura
kenichi
yoshikawa
tetsushi
komori
kumiko
kanatani
ippei
ikushima
background
tedizolid
phosphat
tzp
novel
antibiot
infect
due
gramposit
pathogen
includ
mrsa
current
studi
investig
safeti
toler
tzp
japanes
healthi
subject
clinic
develop
nosocomi
pneumonia
skin
soft
tissu
infect
method
japanes
healthi
male
subject
n
receiv
tzp
intraven
iv
min
singl
infus
mg
step
n
mg
step
n
placebo
n
step
step
subject
receiv
tzp
oral
po
mg
n
placebo
n
iv
mg
n
placebo
n
twoway
crossov
design
safeti
investig
includ
assess
advers
event
ae
vital
sign
ecg
paramet
laboratori
test
result
total
subject
receiv
iv
tzp
experienc
ae
subject
step
subject
step
one
subject
receiv
iv
placebo
solut
experienc
ae
ie
laboratori
chang
one
drugrel
ae
subject
occur
subject
receiv
iv
tzp
mg
subject
tzp
administr
discontinu
perman
ae
ie
allerg
rash
resolv
appropri
treatment
ae
occur
subject
receiv
iv
tzp
mg
po
tzp
mg
po
placebo
seriou
ae
report
group
clinic
signific
chang
vital
sign
ecg
paramet
laboratori
evalu
tzp
administr
conclus
singledos
administr
tzp
mg
iv
po
welltoler
japanes
healthi
male
subject
background
tedizolid
phosphat
tzp
novel
antibiot
current
clinic
develop
phase
iii
treatment
nosocomi
pneumonia
success
complet
two
global
phase
iii
studi
acut
bacteri
skin
soft
tissu
infect
absssi
current
phase
studi
investig
safeti
toler
tzp
japanes
healthi
male
subject
support
develop
nosocomi
pneumonia
skin
soft
tissu
infect
japan
method
twenti
four
subject
randomis
receiv
tzp
mg
placebo
daili
day
either
intraven
iv
minut
oral
cohort
iv
tzp
n
placebo
n
cohort
oral
tzp
n
placebo
n
subject
follow
day
safeti
investig
includ
assess
advers
event
ae
vital
sign
ecg
paramet
ophthalmolog
examin
laboratori
test
result
nine
subject
experienc
ae
subject
receiv
tzp
cohort
subject
receiv
placebo
cohort
subject
report
least
drugrel
ae
seriou
ae
report
group
cohort
frequent
report
drugrel
ae
inject
site
paraesthesia
inject
site
pain
subject
receiv
tzp
mild
sever
cohort
atrial
fibril
occur
moder
sever
one
subject
receiv
placebo
deem
investig
drugrel
ae
placebo
administr
discontinu
subject
clinic
signific
chang
found
laboratori
evalu
vital
sign
ecg
paramet
ophthalmolog
examin
physic
examin
studi
conclus
tedizolid
phosphat
iv
oral
welltoler
japanes
healthi
male
subject
administr
followup
period
background
asthma
well
recogn
heterogen
diseas
studi
involv
mast
cell
mc
base
phenotyp
asthma
induc
sputum
method
induc
sputum
sampl
collect
healthi
subject
n
adult
stabl
asthma
n
inflammatori
cell
count
wholegenom
gene
express
microarray
induc
sputum
analyz
mc
phenotyp
induc
sputum
classifi
accord
mc
biomark
tryptas
chymas
carboxypeptidas
differenti
gene
mc
phenotyp
valid
qpcr
result
nonmc
n
mctc
n
mct
n
phenotyp
success
identifi
base
whether
mrna
express
tryptas
chymas
present
microarray
analysi
induc
sputum
p
detect
valu
mctc
subtyp
although
similar
demograph
medic
characterist
comparison
nonmc
mct
subtyp
increas
feno
eosinophil
count
proport
induc
sputum
bronchial
sensit
reactiv
worsen
asthma
control
level
p
would
result
differenti
gene
express
profil
cebp
clc
hdc
furthermor
higher
proport
mctc
subtyp
eosinophil
asthma
ea
cellular
inflamm
phenotyp
p
although
eosinophil
proport
count
induc
sputum
associ
tryptas
r
p
r
p
respect
r
p
r
p
respect
multivari
logist
regress
model
indic
confid
interv
p
trptase
ci
p
contribut
ea
conclus
mcbase
phenotyp
asthma
induc
sputum
establish
mctc
phenotyp
play
import
role
underli
pathobiolog
ea
target
mctc
would
promis
approach
treat
ea
studi
lung
sound
sixtyeight
case
asthma
tri
describ
breath
sound
object
ie
numer
divid
lung
sound
vesicular
v
n
vesicularbronchovesicular
vbv
n
bronchovesicular
bv
n
bronchial
b
n
sound
auscultatori
find
measur
expiratoryinspiratori
ei
sound
power
ratio
highest
frequenc
inspiratori
hfi
expiratori
hfe
sound
sound
power
sound
frequenc
correl
well
auscultatori
find
ei
power
ratio
v
vbv
bv
b
mean
sd
hfe
v
vbv
bv
b
hz
hfi
v
vbv
bv
b
subject
without
wheez
n
ei
hfe
hfi
se
respect
subject
wheez
n
ei
hfe
hfi
breath
sound
patient
wheez
show
higher
hfe
hfi
ei
without
wheez
subject
rhonchi
n
ei
hfe
hfi
subject
rumbl
rhonchi
n
ei
hfe
hfi
basic
breath
sound
wheez
patient
bronchial
nonwheez
patient
vesicular
basic
breath
sound
differ
patient
without
rumbl
rhonchi
conclud
numer
descript
vesicular
bronchial
breath
sound
possibl
sound
analysi
reveal
basic
breath
sound
wheez
patient
bronchial
breath
sound
differ
supress
capac
regulatori
cell
cell
patient
asthma
attack
jing
liu
jinzhi
yin
ke
wang
object
studi
differ
supress
capac
regulatori
cell
treg
cell
patient
asthma
attack
method
recruit
asthmat
patient
n
healthi
control
n
collect
peripher
venou
blood
healthi
control
asthmat
patient
attack
stage
stabl
stage
respect
isol
treg
cell
immunomagnet
bead
method
puriti
effect
cell
cultur
pha
stimul
without
treg
measur
prolifer
express
tbet
rtpcr
product
ifnr
lumnex
effect
cell
without
treg
intervent
analyz
supress
capac
treg
cell
asthmat
patient
attack
stage
stabl
stage
compar
control
group
result
treg
could
suppress
prolifer
effect
cell
asthmat
healthi
group
suppress
capac
treg
patient
asthma
attack
decreas
significantli
compar
healthi
group
p
signific
declin
stabl
asthma
p
suppress
capac
treg
express
product
patient
asthma
attack
less
effect
healthi
group
suppress
capac
express
tbet
product
ifnr
asthma
attack
decreas
supress
capac
treg
asthmat
patient
stabl
stage
modifi
degre
compar
asthma
attack
conclus
defici
suppress
capac
treg
effect
cell
prolifer
cell
function
asthma
attack
defici
modifi
degre
stabl
asthma
defici
suppress
capac
treg
cell
may
indic
asthma
develop
key
word
treg
cell
asthma
attack
suppress
capac
object
investig
situat
adult
asthma
control
manag
jilin
provinc
method
telephon
interview
adult
patient
moder
sever
asthma
discharg
second
hospiatl
jilin
univers
patient
visit
finish
questionar
telephon
questionnair
includ
possibl
risk
factor
age
sex
popul
group
area
resid
occup
incom
number
hospit
emerg
room
admiss
next
year
follow
discharg
second
hospiatl
jilin
univers
educ
physician
patient
partnership
physician
patient
understand
gina
use
labaic
patient
area
resid
categoris
urban
rural
result
physician
emerg
gener
medicin
respiratori
medicin
could
educ
treatment
asthmat
patient
base
gina
patient
hospit
follow
rate
patient
low
adult
asthma
control
jilin
provinc
poor
rate
hospit
emerg
room
admiss
within
one
year
discharg
high
risk
factor
hospit
emerg
room
admiss
within
one
year
discharg
femal
older
incom
per
month
less
rmb
elementari
school
lower
educ
level
rural
resid
use
labaic
regularli
keep
touch
close
doctor
dischag
odd
ratio
respect
compar
urban
resid
adult
asthma
control
worser
rural
resid
conclus
adult
asthma
control
jilin
provinc
poor
special
rural
resid
may
due
partli
lower
econom
educ
level
provinc
key
word
adult
asthma
control
jilin
provinc
rural
resid
background
high
preval
exerciseinduc
bronchoconstrict
eib
found
elit
athlet
underli
mechan
remain
elus
method
airway
respons
ngf
epi
level
chromaffin
cell
structur
highmoder
intens
train
hitrmotr
rat
without
ovalbumin
sensit
measur
total
sd
male
rat
express
ngfassoci
gene
rat
adren
medulla
test
result
hitr
ova
intervent
significantli
increas
airway
resist
aerosol
methacholin
measur
wholebodi
plethysmographi
hitr
significantli
increas
inflammatori
reaction
lung
major
increas
peribronchi
lymphocyt
infiltr
wherea
ova
significantli
increas
infiltr
variou
inflammatori
cell
increas
eosinophil
level
bronchoalveolar
lavag
hitrand
ovaintervent
upregul
circul
ngf
level
peripherin
level
adren
medulla
downregul
phenylethanolamin
nmethyl
transferas
level
adren
medulla
circul
epi
level
hitrova
hitrexhex
exhaust
exercis
intervent
significantli
enhanc
hitr
effect
elev
ngf
level
significantli
associ
neuron
convers
adren
medulla
chromaffin
cell
amcc
level
significantli
increas
level
pjnk
significantli
decreas
adren
medulla
hitr
ova
rat
inject
ngf
antiserum
moderateintens
train
revers
chang
observ
hitr
andor
ova
rat
conclus
studi
suggest
ngf
may
play
vital
role
pathogenesi
eib
induc
neuron
transdifferenti
amcc
via
mapk
pathway
subsequ
decreas
circul
epi
bulki
natsir
faisal
yunu
budhi
antariksa
triya
damayanti
depart
pulmonolog
respiratori
medicin
univers
indonesia
jakarta
indonesia
background
aim
studi
mani
patient
asthma
inadequ
control
caus
frequent
emerg
depart
ed
visit
hospit
admiss
improp
inhal
devic
techniqu
like
one
major
caus
associ
uncontrol
asthma
object
evalu
inhal
techniqu
among
asthmat
patient
relationship
asthma
control
ed
visit
also
investig
factor
associ
improp
use
inhal
devic
method
crosssect
studi
done
patient
visit
asthma
clinic
persahabatan
hospit
june
diagnosi
bronchial
asthma
use
steroid
inhal
control
data
collect
demographi
sever
asthma
asthma
manag
assess
inhal
techniqu
patient
use
inhal
techniqu
checklist
base
global
initi
asthma
result
total
asthma
patient
includ
studi
male
mean
age
year
femal
mean
age
improp
use
asthma
inhal
devic
observ
patient
associ
level
formal
educ
p
irregular
clinic
followup
p
uncontrol
asthma
act
score
p
ed
visit
p
multipl
logist
regress
analysi
reveal
lack
regular
followup
p
level
educ
p
like
lead
improp
use
asthma
inhal
devic
conclus
improp
asthma
inhal
devic
use
associ
level
educ
irregular
clinic
follow
up
poor
asthma
control
ed
visit
suggest
prospect
analyt
studi
determin
risk
factor
lead
improp
asthma
inhal
techniqu
asthma
exacerb
naoya
takeda
akira
matsui
ayako
miyazawa
toshiyuki
katoh
depart
respiratori
medicin
allergolog
kariya
toyota
gener
hospit
aichi
japan
background
obes
risk
factor
develop
asthma
adipokin
also
shown
increas
airway
inflamm
hyper
respons
howev
littl
known
role
adipokin
asthma
exacerb
object
purpos
studi
evalu
effect
adipokin
asthma
exacerb
method
studi
enrol
hospit
patient
acut
exacerb
stabl
patient
mild
moder
asthma
normal
subject
comparison
serum
leptin
adiponectin
level
evalu
treatment
system
corticosteroid
result
serum
adiponectin
level
differ
significantli
among
acut
exacerb
patient
stabl
asthmat
normal
subject
moreov
serum
adiponectin
level
hospit
patient
treatment
increas
significantli
howev
differ
serum
leptin
level
among
acut
exacerb
patient
ngml
treatment
ngml
stabl
asthmat
ngml
normal
subject
ngml
conclus
decreas
serum
adiponectin
level
may
associ
acut
exacerb
asthma
may
consid
one
mechan
refractori
asthma
obes
subject
background
one
filipino
children
suffer
bronchial
asthma
increas
preval
worldwid
past
decad
caus
signific
morbid
patient
famili
uncontrol
develop
countri
form
medicin
cost
access
medic
signific
factor
achiev
good
control
symptom
studi
aim
determin
use
low
dose
oral
corticosteroid
safe
effect
altern
treatment
children
persist
asthma
method
forti
patient
year
old
newli
diagnos
moder
persist
asthma
random
two
group
month
control
group
receiv
inhal
corticosteroid
budesonid
mcg
twice
daili
treatment
group
receiv
singl
morn
dose
oral
cosrticosteroid
prednison
mgkg
maximum
dose
mgday
efficaci
assess
base
daytim
nighttim
cough
limit
activ
use
bronchodil
pefr
level
asthma
control
safeti
paramet
evalu
blood
pressur
pre
posttreat
determin
serum
cortisol
fast
blood
sugar
level
result
studi
particip
group
show
compar
improv
daytim
nighttim
cough
need
bronchodil
limit
activ
pefr
paramet
show
signific
differ
particip
inhal
corticosteroid
group
show
lower
pefr
valu
oral
corticosteroid
group
throughout
entir
studi
period
signific
differ
basic
trend
pefr
signific
differ
safeti
paramet
evalu
studi
particip
group
show
decreas
cortisol
level
month
treatment
none
sign
symptom
adren
insuffici
conclus
signific
differ
safeti
efficaci
oral
versu
inhal
corticosteroid
treatment
children
moder
persist
asthma
month
treatment
transfer
care
paediatr
asthma
patient
adult
hospit
usual
done
approxim
year
age
current
structur
transit
program
exist
aim
studi
evalu
qualiti
life
experi
highrisk
asthma
patient
transfer
paediatr
adult
care
method
cross
section
questionnair
surveri
highrisk
asthma
patient
whose
care
transfer
kkh
adult
hospit
done
self
administ
asthma
qualiti
life
questionnair
standardis
aqlq
use
assess
qualiti
life
result
patient
respons
rate
return
complet
questionnair
aqlq
median
iqr
aqlq
score
particip
felt
transfer
adult
servic
hospit
appropri
age
subject
state
given
suffici
informationguid
transfer
care
knew
expect
adult
servic
none
respond
face
challeng
difficulti
transfer
care
process
suggest
improv
respond
includ
need
detail
transfer
medic
report
receiv
physician
b
better
continu
care
c
improv
commun
variou
level
conclus
asthma
patient
transfer
kkh
adult
hospit
continu
enjoy
good
qualiti
life
result
studi
highlight
need
well
coordin
robust
transit
care
arrang
improv
qualiti
care
adolesc
chronic
ill
background
aim
studi
fluticason
furoat
ff
oncedaili
inhal
corticosteroid
ic
vilanterol
vi
longact
agonist
laba
develop
oncedaili
od
combin
therapi
asthma
assess
efficaci
safeti
od
ffvi
compar
twicedaili
bd
fluticason
propion
fp
patient
asian
ancestri
method
randomis
doubleblind
doubledummi
parallelgroup
studi
elig
patient
use
stabl
highdos
ic
middos
ic
laba
week
screen
ic
alon
runin
randomis
receiv
ffvi
mcg
od
fp
mcg
bd
week
primari
endpoint
chang
baselin
daili
even
peak
expiratori
flow
pef
averag
treatment
period
safeti
endpoint
includ
advers
event
ae
vital
sign
ecg
laboratori
evalu
result
itt
popul
compris
patient
mean
age
year
femal
complet
studi
ffvi
produc
significantli
greater
improv
baselin
even
pef
fp
lmin
ci
p
statist
clinic
signific
treatment
differenti
appar
week
maintain
incid
ae
overal
similar
group
ffvi
fp
incid
drugrel
ae
group
common
drugrel
ae
oropharyng
pain
ffvi
fp
three
patient
ffvi
fp
report
total
five
seriou
ae
withdrawn
clinic
signific
chang
vital
sign
ecg
paramet
laboratori
evalu
conclus
oncedaili
ffvi
mcg
demonstr
clinic
statist
signific
improv
lung
function
compar
fp
mcg
bd
patient
asian
ancestri
appar
week
maintain
week
safeti
issu
clinic
concern
identifi
either
treatment
find
consist
previou
observ
mixedethn
popul
obyrn
pm
er
fund
glaxosmithklin
background
asthma
chronic
inflammatori
disord
airway
mani
cell
cellular
element
play
role
appropri
treatment
clinic
manifest
asthma
control
associ
airway
inflamm
asthma
control
level
clear
present
studi
conduct
explor
relationship
inflammatori
cell
sputum
induct
asthma
control
level
determin
asthma
control
test
act
method
cross
section
analyt
studi
consecut
sampl
conduct
asthma
outpati
clinic
dr
soetomo
teach
hospit
surabaya
indonesia
particip
stabl
asthma
patient
met
inclus
exclus
criteria
result
data
patient
analyz
well
control
well
control
uncontrol
percentag
eosinophil
basophil
neutrophil
lymphocyt
monocyt
total
cell
count
signific
correl
inflammatori
cell
sputum
induct
act
total
score
p
conclus
inflammatori
cell
induc
sputum
examin
use
paramet
determin
level
asthma
control
vice
versa
keyword
asthma
inflammatori
cell
induc
sputum
asthma
control
level
result
incid
sever
exacerb
fpform
ci
studi
ci
studi
pool
incid
ci
report
incid
exacerb
fpsalmeterol
sal
budesonid
bud
form
respect
free
combin
fp
bud
beclometason
laba
conclus
longterm
fpform
therapi
associ
low
rate
sever
exacerb
distinct
studi
popul
incid
compar
favour
longterm
studi
fpsal
budform
free
combin
ic
laba
data
support
util
fpform
reduc
incid
asthma
exacerb
tabl
incid
annual
rate
exacerb
significantli
lower
fpform
conclus
fpform
significantli
improv
lung
function
asthma
control
measur
associ
lower
incid
exacerb
compar
fp
background
aim
studi
efficaci
omalizumab
antiig
antibodi
studi
patient
sever
bronchial
asthma
report
omalizumab
unabl
improv
object
result
howev
improv
seen
subject
symptom
asthmat
patient
aim
studi
evalu
efficaci
omalizumab
longterm
diseas
therapi
sever
persist
asthmaic
patient
assess
pulmonari
function
test
ahq
score
act
score
number
emerg
visit
dosag
methylprednisolon
method
omalizumab
administ
subcutan
everi
week
base
serum
ige
level
bodi
weight
patient
pulmonari
function
test
ahq
act
number
emerg
visit
dosag
methylprednisolon
period
compar
previou
year
result
ten
patient
enrol
treatment
omalizumab
yield
improv
lung
function
howev
number
emerg
visit
p
dosag
methylprednisolon
mg
mg
p
show
signific
reduct
compar
previou
year
ahq
act
week
improv
significantli
compar
studi
baselin
week
signific
improv
note
conclus
omalizumab
significantli
reduc
number
emerg
visit
methylprednisolon
usag
ahq
act
consid
use
assess
subject
symptom
asthmaic
patient
background
aim
studi
recent
progress
made
understand
link
innat
adapt
immun
asthma
previous
report
distinct
sensit
pattern
associ
thymic
stromal
lymphopoietin
tslp
gentyp
aim
studi
identifi
characterist
asthma
phenotyp
determin
cluster
analysi
ige
respons
relationship
asthma
phenotyp
tslp
genotyp
method
studi
adult
patient
asthma
ibaraki
prefectur
central
japan
adult
kamishihoro
cedarfre
birchdomin
town
northern
japan
level
total
serum
ige
specif
ige
antibodi
toward
major
inhal
allergen
measur
use
measur
cluster
analysi
appli
classifi
phenotyp
adult
asthma
also
examin
genet
effect
tslp
function
singl
nucleotid
polymorph
snp
develop
asthma
phenotyp
use
multinomi
logist
regress
analysi
univers
aberdeen
aberdeen
uk
background
aim
studi
patient
attitud
toward
asthma
vari
may
impact
diseas
manag
analysi
design
group
respond
larg
european
survey
cluster
base
attitud
toward
asthma
manag
method
onlin
survey
complet
patient
asthma
age
year
prescript
last
year
countri
cluster
analysi
use
identifi
differ
cluster
patient
base
attitud
toward
asthma
result
four
differ
cluster
identifi
cluster
defin
high
level
confid
manag
asthma
low
level
concern
diseas
cluster
adher
therapi
less
like
ignor
hcp
instruct
cluster
cluster
concern
asthma
consid
seriou
want
improv
diseas
manag
cluster
lowest
level
ginadefin
control
cluster
less
adher
therapi
like
ignor
hcp
instruct
cluster
cluster
like
seek
addit
inform
asthma
conclus
survey
identifi
four
distinct
cluster
patient
asthma
differ
attitud
adher
educ
need
understand
differ
may
facilit
develop
appropri
asthma
manag
strategi
cluster
n
cluster
n
cluster
n
cluster
n
introduct
asthma
audit
found
asthma
manag
thailand
suboptim
assess
asthma
sever
asthma
control
mainli
symptom
peak
expiratori
flow
measur
asthma
visit
outpati
clinic
inhal
corticosteroid
prescrib
visit
nation
asthma
program
undertaken
nation
health
secur
offic
improv
asthma
manag
use
easi
asthma
clinic
model
method
program
support
set
easi
asthma
clinic
hospit
throughout
thailand
easi
asthma
clinic
simplifi
special
asthma
clinic
run
gp
clinic
simplifi
asthma
guidelin
organ
system
facilit
team
work
emphas
role
nurs
pharmacist
help
doctor
also
develop
onlin
web
databas
regist
monitor
patient
nation
health
secur
offic
also
reimburs
use
inhal
corticosteroid
introduct
allerg
bronchopulmonari
mycosi
abpm
character
type
iii
iv
allerg
reaction
fungal
antigen
seroposit
abpm
sabpm
specif
ige
igg
antibodi
fungal
antigen
condit
preced
abpm
character
centrilobular
bronchiectasi
investig
differ
product
cell
cell
produc
regulatori
treg
cell
cell
patient
abpm
sabpm
bronchial
asthma
method
recruit
patient
abpm
patient
sabpm
patient
bronchial
asthma
diagnosi
abpm
base
rosenberg
criteria
sabpm
defin
presenc
specif
ige
antibodi
antigenspecif
precipit
antibodi
fungal
antigen
ouchterloni
doubl
immunodiffus
test
absenc
centrilobular
bronchiectasi
use
flow
cytometri
examin
percentag
cell
cell
produc
peripher
blood
patient
abpm
sabpm
asthma
phase
without
exacerb
percentag
cell
produc
greater
patient
abpm
p
sabpm
p
asthma
patient
abpm
fewer
p
cell
group
howev
percentag
cell
decreas
patient
sabpm
compar
bronchial
asthma
conclus
among
patient
abpm
sabpm
peripher
cell
increas
rel
product
specif
ige
igg
antibodi
fungal
antigen
serum
mainten
treg
cell
patient
sabpm
may
suppress
progress
abpm
minami
tokushima
clinic
tokushima
japan
naga
hospit
wakayama
japan
background
relationship
allerg
rhiniti
asthma
well
accept
howev
littl
known
mechan
underli
interact
upper
lower
airway
object
investig
symptomat
inflammatori
linkag
allerg
rhiniti
asthma
atop
patient
method
enrol
asthmat
take
inhal
steroid
examin
use
asthma
control
questionnair
acq
spirometri
exhal
nitric
oxid
fraction
feno
visual
analog
scale
va
nasal
symptom
allerg
rhiniti
questionnair
serum
specif
ige
studi
symptomat
inflammatori
marker
respons
nasal
steroid
patient
incomplet
control
asthma
acq
moderatesever
persist
allerg
rhiniti
also
investig
studi
result
total
patient
atopi
allerg
rhiniti
strike
differ
proport
patient
incomplet
asthma
control
depend
presenc
well
activ
rhiniti
rhiniti
mild
intermitt
moderatesever
intermitt
mild
persist
moderatesever
persist
feno
level
increas
activ
rhiniti
nasal
va
posit
correl
feno
level
r
p
addit
treatment
nasal
steroid
improv
nasal
va
acq
feno
level
chang
variabl
correl
paramet
p
conclus
observ
studi
atop
patient
indic
ongo
allerg
rhiniti
relat
worsen
asthma
enhanc
lower
airway
inflamm
evalu
activ
allerg
rhiniti
appear
use
assess
impact
rhiniti
asthma
effect
intervent
area
could
improv
manag
efficaci
yotaro
takaku
kazuyuki
nakagom
background
eosinophil
play
import
role
pathogenesi
bronchial
asthma
exacerb
recent
report
suggest
involv
protein
kda
virusinduc
asthma
exacerb
object
studi
examin
whether
modifi
effector
function
eosinophil
method
eosinophil
isol
blood
healthi
donor
stimul
gener
eosinophil
superoxid
anion
examin
base
superoxid
dismutaseinhibit
reduct
cytochrom
c
eosinophilderiv
neurotoxin
edn
releas
evalu
determin
whether
induc
eosinophil
degranul
cytokin
chemokin
product
eosinophil
examin
use
bioplex
assay
result
significantli
induc
eosinophil
presenc
enhanc
inhibit
integrin
mab
mab
increas
releas
edn
increas
product
number
cytokin
chemokin
eosinophil
conclus
find
suggest
directli
upregul
effector
function
eosinophil
effect
might
involv
activ
infiltr
eosinophil
airway
asthma
especi
virusinduc
asthma
exacerb
background
reduct
mortal
rate
bronchial
asthma
invers
relat
wide
spread
inhal
corticosteroid
use
addit
devic
combin
inhal
corticosteroid
longact
betaagonist
contribut
eas
control
asthma
symptom
patient
asthma
current
two
differ
avail
devic
combin
inhal
corticosteroid
longact
betaagonist
salmeterolfluticason
sfc
formoterolbudesonid
fbc
japan
drug
profil
differ
effect
switch
fbc
sfc
still
unclear
patient
method
asthmat
patient
treat
fbc
two
month
persist
asthmat
symptom
score
asthma
control
test
act
less
score
asthma
control
questionnair
time
week
switch
fbc
sfc
asthmat
symptom
assess
act
spirometr
analysi
fvc
pef
evalu
airway
resist
assess
impuls
oscil
system
exhal
level
nitric
oxid
measur
nioxmino
avail
patient
monthli
cost
asthma
treatment
patient
also
evalu
result
asthmat
symptom
assess
act
statist
signific
switch
fbc
sfc
spirometr
analysi
also
reveal
chang
fvc
pef
statist
signific
switch
fbc
sfc
addit
monthli
cost
bronchial
asthma
treatment
patient
significantli
reduc
switch
fbc
sfc
conclus
switch
fbc
sfc
seem
altern
treatment
option
term
effect
treat
asthma
also
treatment
cost
patient
asthma
background
preval
elderli
asthmat
increas
mortal
morbid
higher
young
asthmat
characterist
atopi
bronchial
hyperrespons
lung
function
elderli
asthmat
worthi
investig
order
facilit
asthma
manag
method
retrospect
hospitalbas
studi
asthmat
patient
newli
diagnos
untreat
month
outpati
clinic
recruit
divid
two
group
young
age
year
mean
year
old
n
elderli
mean
year
old
n
asthmat
lung
function
methacholin
provoc
test
mct
bronchodil
test
bdt
smoke
histori
atopi
defin
posit
serum
allergen
immunoassay
serum
ige
level
obtain
result
preval
atopi
serum
ige
level
significantli
lower
elderli
group
compar
young
group
bronchial
hyperrespons
revers
determin
mct
bdt
similar
group
gener
patient
bronchial
hyperrespons
poor
forc
expiratori
volum
one
second
predict
valu
pred
higher
proport
atopi
elderli
asthmat
atopi
wors
elderli
nonatop
asthmat
vs
pred
contrari
young
atop
asthmat
better
compar
young
nonatop
asthmat
young
atop
asthmat
significantli
associ
airway
hyperrespons
young
nonatop
asthmat
p
observ
elderli
group
conclus
characterist
atopi
bronchial
hyperrespons
lung
function
elderli
asthmat
differ
young
asthmat
may
reflect
distinct
pathophysiolog
least
part
elderli
asthmat
airway
background
sinc
fraction
concentr
exhal
nitric
oxid
feno
set
monitor
airway
eosinophil
inflamm
asthma
clinic
valu
real
life
practic
never
investig
materi
method
cross
section
studi
adult
asthma
patient
treat
ramathibodi
hospit
feno
measur
use
portabl
analyz
bedford
uk
feno
express
ppb
secondexhal
posit
pressur
assur
velum
closur
asthma
control
simultan
assess
thai
version
asthma
control
test
questionnair
act
visit
data
analyz
spss
version
result
consecut
patient
complet
accept
feno
measur
outpati
clinic
mean
age
year
femal
patient
asthma
treatment
mainli
icslaba
combin
asthma
control
test
score
act
perform
prior
physician
visit
therefor
patient
classifi
control
asthma
act
uncontrol
asthma
act
among
patient
label
uncontrol
asthma
patient
n
mean
feno
ppb
addit
mean
feno
control
asthmat
n
ppb
measur
feno
significantli
differ
two
group
patient
p
valu
conclus
despit
presenc
control
asthma
assess
composit
score
asthma
control
act
substanti
number
patient
consider
high
feno
repres
persist
eosinophil
airway
inflamm
discuss
high
feno
level
may
warrant
physician
patient
persist
airway
eosinophilia
suscept
loss
asthma
control
discontinu
reduc
asthma
treatment
introduct
asthma
elderli
associ
poor
outcom
physic
cognit
function
impair
may
contribut
factor
materi
method
cross
section
studi
patient
age
year
clinic
data
regard
asthma
collect
physic
function
cognit
function
test
result
total
elderli
asthma
sampl
asthma
clinic
mean
age
year
femal
overweight
patient
airflow
obstruct
grade
mild
moder
sever
common
medic
comorbid
hypertens
dyslipidemia
rhiniti
arthriti
commonli
prescrib
inhal
therapi
corticosteroid
long
act
agonist
common
oral
agent
theophyllin
regard
inhal
devic
mdi
prescrib
follow
turbuhal
accuhal
mdi
spacer
unschedul
visit
due
asthma
worsen
past
year
note
patient
act
score
classifi
less
low
handgrip
strength
measur
use
dynamomet
kg
note
rest
intent
tremor
note
complet
incisor
note
patient
normal
miniment
statu
examin
mmse
point
inhal
devic
techniqu
assess
grade
good
techniqu
associ
hand
grip
strength
abil
press
canist
p
nevertheless
incomplet
incisor
associ
abil
complet
cover
mouthpiec
mdi
use
conclus
signific
proport
uncontrol
asthma
experienc
unplan
visit
observ
elderli
half
case
poor
inhal
techniqu
may
relat
physic
impair
discuss
despit
appropri
asthma
pharmacotherapi
major
elderli
uncontrol
inhal
devic
techniqu
problem
relat
physic
impair
concern
patient
object
improv
understand
supraglott
neurofibroma
discuss
atyp
clinic
sign
larynx
neoplasm
method
case
supraglott
neurofibroma
diagnos
april
report
relat
literatur
review
result
case
yearold
femal
patient
misdiagnos
bronchial
asthma
local
hospit
admit
hospit
short
breath
exercis
half
year
aggrav
day
admiss
bronchoscopi
show
giant
spaceoccupi
lesion
locat
glottis
smooth
surfac
complet
encapsul
supraglott
interarytenoid
region
subsequ
tumor
resect
laryngoscop
gener
anesthesia
proform
patholog
report
oper
show
spindl
cell
tumor
immunohistochemistri
show
accordingli
diagnos
supraglott
neurofibroma
symptom
short
breath
disappear
oper
far
local
recurr
distant
metastasi
month
followup
conclus
supraglott
neurofibroma
rare
occur
larynx
easi
misdiagnos
make
definit
diagnosi
reli
histopatholog
immunohistochemistri
test
especi
posit
result
met
patient
clinic
care
ask
case
histori
physic
examin
combin
clinic
symptom
pay
attent
distinct
wheez
sound
upper
lower
respiratori
tract
effect
lower
misdiagnosi
possibl
give
time
diagnos
right
treatment
object
analyz
relationship
snp
tslp
atop
statu
pf
ahr
asthmat
method
recruit
asthmat
current
studi
visit
asthma
outpati
clinic
iwat
medic
univers
hospit
subject
genotyp
use
fast
realtim
pcr
system
appli
biosystem
usa
pf
evalu
spiromet
ahr
methacholin
measur
astograph
jupitor
chest
japan
ahr
express
min
u
studi
approv
ethic
committe
iwat
medic
univers
result
genotyp
show
cc
ct
tt
atop
statu
cc
cttt
significantli
differ
chisquar
analysi
neither
pf
min
genotyp
significantli
differ
howev
signific
differ
predict
cc
cttt
never
smoker
asthma
p
mannwhitney
utest
conclus
snp
tslp
associ
atop
statu
predict
never
smoker
current
asthmat
popul
suggest
tslp
involv
immun
respons
induc
allergen
modif
immun
reaction
smoke
background
daili
care
asthma
degre
airflow
obstruct
measur
spirometri
use
index
asthma
control
implement
spirometri
requir
maxim
forc
expir
subject
examin
burden
elderli
subject
impuls
oscil
system
io
abl
measur
airway
resist
reactanc
quiet
breath
use
impuls
wave
howev
use
evalu
io
paramet
elderli
asthmat
clear
investig
use
io
correl
io
spirometri
elderli
patient
asthma
method
io
spirometri
flow
volum
curv
perform
elderli
year
old
older
elderli
group
nonelderli
year
old
nonelderli
group
patient
asthma
result
signific
correl
io
paramet
fre
lung
function
mmf
group
fre
significantli
correl
age
fre
show
strongest
associ
vs
p
vs
p
fre
p
significantli
higher
elderli
group
compar
nonelderli
group
show
significantli
low
valu
elderli
group
nonelderli
group
vs
p
conclus
result
suggest
io
use
reveal
small
airway
lesion
elderli
patient
asthma
use
method
evalu
airway
lesion
patient
asthma
background
acclaim
year
estim
one
billion
popul
infect
tuberculosi
indonesian
health
ministri
perform
sensit
survey
papua
mdr
tb
much
among
new
case
tb
among
previous
treat
case
resist
two
line
antitb
drug
lead
poor
sputum
convers
treatment
failur
studi
aim
find
correl
line
antitb
drug
sensit
test
sputum
convers
intens
phase
new
case
tb
patient
method
prospect
analyt
cohort
studi
perform
dot
outpati
clinic
dr
soetomo
teach
hospit
septemb
decemb
nineteen
patient
enrol
studi
particip
new
case
sputum
posit
met
inclus
exclus
criteria
result
sputum
posit
new
case
tb
patient
patient
sensit
first
line
tb
drug
patient
monoresist
patient
polyresist
patient
mdr
among
fulli
suscept
patient
show
sputum
convers
monoresist
patient
show
sputum
convers
patient
poliresist
show
sputum
convers
convers
report
mdrtb
patient
end
intens
phase
conclus
signific
correl
sensit
test
result
sputum
convers
end
intens
phase
new
case
sputum
posit
tb
patient
treat
first
categori
tb
drug
key
word
tb
new
case
sensit
test
sputum
convers
woman
present
initi
phnom
penh
heart
center
chief
complaint
chest
pain
dyspnea
heart
investig
normal
chest
x
ray
show
atelectasi
lower
lobe
left
lung
refer
oncolog
ward
calmett
hospit
investig
present
threemoth
histori
dri
cough
short
breath
anorexia
weight
loss
progress
back
pain
live
mother
treat
pulmonari
tuberculosi
year
ago
physic
examin
thinli
built
vital
sign
stabl
lymphadenopathi
enlarg
liver
spleen
examin
respiratori
system
reveal
diminish
vesicular
breath
sound
vocal
reson
left
lower
lung
examin
unremark
could
obtain
avail
sputum
sampl
examin
acidfast
bacilli
complet
blood
count
normal
wbc
gigal
rbc
teral
hb
gl
platelet
gigal
crp
mgl
renal
function
test
liver
function
test
normal
hiv
serolog
negar
chest
radiographi
show
atelectasi
lower
lobe
left
lung
chest
comput
tomographi
demonstr
mass
left
lower
lobe
destruct
vertebr
bodi
flexibl
bronchoscopi
show
mass
carina
biopsi
perform
result
anapatholog
show
inflammatori
reaction
granuloma
tissu
suggest
tubercul
infect
patient
put
classic
antituberculosi
treatment
categori
one
month
treatment
report
remark
improv
symptom
increas
appetit
carri
studi
assess
current
preval
mdrtb
new
previous
treat
case
pulmonari
tb
varanasi
district
uttar
pradesh
observ
transmiss
mdr
isol
among
popul
around
area
method
total
tuberculosi
isol
obtain
patient
diagnos
pulmonari
tuberculosi
ptb
untreat
subject
patient
treat
tuberculosi
past
sputum
sampl
cultur
lowensteinjensen
media
isol
mycobacteria
drug
suscept
pattern
isol
tuberculosi
isol
record
use
per
cent
proport
method
transmiss
mdr
isol
commun
access
random
amplifi
polymorph
dna
rapd
isol
show
band
pattern
rapd
retyp
use
differ
primer
target
invert
repeat
sequenc
copi
tuberculosi
genom
result
preval
mdr
per
cent
initi
acquir
per
cent
respect
preval
resist
drug
mdr
individu
drug
resist
isoniazid
streptomycin
ethambutol
rifampicin
significantli
higher
patient
treat
past
genotyp
similar
cluster
seen
level
health
care
alway
possibl
establish
geograph
connect
within
cluster
conclus
high
preval
initi
acquir
mdr
note
tuberculosi
isol
collect
pulmonari
tuberculosi
patient
presenc
small
cluster
mdr
isol
health
care
level
suggest
transmiss
within
studi
commun
background
gain
bronchial
wash
use
diagnosi
pulmonari
tuberculosi
tb
patient
neg
sputum
smear
lack
sputum
howev
benefit
gain
serial
bronchial
wash
specimen
tb
diagnosi
studi
therefor
conduct
retrospect
studi
determin
diagnost
util
addit
bronchial
wash
specimen
suspect
patient
method
retrospect
analysi
perform
patient
sputum
smearneg
n
lack
sputum
specimen
n
receiv
bronchoscopi
two
bronchial
wash
specimen
microbiolog
confirm
tb
samsung
medic
center
januari
decemb
result
tb
diagnos
first
bronchial
wash
specimen
patient
addit
bronchial
wash
specimen
establish
diagnosi
exclus
patient
smear
acidfast
bacilli
posit
patient
first
bronchial
wash
specimen
thirteen
patient
posit
smear
addit
bronchial
wash
specimen
combin
smear
posit
first
second
bronchial
wash
specimen
significantli
higher
compar
first
bronchial
wash
specimen
alon
total
case
vs
p
case
smear
neg
sputum
vs
p
case
poor
expector
vs
p
diagnost
yield
determin
cultur
also
significantli
higher
combin
two
serial
bronchial
wash
specimen
compar
first
bronchial
wash
total
case
vs
p
case
smear
neg
sputum
vs
p
case
poor
expector
vs
p
conclus
obtain
addit
bronchial
wash
specimen
could
benefici
consider
option
tb
diagnosi
patient
smear
neg
sputum
lack
sputum
specimen
correct
ad
octob
print
public
first
onlin
public
conclus
section
edit
includ
last
text
patient
smear
neg
sputum
lack
sputum
specimen
abstract
patient
er
yo
femal
nonsmok
seen
outpati
week
histori
nonproduct
cough
hoars
note
fever
weightloss
anorexia
treat
case
pnuemonia
given
sever
cours
antibiot
relief
week
difficulti
breath
difficulti
sleep
describ
choke
sensat
patient
stabl
vital
sign
afebril
satur
room
air
stridor
basal
ronchi
laryngoscopi
show
hyperem
vocal
cord
polypoid
mass
right
vocal
fold
cxray
infiltr
left
upper
lobe
ct
scan
show
ground
glass
opac
superior
segment
lower
lobe
fibrosi
left
apic
lobe
narrow
right
main
stem
bronchu
lymphadenopathi
neck
ct
scan
mass
irregular
border
right
bronchu
collaps
right
upper
lobe
bronchosocpi
cobbl
stone
hard
protrud
cartilagin
structur
cover
cottoni
exud
seen
trachea
right
main
bronchu
bronchial
wash
posit
kliebsiella
pnuemonia
biopsi
show
cartilag
fibrin
materi
inflammatori
cell
afb
stain
posit
acid
fast
bacilli
start
inhrifpzaemb
month
rigid
bronchosopi
done
remov
remain
cartilagin
materi
histopatholog
confim
diagnosi
tracheopathiaosteochondroplastica
reveal
cartilag
area
ossif
note
improv
symptom
tracheopathiaosteochondroplastica
rare
disord
affect
larg
airway
describ
multipl
osseou
cartilagein
nodul
submucosa
trachea
main
bronchi
ecchondrosi
exositosi
tracheal
ring
metaplasia
submucos
connect
tissu
cartialag
andor
bone
tissu
theori
develop
associ
rare
diseas
entiti
activ
pulmonari
tuberculosi
present
new
tuberculosi
patient
treat
standard
medic
regimen
influenc
hepat
may
sever
death
hepat
patient
must
stay
hospit
die
sever
hepat
studi
examin
preval
risk
factor
influenc
hepat
descript
retrospect
studi
sampl
treat
uttaradit
hospit
uttaradit
provinc
thailand
southeast
asia
januari
june
characterist
medicin
liver
function
test
risk
factor
collect
analyz
patient
profil
question
patient
result
show
hepat
male
femal
relationship
level
malnutrit
hepat
p
malnutrit
stage
sever
moder
mild
normal
experienc
hepat
respect
risk
factor
p
influenc
hepat
consist
chronic
diseas
addit
high
dose
medicin
induc
hepat
time
normal
dose
significantli
p
malnutrit
induc
hepat
time
normal
nutrit
p
conclus
high
dose
medicin
malnutrit
chronic
diseas
influenc
induc
hepat
henc
pharmacist
must
evalu
risk
factor
monitor
liver
function
test
counsel
patient
evalu
signsymptom
prevent
sever
hepat
key
word
risk
factor
hepat
thailand
psoa
abscess
rare
clinic
disord
primari
follow
haematogen
dissemin
secondari
one
local
extens
infecti
process
near
psoa
muscl
case
year
old
male
patient
complaint
present
cough
began
month
ago
evid
last
month
loss
appetit
fatigu
weight
loss
kg
approxim
night
sweat
back
pain
patient
textil
worker
nonsmok
physic
examin
fever
blood
pressur
mmhg
puls
breath
lomber
parasacr
region
pain
palpat
right
hip
extens
pain
right
hip
joint
rang
motion
rom
limit
posteroanterior
chest
xray
reveal
abnorm
lower
section
thorax
ct
retroperiton
abscess
observ
lumbar
mr
date
view
evalu
psoa
abscess
spondylodisc
bcg
vaccin
ppd
mm
crp
esr
mmh
serolog
test
rose
bengal
test
neg
hour
urin
smear
afb
neg
respect
sputum
smear
cultur
result
report
afb
neg
three
time
hiv
neg
case
evalu
second
psoa
abscess
local
extens
spondylodisc
abscess
fulli
drain
oper
abscess
materi
afb
posit
ezn
stain
short
cours
tuberculosi
treatment
start
inh
rif
etb
mpz
two
month
dual
treatment
inh
rif
continu
process
patient
pain
decreas
night
sweat
decreas
increas
bodi
weight
kilogram
also
interest
find
cough
disappear
month
treatment
regimen
control
mr
seen
complet
respons
achiev
background
urogenit
tuberculosi
common
extrapulmonari
manifest
primari
tuberculosi
caus
dissemin
mycobacterium
tuberculosi
primari
complex
although
incid
urogenit
tuberculosi
extrapulmonari
tuberculosi
diagnosi
urogenit
tuberculosi
easi
case
femal
came
sanglah
hospit
chief
complaint
dysuria
also
complain
right
back
pain
hematuria
fever
unclear
histori
lung
tuberculosi
urolog
usg
found
right
moder
hydronephrosi
simpl
cyst
cystiti
retrograd
pyelographyureterorenoscopi
show
uret
strictur
et
causa
suspicion
urethr
tuberculosi
pcr
tb
pu
posit
conclus
femal
chief
complaint
dysuria
undergon
seri
examin
test
diagnos
urogenit
tuberculosi
patient
given
antituberculosi
drug
keyword
tuberculosi
urogenit
pcr
background
aim
studi
tbdc
committe
respons
evalu
case
tb
symptomat
smear
whose
chest
radiograph
show
lesion
suggest
tuberculosi
set
origin
depart
health
nation
tb
program
ntp
advis
whowestern
pacif
region
offic
meet
held
least
everi
two
week
univers
santo
toma
hospit
ust
manila
philippin
high
tb
burden
countri
studi
aim
describ
demograph
profil
patient
refer
committe
method
outpati
inpati
case
ust
hospit
seen
tbdc
march
march
includ
studi
review
tbdc
form
done
summari
report
meet
tabul
descript
statist
done
use
spss
version
result
patient
includ
studi
male
year
old
non
smoker
known
comorbid
comorbid
hypertens
diabet
known
cancer
prior
intak
antitb
medic
least
one
month
complet
outcom
known
major
activ
tb
requir
treatment
categori
categori
ii
multipl
sign
symptom
name
cough
weight
loss
dyspnea
common
chest
xray
find
includ
fibrot
ill
defin
infiltr
fibrocyst
fibronodular
granuloma
suspici
fibrot
infiltr
cavitari
dissemin
tb
conclus
clinician
must
look
mani
possibl
direct
sputum
smear
microscopi
number
patient
cavitari
dissemin
tb
neg
signific
percentag
patient
also
multi
drug
resist
tb
mdrtb
suspect
kenjiro
shima
takuro
sakagami
yoshinari
tanab
nobumasa
aoki
hiroshi
moro
toshiyuki
koya
takashi
hasegawa
eiichi
suzuki
ichiei
narita
divis
respiratori
medicin
infecti
diseas
niigata
univers
niigata
japan
depart
gener
medicin
niigata
univers
medic
dental
hospit
niigata
japan
rational
expos
subject
nontubelculous
mycobacterium
ntm
speci
develop
activ
infect
like
reflect
underli
host
suscept
factor
recent
report
shown
anti
interferongamma
ifngamma
neutral
autoantibodi
ifngamma
ab
associ
dissemin
ntm
patient
without
known
evid
immunodefici
purpos
studi
establish
screen
method
subject
ifngamma
ab
report
novel
bioassay
evalu
ifngamma
signal
whole
blood
human
tcell
line
patient
plasma
base
ifngamma
stimul
ifngamma
receptormedi
phosphoryl
name
phosphoryl
index
method
blood
obtain
patient
dissemin
ntm
pulmonari
ntm
healthi
control
evalu
neutral
capac
ifngamma
phosphoryl
leukocyt
tcell
line
stimul
variou
concentr
exogen
ifngamma
rang
ngml
evalu
use
flow
cytomet
strength
phosphoryl
describ
calcul
mean
fluoresc
cell
prime
assign
concentr
ifngamma
minu
unprim
cell
divid
unprim
cell
multipli
antigen
captur
assay
perform
measur
rel
titer
igg
fraction
ifngamma
ab
result
increas
proport
ifngamma
concentr
reach
maximum
valu
near
ngml
time
reach
minut
stimul
plasma
dissemin
ntm
patient
inhibit
diseas
healthi
subject
n
plu
minu
n
plu
minu
n
plu
minu
p
subject
inhibit
high
concentr
ifngamma
ab
mean
eu
conclus
simpl
use
flow
cytometrybas
method
measur
ifngamma
signal
evalu
dissemin
ntm
patient
suspect
ifngamma
ab
background
bacteriolog
diagnosi
pulmonari
tuberculosi
confirm
even
though
success
rate
selfexpector
sputum
limit
previou
studi
sputum
specimen
induc
hyperton
salin
nebul
facilit
bacteriolog
diagnosi
higher
sensit
selfexpector
sputum
benefit
sputum
induct
investig
diagnosi
pulmonari
tuberculosi
method
prospect
random
casecontrol
studi
one
hospit
subject
highli
suspici
pulmonari
tuberculosi
ask
provid
pair
sputum
specimen
consecut
day
first
pair
specimen
obtain
either
selfexpector
se
next
day
visit
sputum
induct
salin
nebul
present
hs
pair
collect
way
sampl
use
acid
fast
bacilli
stain
mycobacteri
cultur
pcr
outcom
bacteriolog
detect
compar
result
seventi
one
patient
assign
either
se
subject
age
male
hs
forti
one
subject
pulmonari
tuberculosi
nontubercul
mycobacteri
infect
diagnos
present
se
hs
reveal
scanti
amount
sputum
p
mycobacteri
detect
hs
subject
se
show
differ
p
consequ
se
hs
clinic
diagnos
treat
pulmonari
tuberculosi
p
conclus
sputum
induct
hyperton
salin
even
patient
scanti
sputum
facilit
bacteriolog
confirm
pulmonari
tuberculosi
background
aim
studi
chronic
hepat
c
viru
hcv
infect
pulmonari
tuberculosi
tb
preval
worldwid
howev
associ
hcv
infect
pulmonari
tb
complet
understood
method
identifi
adult
newli
diagnos
hepat
c
infect
taiwan
nation
health
insur
research
databas
comparison
group
consist
adult
without
hepat
c
infect
randomli
select
dataset
frequenc
match
age
sex
event
pulmonari
tb
ascertain
medic
claim
intern
classif
diseas
ninth
revis
clinic
modif
code
multivari
adjust
hazard
ratio
hr
confid
interv
ci
estim
potenti
associ
factor
includ
hcv
infect
age
sex
lowincom
statu
urban
cessat
cigarett
smoke
alcoholrel
ill
obes
histori
chronic
diseas
medic
use
result
followup
period
newli
diagnos
pulmonari
tb
case
adjust
result
show
male
hr
ci
age
increment
hr
ci
lowincom
statu
hr
ci
risk
factor
risk
pulmonari
tb
cumul
risk
pulmonari
tb
peopl
hepat
c
without
hcv
infect
respect
p
compar
peopl
without
hepat
c
infect
adjust
hr
pulmonari
tb
ci
peopl
hcv
infect
conclus
chronic
hcv
infect
increas
risk
pulmonari
tb
consid
import
independ
risk
factor
background
aim
studi
host
effector
mechan
mycobacterium
tuberculosi
mtb
infect
depend
innat
immun
respons
macrophag
neutrophil
alter
balanc
adapt
immun
coordin
releas
cytolyt
effector
molecul
nk
cell
effector
cell
subsequ
granuleassoci
kill
infect
cell
document
howev
role
clinic
tuberculosi
tb
still
controversi
studi
aim
investig
whether
circul
granulysin
effector
molecul
associ
number
nk
cell
inkt
cell
cell
cell
cell
associ
influenc
clinic
outcom
diseas
patient
pulmonari
tb
hivtb
coinfect
method
circul
granulysin
perforin
granzymeb
level
determin
elisa
isoform
granulysin
analyz
western
blot
analysi
effector
cell
analyz
flow
cytometri
result
circul
granulysin
perforin
level
tb
patient
lower
healthi
control
wherea
granulysin
level
hivtb
coinfect
much
higher
group
tb
hiv
without
receiv
haart
correspond
number
cell
kept
high
nk
cell
possibl
cellular
sourc
granulysin
addit
kda
kda
kda
isoform
granulysin
recogn
plasma
hivtb
coinfect
increas
granulysin
decreas
level
hivtb
coinfect
tb
complet
antitb
therapi
observ
conclus
result
suggest
alter
circul
granulysin
perforin
potenti
function
host
immun
respons
tb
hivtb
coinfect
first
demonstr
far
granulysin
hivtb
coinfect
result
pulmonari
tuberculosi
confirm
sputum
cultur
patient
mdrtb
confirm
etiolog
patient
patient
new
onset
patient
recurr
pulmonari
tuberculosi
among
patient
mdrtb
male
femal
patient
median
age
year
four
patient
diagnos
hiv
patient
admiss
patient
hiv
less
one
year
patient
hiv
one
year
present
symptom
cough
fever
night
sweat
weight
loss
mean
bmi
kgm
median
mean
led
mm
hour
diagnosi
cellsml
normal
plain
chest
radiographi
seen
patient
common
abnorm
found
plain
chest
radiographi
bilater
extens
lung
infiltr
patient
conclus
mdrtb
indonesia
present
high
frequenc
earli
detect
mdrtb
perform
hiv
patient
pulmonari
tuberculosi
sinc
clinic
featur
similar
pulmonari
tuberculosi
due
non
mdrtb
pathogen
key
word
clinic
profil
hiv
mdrtb
introduct
massiv
hemoptysi
frighten
event
mani
patient
one
respiratori
emerg
associ
high
mortal
tuberculosi
along
bronchiectasi
lung
abcess
account
case
case
report
report
year
old
male
patient
refer
chief
complain
hemoptysi
day
admiss
patient
histori
tuberculosi
year
prior
sever
rehospitalis
hemoptysi
chest
radiograph
show
old
tuberculosi
lesion
right
upper
lobe
sputum
bronchoalveolar
lavag
smear
examin
result
neg
acid
fast
bacilli
chest
ct
scan
show
lung
caviti
pull
trachea
later
flexibl
bronchoscopi
show
teleangiectasia
one
third
distal
portion
trachea
broncoalveolar
lavag
taken
citolog
result
suppur
inflamm
despit
medic
patient
still
experienc
recurr
hemoptysi
patient
plan
undergo
thoracothomi
procedur
control
bleed
conclus
pulmonari
fibrosi
caus
cicatrix
airway
lung
parenchym
one
tuberculosi
sequela
complic
hemoptysi
caus
ruptur
rasmussen
aneurysm
surgeri
option
may
taken
treat
recurr
uncontrol
bleed
key
word
hemoptysi
tuberculosi
sequela
lung
fibrosi
background
aim
studi
tuberculosi
one
common
present
ill
lead
caus
death
among
hivinfect
patient
hiv
infect
increas
risk
pulmonari
tuberculosi
due
mdrtb
still
unknown
whether
occur
recurr
increas
event
mdrtb
infect
patient
hiv
investig
associ
pulmonari
tuberculosi
categori
mdrtb
infect
event
patient
hiv
method
perform
crosssect
studi
hivinfect
patient
pulmonari
tuberculosi
januari
april
cipto
mangunkusumo
hospit
mdrtb
confirm
phenotyp
drugsuscept
test
compar
proport
mdrtb
event
new
onset
recurr
pulmonari
tuberculosi
fisher
exact
test
result
total
patient
involv
studi
patient
includ
patient
includ
mdrtb
found
patient
patient
patient
fisher
exact
test
show
differ
mdrtb
infect
event
group
p
conclus
recurr
pulmonari
tuberculosi
relat
increas
event
mdrtb
infect
patient
hiv
key
word
hiv
recurr
mdrtb
background
aim
studi
tuberculosi
tb
common
opportunist
infect
main
caus
death
patient
infect
human
immunodefici
viru
hiv
tbhiv
case
show
mark
increas
last
year
studi
profil
tbhiv
patient
cipto
mangunkusumo
hospit
aim
studi
assess
demograph
clinic
laboratori
radiolog
characterist
tbhiv
patient
method
conduct
descript
crosssect
studi
brows
medic
record
tbhiv
patient
seek
medic
treatment
integr
hiv
outpati
clinic
pokdisu
cipto
mangunkusumo
hospit
within
period
juli
patient
medic
record
confidenti
maintain
throughout
studi
result
total
patient
elig
studi
subject
mostli
male
major
age
group
demograph
characterist
show
follow
marri
belong
batavian
ethnic
group
subject
high
school
graduat
transmiss
intraven
drug
user
main
mode
transmis
oral
candidiasi
hepat
c
common
coinfect
chronic
cough
common
clinic
manifest
follow
prolong
fever
weight
loss
neg
acid
fast
bacilli
smear
found
count
lt
l
show
radiolog
chest
xray
imag
characterist
tb
conclus
profil
tbhiv
patient
studi
less
similar
studi
report
develop
countri
high
rate
intraven
drug
user
mode
transmiss
show
need
intervent
order
reduc
risk
factor
background
intracellular
cytokin
flow
cytometri
iccfc
explor
detect
tuberculosi
tb
infect
howev
littl
data
regard
use
examin
dynam
respons
mycobacterium
tuberculosi
mtb
specif
tcell
antitubercul
therapi
aim
present
studi
analyz
dynam
chang
function
mtb
antigenspecif
tcell
subset
interferongamma
level
use
iccfc
quantiferontb
gold
intub
qftit
test
respect
follow
antitubercul
treatment
patient
activ
tb
method
twentysix
patient
activ
tb
enrol
studi
qftit
iccfc
perform
simultan
treatment
level
qftit
test
number
tumor
necrosi
factoralpha
express
tcell
iccfc
assay
examin
stimul
mtb
antigen
result
signific
reduct
mean
concentr
measur
qftit
test
antitubercul
treatment
p
iccfc
analysi
show
number
tcell
tcell
produc
either
alon
combin
significantli
reduc
antitubercul
treatment
tcell
subset
show
greatest
differ
untreat
treat
patient
activ
tb
area
curv
p
conclus
unlik
qftit
test
iccfc
provid
divers
immunolog
inform
dynam
chang
number
mtb
antigenspecif
tcell
follow
antitubercul
therapi
thu
analysi
mtb
antigenstimul
tcell
respons
use
iccfc
might
role
play
monitor
treatment
respons
patient
activ
tb
conclus
treatment
outcom
ofloxacinresist
mdrtb
patient
significantli
better
moxifloxacinsuscept
tb
moxifloxacinresist
tb
background
earli
diagnosi
treatment
nontubercul
mycobacteri
lung
diseas
ntmld
pulmonari
tuberculosi
ptb
import
clinic
issu
present
studi
aim
compar
identifi
chest
ct
characterist
help
distinguish
ntm
lung
diseas
ptb
patient
acidfast
bacilli
afb
smearposit
sputum
method
patient
januari
april
receiv
afb
smearposit
sputum
specimen
total
ct
scan
obtain
patient
analyz
scan
patient
ptb
scan
ntmld
typic
chest
ct
find
mycobacteri
diseas
analyz
result
patient
ptb
preval
pleural
effus
vs
p
nodul
mm
size
vs
p
treeinbud
pattern
vs
p
caviti
vs
p
significantli
higher
patient
ntm
patient
ntm
lung
diseas
honeycomb
appear
significantli
higher
patient
ptb
vs
p
multivari
analysi
ct
scan
find
nodul
independ
associ
patient
diagnos
ptb
odd
ratio
confid
interv
ci
presenc
honeycomb
ct
scan
strongli
associ
patient
ntmld
ci
conclus
ct
distinct
ntmld
ptb
may
help
radiologist
physician
know
like
diagnos
afbsmear
posit
patient
avoid
unnecessari
advers
effect
relat
cost
antitb
drug
endem
area
yiwen
huang
hsinchieh
tsai
thoma
changyao
tsao
institut
medicin
chung
medic
univers
taichung
taiwan
pulmonari
critic
care
unit
changhua
hospit
depart
health
changhua
taiwan
background
sputum
examin
still
gold
standard
confirm
tuberculosi
evalu
treatment
outcom
antituberculosi
medic
howev
poor
qualiti
sputum
lead
lack
growth
specimen
studi
aim
investig
sputum
detect
rate
compar
two
collect
method
neg
pressur
room
spot
home
earli
morn
method
subject
changhua
hospit
present
cough
week
sputum
abnorm
xray
exist
tuberculosi
includ
studi
sputa
taken
subject
rins
distil
water
spot
collect
perform
neg
pressur
room
supervis
medic
staff
home
earli
morn
collect
undertaken
patient
first
woke
sputa
smear
cultur
result
compar
analyz
determin
posit
tuberculosi
tb
rate
nontubercul
mycobacterium
ntm
rate
contamin
rate
result
total
set
sputum
sampl
collect
januari
decemb
analyz
report
earli
morn
sputa
gener
yield
best
number
organ
howev
studi
show
higher
posit
tb
detect
rate
spot
collect
earli
morn
collect
ntm
contamin
rate
much
higher
earli
morn
collect
spot
collect
respect
could
due
poor
sputum
qualiti
collect
home
subject
fail
rins
distil
water
sputum
collect
lack
staff
supervis
collect
saliva
instead
deep
respiratori
secret
chest
conclus
supervis
medic
staff
rins
distil
water
found
improv
qualiti
sputa
background
tuberculosi
occur
anywher
bodi
lung
parenchym
factor
play
role
control
mtb
infect
cell
macrophag
cytokin
fagosit
mtb
macrophag
stimul
produc
proinflammatori
cell
migrat
transendotheli
lung
form
granuloma
prevent
spread
mtb
lock
aim
studi
identifi
analyz
mean
level
pulmonari
tb
patient
without
tb
investig
relationship
incid
pulmonari
tb
use
evalu
tb
treatment
method
casecontrol
preval
analyt
design
cross
section
approach
perform
pulmonari
clinic
inpati
intern
medicin
rsmh
palembang
march
januari
sampl
meet
inclus
exclus
criteria
drawn
consecut
sampl
number
case
control
result
total
subject
compris
men
women
mean
age
year
point
level
pgml
odd
ratio
confid
interv
mean
serum
level
pulmonari
tb
pgml
signific
higher
tb
pgml
conclus
signific
differ
level
pulmonari
tb
tb
signific
associ
serum
level
pulmonari
tuberculosi
incid
keyword
pulmonari
tuberculosi
background
cell
play
import
role
immun
system
especi
intracellular
bacteri
infect
one
cytokin
produc
cell
interferongamma
play
import
role
elimin
mtuberculosi
studi
aim
see
level
pulmonari
tb
incid
method
serum
level
measur
elisa
tb
patient
patient
tuberculin
test
mm
patient
tuberculin
test
mm
use
receiv
oper
characterist
roc
odd
ratio
analyz
relationship
level
tuberculosi
result
result
level
pulmonari
tuberculosi
patient
obtain
pgml
rang
pgml
subject
tuberculin
test
mm
pgml
rang
pgml
subject
tuberculin
test
mm
pgml
rang
pgml
signific
differ
serum
three
group
p
cutoff
point
gain
pgml
sensit
specif
signific
associ
serum
level
incid
pulmonari
tuberculosi
p
conclus
signific
differ
among
three
group
correl
incid
pulmonari
tuberculosi
serum
level
use
marker
tb
infect
determin
activ
latent
tb
key
word
pulmonari
tuberculosi
tuberculin
skin
test
suzanna
jappar
su
ying
low
singapor
gener
hospit
singapor
background
poor
complianc
tuberculosi
tb
treatment
mani
advers
consequ
includ
longer
treatment
period
drug
resist
relaps
possibl
infect
other
aim
profil
tuberculosi
patient
miss
appoint
method
june
decemb
patient
activ
follow
tb
miss
schedul
appoint
contact
via
telephon
elucid
reason
default
result
month
total
patient
account
visit
singapor
gener
hospit
sgh
follow
tb
treatment
patient
absent
appoint
wherebi
patient
miss
patient
miss
twice
patient
miss
twice
patient
treat
mostli
singaporean
male
chines
age
greater
year
old
howev
malay
like
miss
appoint
analysi
show
patient
year
old
miss
appoint
twice
patient
age
rang
unfortun
larg
proport
could
nt
contact
via
telephon
elucid
reason
default
howev
common
reason
default
readmiss
hospit
patient
forget
appoint
migrat
death
patient
older
year
old
like
absent
due
readmiss
hospit
foreign
tend
absent
due
migrat
patient
miss
appoint
first
time
letter
sent
patient
return
followup
patient
miss
appoint
second
time
recal
letter
sent
patient
return
conclus
profil
malay
ethnic
patient
year
higher
risk
default
success
rate
recal
letter
around
implement
pretb
treatment
educ
could
improv
patient
understand
diseas
import
complianc
treatment
perhap
reduc
default
rate
background
aim
studi
primari
sourc
exercis
limit
peopl
chronic
obstruct
pulmonari
diseas
copd
dyspnoea
part
caus
attribut
chang
chest
wall
mechan
decreas
chest
wall
mobil
contribut
decreas
lung
function
manual
therapi
mt
known
increas
joint
mobil
administ
mt
peopl
copd
introduc
potenti
revers
process
even
short
term
aim
trial
investig
effect
lung
function
includ
mt
pulmonari
rehabilit
pr
program
patient
copd
method
particip
copd
age
year
mean
year
randomli
assign
three
group
pr
soft
tissu
manual
therapi
st
pr
st
spinal
mobilis
sm
pr
outcom
measur
record
week
result
clinic
signific
increas
report
forc
vital
capac
fvc
three
group
week
p
stsmpr
group
versu
pr
increas
litr
se
p
six
minut
walk
test
despit
signific
differ
group
week
p
individu
group
increas
signific
major
moder
advers
event
report
follow
administr
st
sm
intervent
conclus
increas
fvc
uniqu
find
although
underli
mechan
respons
outcom
yet
understood
like
explan
synergist
effect
result
combin
intervent
result
support
call
investig
use
mt
copd
background
per
chronic
obstruct
pulmonari
diseas
copd
manag
network
ishinomaki
district
hospit
manag
pulmonari
rehabilit
pr
copd
patient
area
method
sixteen
consecut
male
copd
patient
mean
age
year
old
enrol
copd
patient
diagnos
pulmonologist
gener
hospit
refer
hospit
pr
assess
symptom
respiratori
muscl
strength
flexibl
breath
pattern
walk
distanc
prepar
individu
suitabl
rehabilit
program
everi
week
patient
underw
pr
involv
light
moder
heavyintens
exercis
symptom
respiratori
muscl
strength
flexibl
breath
method
learn
exercis
toler
activ
daili
live
adl
mental
state
spirometri
blood
ga
analys
monitor
result
seventyf
percent
patient
gold
stage
ii
iii
equal
number
grade
mrc
breathless
scale
thirti
percent
score
bode
index
pr
mean
predict
gold
stage
ii
walk
distanc
paramet
unchang
month
pr
adl
preserv
group
p
amelior
group
patient
deterior
group
pr
group
significantli
lower
walk
peak
heart
rate
hr
group
p
p
group
significantli
lower
rate
good
train
comprehens
group
p
p
pr
improv
adl
sixminut
walk
peak
hr
good
train
comprehens
associ
good
pr
outcom
conclus
pr
use
preserv
improv
adl
copd
patient
physiolog
valu
tai
chi
tc
use
mode
pulmonari
rehabilit
copd
remain
poorli
understood
especi
comparison
gener
accept
threshold
maxim
load
consid
necessari
pulmonari
rehabilit
compar
physiolog
work
judg
oxygen
uptak
esophag
pressur
swing
diaphragm
electromyographi
entail
tc
compar
entail
constant
rate
treadmil
walk
maxim
load
quadricep
fatigu
task
assess
eleven
patient
age
year
rang
copd
sever
predict
studi
intens
workload
entail
tc
differ
treadmil
walk
tc
elicit
quadricep
fatigu
mean
fall
tw
q
p
conclus
tc
constitut
physiolog
suffici
stimulu
exercis
load
use
pulmonari
rehabilit
may
cultur
accept
part
world
background
aim
studi
copd
assess
test
cat
use
tool
evalu
healthrel
qualiti
life
hrqol
copd
outpati
although
eclips
studi
show
hrqol
predict
factor
acut
exacerb
addit
histori
prior
exacerb
littl
known
whether
cat
score
predict
acut
exacerb
copd
aim
investig
influenc
cat
score
incid
acut
exacerb
copd
method
enrol
copd
outpati
hospit
observ
year
measur
bodi
mass
index
bmi
cat
score
pulmonari
function
test
histori
least
one
acut
exacerb
previou
year
analyz
correl
incid
acut
exacerb
next
year
acut
exacerb
defin
event
led
care
provid
prescrib
antibiot
corticosteroid
led
hospit
result
exacerb
occur
patient
year
univari
analysi
bmi
cat
score
histori
exacerb
within
previou
year
vc
pred
pred
indic
signific
correl
incid
acut
exacerb
next
year
multivari
analysi
cat
score
hr
p
histori
exacerb
within
previou
year
hr
p
good
predict
factor
acut
exacerb
conclus
addit
prior
exacerb
cat
score
predict
acut
exacerb
copd
haruhiko
hirata
hiroko
kitaoka
takashi
kijima
osamu
honda
respiratori
medicin
allergi
rheumat
diseas
osaka
univers
graduat
school
medicin
osaka
japan
divis
engin
technolog
jsol
corpor
nagoya
japan
diagnost
intervent
radiolog
osaka
univers
graduat
school
medicin
osaka
japan
rational
function
disord
pulmonari
emphysema
believ
due
dynam
compress
peripher
small
airway
caus
decreas
parenchym
elast
recoil
howev
direct
evid
propos
mechan
never
shown
analyz
endinspiratori
endexpiratori
data
set
propos
hypothesi
overinfl
lung
compress
inramediastin
airway
ima
intrathorac
trachea
main
bronchi
right
lobar
bronchi
begin
forc
expir
would
let
ima
collaps
due
bernoulli
effect
emphysema
patient
present
howev
breathhold
static
imag
could
reflect
dynam
behavior
breath
object
evalu
morpholog
volumetr
chang
ima
maximum
forc
expir
investig
relationship
valu
method
five
emphysema
patient
normal
subject
underw
multidetector
row
ct
maximum
forc
expir
sec
supin
postur
voxel
size
mm
time
interv
sec
volum
intrathorac
trachea
bilater
main
bronchi
measur
expir
rel
volum
volum
begin
forc
expir
calcul
frame
result
imaof
emphysema
patient
extrem
narrow
immedi
begin
forc
expir
slightli
recov
later
membran
part
ima
invagin
insid
appar
shape
chang
normal
subject
secrel
volum
highli
correl
r
conclus
imag
reveal
low
valu
emphysema
patient
caus
dynam
collaps
ima
due
bernoulli
effect
current
concept
respiratori
mechan
pulmonari
function
test
copd
urgent
reconsid
background
roflumilast
oral
select
inhibitor
shown
improv
lung
function
copd
patient
investig
whether
roflumilast
along
convent
therapi
would
improv
lung
function
bangladeshi
copd
patient
method
singl
blind
random
placebo
control
studi
carri
depart
respiratori
medicin
nation
institut
diseas
chest
hospit
nidch
dhaka
bangladesh
patient
recruit
initi
randomli
distribut
groupa
patient
got
convent
therapi
inhal
salmeterol
fluticason
tiotropium
roflumilast
mg
daili
groupb
patient
got
placebo
convent
therapi
studi
durat
month
patient
develop
exacerb
requir
emerg
treatment
exclud
studi
patient
groupa
patient
groupb
complet
studi
spirometri
cat
copd
assess
test
score
perform
case
begin
monthli
month
differ
mean
catscor
baselin
two
group
measur
assess
roflumilast
activ
primari
outcom
variabl
chang
mean
secondari
outcom
variabl
chang
mean
cat
score
base
line
result
clinic
characterist
studi
popul
term
cough
dyspnoea
wheez
sputum
product
loss
weight
appetit
statist
signific
group
mean
increas
mean
cat
score
chang
three
visit
chang
statist
signific
conclus
copd
patient
receiv
roflumilast
along
convent
therapi
experi
better
lung
function
symptomat
improv
convent
therapi
alon
result
patient
randomis
chines
receiv
studi
treatment
complet
studi
week
trough
improv
significantli
indacaterol
dose
vs
placebo
p
indacaterolplacebo
differ
exceed
prespecifi
minim
clinic
import
differ
l
l
indacaterol
respect
tdi
score
week
superior
placebo
indacaterol
dose
point
p
percentag
patient
clinic
relev
improv
point
vs
p
week
dose
provid
improv
baselin
sgrq
score
numer
greater
placebo
unadjust
mean
vs
point
similar
pattern
seen
percentag
patient
clinic
relev
improv
sgrq
score
vs
incid
advers
event
compar
across
treatment
group
conclus
indacaterol
provid
effect
bronchodil
predominantli
chines
popul
signific
improv
breathless
health
statu
background
aim
studi
arteri
blood
ga
analysi
show
variou
indic
patient
acut
exacerb
copd
aecopd
evalu
aim
studi
investig
characterist
arteri
blood
ga
analysi
relationship
mortal
method
retrospect
cohort
studi
analyz
medic
record
male
adult
hospit
aecopd
persahabatan
hospit
march
februari
arteri
blood
ga
paramet
ph
analyz
admiss
hospit
stay
result
total
hospit
aecopd
patient
mean
age
sd
bmi
sd
includ
signific
associ
age
brinkman
index
bmi
bun
mortal
rate
acidbas
balanc
rate
admiss
normal
n
acidosi
n
alkalosi
n
hyperoxia
n
hypoxia
n
hypercapnia
n
hypocapnia
n
acidbas
balanc
follow
normal
n
acidosi
n
alkalosi
n
hyperoxia
n
hypoxia
n
hypercapnia
n
hypocapnia
n
mortal
rate
n
signific
mean
differ
level
admiss
sd
vs
sd
p
level
follow
sd
vs
sd
p
level
follow
sd
vs
sd
p
death
surviv
patient
correl
level
admiss
level
follow
conclus
arteri
blood
ga
paramet
signific
relationship
mortal
hospit
aecopd
patient
alter
might
help
clinician
patient
manag
decreas
hospit
mortal
rate
background
global
health
problem
copd
may
contribut
signific
health
problem
pilgrimag
moslem
indonesian
ministri
health
document
acut
exacerb
copd
aecopd
second
lead
caus
death
pilgrim
total
mortal
identifi
individu
higher
risk
aecopd
prior
embark
essenti
therefor
use
cat
score
assess
risk
acut
aecopd
special
popul
merit
investig
method
cohort
studi
recruit
copd
patient
jakarta
embark
point
patient
complet
cat
subject
pilgrim
group
doctor
given
diari
card
record
symptom
exacerb
pilgrimag
arriv
disembark
point
subject
underw
histori
take
health
examin
diari
card
collect
aecopd
determin
diari
card
individu
health
record
book
carri
everi
pilgrim
result
patient
complet
studi
subject
male
mean
age
studi
year
thirti
five
patient
suffer
aecopd
pilgrimag
cat
score
rang
mean
subject
within
low
impact
group
cat
score
compris
subject
remain
medium
high
impact
group
cat
score
mean
cat
score
exacerb
group
significantli
higher
nonexacerb
group
vs
p
independ
ttest
conclus
studi
indic
use
cat
may
valuabl
tool
identifi
individu
risk
aecopd
prior
pilgrim
embark
background
chronic
obstruct
pulmonari
diseas
multisystem
inflamm
high
morbid
mortal
comorbid
anemia
common
patient
chronic
diseas
eosinopenia
marker
inflamm
evalu
studi
investig
preval
associ
anemia
eosinopenia
mortal
rate
rehospit
patient
copd
excacerb
method
retrospect
studi
analyz
medic
record
male
adult
hospit
copd
excacerb
persahabatan
hospit
januari
decemb
hemoglobin
hb
eosinophil
admiss
asses
patient
classifi
anem
hb
gdl
nonanem
eosinopen
eosinophil
count
cellmm
noneosinopen
calcul
preval
anemia
eosinopenia
compar
mortal
rate
rate
rehospit
year
result
total
patient
hospit
copd
excacerb
mean
age
sd
hb
predict
includ
preval
anemia
n
eosinopenia
n
signific
associ
age
brinkman
index
bmi
predict
cardiovascular
diabet
mellitu
comorbid
anemia
eosinopenia
one
year
mortal
rate
n
rate
hospit
per
year
surviv
patient
n
independ
predictor
one
year
mortal
eosinopenia
p
predict
p
one
year
mortal
rate
significantli
differ
p
eosinopenia
group
vs
rr
ci
noneosinopenia
anem
patient
higher
risk
rehospit
nonanem
patient
vs
p
rr
ci
conclus
eosinopenia
might
use
predictor
predict
mortal
anemia
predict
rehospit
patient
copd
excacerb
routin
given
blood
count
patient
admit
hospit
extra
cost
benefici
test
background
aim
studi
chronic
obstruct
pulmonari
diseas
copd
major
caus
mortal
morbid
around
world
major
copd
patient
experi
least
one
exacerb
per
year
frequenc
exacerb
increas
diseas
sever
increas
number
exacerb
report
rapid
declin
aim
research
evalu
incid
exacerb
chang
lung
function
patient
regular
follow
method
conduct
crosssect
studi
cohort
copd
patient
regular
follow
asthmacopd
outpati
clinic
hospit
patient
interview
spirometri
perform
compar
spirometri
data
retrospect
analysi
medic
record
done
exacerb
event
last
two
year
lead
seek
medic
care
result
total
patient
f
evalu
fifteen
percent
n
year
age
year
age
diseas
sever
per
gold
mild
diseas
moder
sever
total
exacerb
record
averag
exacerbationspati
year
patient
infrequ
exacerb
n
averag
ml
decreas
valu
patient
frequent
exacerb
n
declin
averag
mlyear
conclus
patient
higher
number
exacerb
greater
declin
key
word
copd
exacerb
lung
function
background
patient
chronic
obstruct
pulmonari
diseas
copd
multidetectorrow
comput
tomographi
mdct
show
tiotropium
dilat
inner
diamet
airway
third
sixth
gener
bronchi
aim
evalu
morpholog
effect
ad
budesonideformoterol
combin
tiotropium
copd
patient
use
threedimension
mdct
method
pulmonari
function
test
st
georg
respiratori
questionnair
sgrq
mdct
imag
studi
perform
begin
budesonideformoterol
combin
treatment
week
patient
copd
result
median
age
year
mean
forc
expiratori
volum
second
percentag
predict
valu
averag
lumin
area
wall
area
percentag
third
fourth
fifth
gener
correl
sgrq
total
score
budesonideformoterol
induc
insignific
pulmonari
function
chang
signific
symptom
improv
ct
imag
show
increas
inner
lumin
area
decreas
wall
area
budesonid
formoterol
treatment
averag
lumin
area
significantli
increas
mm
third
gener
mm
fourth
gener
mm
fifth
gener
mm
sixth
gener
p
wall
area
percentag
significantli
decreas
third
gener
fourth
gener
fifth
gener
p
emphysema
volumectderiv
total
lung
volum
unchang
treatment
conclus
mdct
demonstr
budesonideformoterolinduc
bronchodil
nonsmal
airway
ct
imag
evalu
drug
therapeut
effect
may
provid
addit
insight
pharmacotherapi
copd
nutrit
statu
greatli
affect
patient
subject
global
assess
well
valid
screen
tool
malnutrit
aim
studi
determin
correl
nutrit
statu
use
sga
pulmonari
function
paramet
newli
diagnos
alreadi
diagnos
copd
patient
accord
gold
criteria
seen
philippin
heart
center
cross
section
studi
patient
year
old
diagnos
copd
includ
nutrit
statu
assess
use
anthropometr
indic
weight
height
bodi
mass
index
bmi
mid
arm
circumfer
mac
subject
global
assess
associ
anthropometr
paramet
pulmonari
function
determin
use
pearson
correl
analysi
analysi
varianc
use
determin
relationship
malnutrit
pulmonari
function
pvalu
consid
signific
one
hundr
fourtyf
copd
patient
particip
studi
forc
vital
capac
fvc
decreas
patient
becam
malnourish
differ
prove
signific
p
forc
expiratori
volum
second
show
signific
decreas
patient
becam
malnourish
p
ratio
diminish
well
nourish
patient
sever
malnourish
patient
prove
likewis
signific
p
among
anthropometr
measur
perform
weight
mid
arm
circumfer
posit
correl
p
p
ratio
p
p
bmi
note
posit
correl
ratio
p
howev
correl
note
leukocyt
count
albumin
pft
paramet
nutrit
statu
assess
use
subject
global
assess
correl
significantli
fvc
ratio
copd
patient
bodi
weight
mac
bmi
found
posit
correl
pft
result
copd
patient
sga
weight
mac
bmi
gaug
monitor
sever
copd
without
frequent
pft
especi
among
difficult
critic
ill
copd
patient
background
tiotropium
recent
develop
inhal
anticholinerg
use
oncedaili
dose
manag
copd
previou
studi
hint
longterm
use
may
lead
increas
risk
cardiovascular
mortal
usfda
issu
statement
indic
cardiovascular
safeti
tiotropium
base
uplift
trial
largest
longest
placebocontrol
trial
tiotropium
howev
still
question
tiotropium
cardiovascular
safeti
especi
comparison
activ
treatment
particularli
inhal
longact
betaagonist
object
determin
efficaci
longterm
tiotropium
use
clinic
endpoint
mortal
exacerb
hospit
compar
inhal
laba
among
patient
stabl
moder
sever
copd
methodolog
rct
identifi
electron
databas
pubm
cochran
librari
ovid
herdin
clinicaltrialsgov
googl
scholar
relev
studi
review
also
handsearch
rct
among
patient
copd
compar
tiotropium
monotherapi
inhal
laba
least
month
followup
select
data
allcaus
mortal
mortal
pulmonari
cardiovascular
caus
rate
hospit
exacerb
identifi
date
last
search
septemb
two
independ
investig
evalu
extract
relev
data
analyz
use
cochran
review
manag
result
titl
abstract
clinic
trial
total
patient
met
inclus
criteria
tiotropium
reduc
allcaus
mortal
rr
ci
mortal
respiratori
caus
rr
ci
mortal
cardiovascular
caus
rr
ci
tiotropium
significantli
decreas
risk
exacerb
rr
ci
exhibit
trend
toward
decreas
hospit
rr
ci
conclus
tiotropium
reduc
allcaus
mortal
mortal
pulmonari
caus
mortal
cardiovascular
caus
compar
inhal
laba
tiotropium
significantli
decreas
risk
exacerb
show
trend
toward
possibl
decreas
hospit
introduct
comorbidi
diabet
mellitu
hypertens
cardiac
diseas
commonli
report
patient
chronic
obstruct
pulmonari
diseas
copd
studi
aim
determin
frequenc
comorbid
condit
multimorbid
hospit
patient
acut
copd
exacerb
method
includ
copd
patient
admit
tertiari
refer
center
southern
marmara
region
hospit
acut
exacerb
medic
record
studi
particip
screen
retrospect
comorbid
diseas
anali
result
total
patient
hospit
acut
copd
exacerb
includ
male
femal
mean
age
preval
diabet
mellitu
hyperlipidemia
hypertens
coronari
arteri
diseaes
respect
multimorbid
frequent
femal
male
patient
copd
exacerb
vs
p
routin
laboratori
blood
test
admiss
serum
creatinin
level
higher
copd
patient
multimorbid
one
comorbid
condit
min
vs
min
p
hand
red
cell
distribut
width
lower
copd
patient
multimorbid
compar
one
comorbid
condit
vs
p
conclus
comorbid
common
patient
hospit
copd
exacerb
femal
sex
significat
risk
factor
multimorbidi
copd
patient
requir
hospit
acut
exacerb
backgroundaim
studi
western
countri
shown
copd
associ
signific
diurnal
symptom
variabl
notabl
morn
howev
unknown
whether
occur
chines
copd
patient
moder
greater
airflow
limit
method
nonintervent
crosssect
studi
conduct
hospit
china
involv
copd
patient
mean
age
mostli
moder
n
sever
n
sever
n
airflow
limit
gold
classif
patient
percept
daili
variabl
copd
symptom
impact
symptom
morn
activ
sleep
qualiti
qualityoflif
qol
assess
via
investigatorappli
questionnair
mmrc
cat
questionnair
also
appli
assess
result
variabl
copd
symptom
day
note
patient
overal
respect
severeveri
sever
airflow
limit
patient
frequent
time
patient
distress
copd
symptom
morn
wake
patient
later
morn
even
patient
sever
airflow
limit
distress
wake
clinic
symptom
questionnair
indic
major
activ
advers
affect
copd
symptom
negoti
stair
patient
physic
activityexercis
shop
sleep
qualiti
rate
patient
poor
score
mmrc
cat
questionnair
significantli
correl
impact
patient
morn
activ
p
conclus
copd
symptom
chines
patient
moder
greater
airflow
limit
exhibit
diurnal
variabl
impact
daili
live
morn
activ
sleep
qualiti
morn
symptom
morn
activ
impact
due
copd
paid
attent
clinic
physician
studi
fund
astrazenca
china
medic
write
support
content
ed
net
introduct
oncedaili
dual
bronchodil
contain
fixeddos
combin
longact
laba
indacaterol
longact
muscarin
antagonist
lama
glycopyrronium
treatment
chronic
obstruct
pulmonari
diseas
copd
beacon
studi
evalu
efficaci
safeti
compar
concurr
administr
monocompon
indacaterol
glycopyrronium
indgli
method
multicent
doubleblind
parallel
group
activ
control
studi
random
patient
moderatetosever
copd
oncedaili
glycopyrronium
placebo
concurr
administr
indacaterol
glycopyrronium
via
breezhal
devic
week
primari
object
demonstr
noninferior
versu
indgli
trough
forc
expiratori
volum
one
second
week
noninferior
margin
ml
secondari
object
includ
area
curv
hour
day
week
symptom
score
rescu
medic
use
safeti
toler
result
random
patient
complet
studi
demonstr
noninferior
versu
indgli
trough
week
treatment
differ
l
confid
interv
ci
treatment
differ
indgli
day
week
l
ci
l
ci
respect
treatment
group
similar
reduct
symptom
score
recus
medic
use
baselin
incid
advers
event
similar
indgli
group
death
report
studi
conclus
oncedaili
improv
lung
function
reduc
symptom
score
rescu
medic
use
similar
safeti
toler
profil
compar
free
combin
monocompon
introduct
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
common
condit
lead
unschedul
health
care
util
impair
health
statu
among
patient
method
studi
assess
infect
etiolog
relat
aecopd
molecular
techniqu
includ
virus
bocaviru
human
metapneumoviru
novel
bacteria
like
streptococc
pseudopneumonia
also
studi
pair
sputum
sampl
panel
virus
subject
posit
nasophargn
aspir
npa
relationship
identif
microorgan
short
term
clinic
outcom
patient
hospit
length
stay
need
noninvas
ventil
mortal
month
assess
result
episod
aecopd
control
copd
subject
stabl
state
studi
overal
subject
posit
npa
commonest
virus
identifi
npa
aecopd
patient
rhinoviru
coronaviru
respiratori
syncyti
viru
control
subject
commonest
organ
detect
npa
specimen
atyp
organ
like
mycoplasma
pneumonia
chlamydia
pneumonia
aecopd
patient
control
subject
posit
sputum
bacteri
test
streptococcu
pseudopneumonia
identifi
subject
aecopd
among
subject
posit
npa
result
show
posit
result
pair
expector
sputum
comparison
subject
organ
identifi
npa
sputum
versu
npa
found
similar
demograph
characterist
short
term
clinic
outcom
conclus
role
high
preval
streptococc
pseudopneumonia
sputum
aecopd
patient
atyp
organ
like
mycoplasma
chlamydia
npa
stabl
copd
subject
need
investig
background
hypoxemia
consequ
alveolar
hypoxia
increas
along
sever
copd
tissu
hypoxia
trigger
degrad
purin
serum
uric
acid
ua
final
product
purin
degrad
shown
increas
hypox
state
therefor
serum
ua
may
reflect
sever
hypoxia
assess
whether
presenc
higher
valu
serum
ua
associ
degre
sever
copd
method
research
conduct
outpati
pulmonari
clinic
soetomo
hospit
surabaya
east
java
indonesia
includ
consecut
patient
copd
patient
clinic
stabl
condit
without
signific
comorbid
condit
degre
sever
compar
oxygen
satur
valu
serum
ua
result
weak
correl
found
hypoxemia
degre
sever
copd
r
p
patient
level
satur
less
correl
serum
ua
valu
degre
sever
copd
present
signific
r
p
conclus
sever
copd
character
decreas
lung
function
result
increas
level
serum
uric
acid
patient
copd
background
system
inflamm
may
contribut
cachexia
copd
patient
one
import
biomark
system
inflamm
aim
studi
analyz
correl
system
inflamm
nutrit
statu
chronic
obstruct
pulmonari
diseas
patient
method
casecontrol
studi
conduct
may
june
respond
stabl
copd
gold
iiv
patient
age
year
case
defin
copd
patient
poor
nutrit
statu
control
defin
copd
patient
good
nutrit
statu
nutrit
statu
measur
use
bodi
mass
index
bmi
percentag
ideal
bodi
weight
lean
bodi
mass
fatfre
mass
serum
measur
use
enzym
immunoassay
correl
nutrit
statu
level
serum
analyz
univariat
multivariat
analysi
result
mean
serum
level
case
group
higher
control
group
pgml
vs
pgml
p
level
serum
correl
bmi
r
p
percentag
ideal
bodi
weight
r
p
lean
bodi
mass
r
p
fatfre
mass
r
p
odd
ratio
ci
p
conclus
serum
correl
decreas
nutrit
statu
copd
patient
keyword
tumor
necrot
factor
system
inflamm
nutrit
statu
copd
background
aim
studi
survey
focus
directli
physician
perspect
treat
copd
physician
survey
aim
describ
physician
belief
behavior
relat
copd
diagnosi
treatment
includ
knowledg
revis
gold
strategi
countri
includ
japan
korea
method
sampl
physician
identifi
incountri
profession
associ
databas
includ
total
n
korea
gener
practition
gp
chest
physician
cp
n
interview
japan
gp
cp
standard
translat
questionnair
conduct
telephon
facetofac
onlin
januari
may
result
awar
gold
strategi
overal
korea
overal
japan
knowledg
higher
among
cp
compar
gp
korea
vs
japan
vs
spirometri
korea
japan
chest
xray
korea
japan
commonli
use
establish
copd
diagnosi
use
patientreport
outcom
korea
japan
lower
countri
sixtyf
percent
korean
physician
japanes
physician
report
discuss
smoke
cessat
patient
everi
visit
perceiv
patient
adher
prescrib
treatment
regimen
low
korean
physician
japanes
physician
indic
least
threequart
patient
alway
compli
treatment
regimen
korean
japanes
physician
indic
medic
cost
common
barrier
access
adher
optim
regimen
conclus
awar
applic
gold
strategi
high
among
respiratori
specialist
physician
korea
japan
opportun
improv
gener
practition
deliv
care
copd
patient
identifi
sponsor
gsk
object
aim
understand
symptom
actual
daili
behavior
degre
satisfact
patient
receiv
treatment
chronic
obstruct
pulmonari
diseas
copd
method
questionnair
survey
target
patient
medic
institut
special
pulmonari
medicin
carri
april
june
includ
patient
age
year
patient
visit
medic
institut
diagnos
copd
via
pulmonari
function
test
patient
provid
consent
particip
survey
treat
doctor
provid
data
pulmonari
function
number
exacerb
treatment
regimen
patient
result
patient
treat
use
longact
inhal
drug
patient
indic
rel
high
degre
satisfact
treatment
cough
sputum
exert
dyspnea
depend
diseas
sever
frequent
observ
patient
report
cough
troublesom
accompani
sputum
h
awaken
exert
dyspnea
also
report
sever
awaken
continu
h
afternoon
patient
report
greater
number
exacerb
doctor
indic
doctor
probabl
complet
understand
suffer
patient
mari
grace
l
luanc
teresita
de
guia
rommel
bayot
philippin
heart
center
east
avenu
quezon
citi
philippin
philippin
heart
center
east
avenu
quezon
citi
philippin
background
copd
assess
test
cat
develop
assist
patient
clinician
assess
quantifi
symptom
impact
copd
enabl
better
commun
patient
physician
consequ
diseas
alreadi
valid
countri
well
philippin
also
strong
correl
sgrq
method
studi
crosssect
stabl
copd
patient
includ
studi
cat
sgrq
questionnair
administ
random
basi
data
describ
mean
sd
frequenc
percent
distribut
kappa
test
use
determin
signific
agreement
cutoff
point
score
system
sever
copd
diagnos
spirometri
result
obtain
show
signific
impair
health
statu
relat
copd
sever
copd
sever
increas
cat
sgrq
score
also
increas
significantli
cat
p
sgrq
p
howev
signific
agreement
cut
score
cat
copd
sever
kappa
test
p
conclus
cat
show
signific
associ
health
relat
impact
copd
sever
good
correl
sgrq
score
system
background
aim
studi
readmiss
rate
deem
import
indic
qualiti
medic
care
china
object
studi
identifi
readmiss
rate
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
evalu
associ
risk
factor
method
retrospect
review
patient
acut
exacerb
copd
aecopd
hospit
januari
novemb
earli
readmiss
group
nonearli
readmiss
group
determin
whether
patient
readmit
within
day
discharg
logist
regress
analysi
perform
identifi
risk
factor
earli
readmiss
follow
aecopd
result
patient
admiss
period
admiss
defin
earli
readmiss
multivari
analysi
show
chronic
pulmonari
heart
diseas
odd
ratio
confid
interv
ci
p
hypoproteinemia
ci
p
level
ci
p
risk
factor
earli
readmiss
aecopd
conclus
readmiss
rate
aecopd
high
aecopd
patient
chronic
pulmonari
heart
diseas
hypoproteinemia
high
level
risk
readmiss
day
hospit
discharg
medic
care
patient
warrant
much
greater
attent
background
chronic
obstruct
pulmonari
diseas
copd
recogn
system
inflammatori
diseas
although
viscer
adipos
tissu
inflamm
known
associ
variou
lifestyl
diseas
diabet
mellitu
atherosclerosi
contribut
system
inflamm
copd
remain
unclear
aim
studi
evalu
associ
lung
function
viscer
adipos
tissu
inflamm
method
studi
includ
patient
underw
surgic
resect
due
earli
stage
abdomin
cancer
gastric
colon
cancer
viscer
adipos
tissu
obtain
oper
inform
consent
quantifi
inflammatori
cell
adipos
tissu
evalu
associ
clinic
paramet
includ
lung
function
studi
approv
institut
ethic
committe
result
number
viscer
adipos
tissu
macrophag
atm
show
signific
correl
differ
patient
n
without
airflow
limit
n
howev
signific
neg
correl
atm
predict
vc
r
p
addit
signific
posit
correl
atm
bodi
mass
index
bmi
level
crp
significantli
higher
patient
low
predict
vc
multivari
analys
demonstr
predict
vc
bmi
independ
associ
number
viscer
atm
conclus
adipos
tissu
inflamm
may
contribut
system
inflamm
advanc
copd
low
lung
volum
independ
bmi
background
chronic
obstruct
pulmonari
diseas
copd
known
associ
variou
comorbid
unfavor
condit
postop
period
howev
limit
data
associ
subclin
airflow
limit
al
comorbid
aim
studi
evalu
frequenc
preoper
pulmonari
dysfunct
among
variou
diseas
assess
associ
pulmonari
dysfunct
clinic
paramet
includ
comorbid
period
hospit
stay
method
studi
includ
patient
undergon
surgic
oper
due
breast
n
lung
n
colorect
n
gastric
n
cardiovascular
diseas
n
retrospect
review
clinic
record
age
sex
bodi
mass
index
smoke
underli
diseas
hospit
day
comorbid
hypertens
hyperlipidemia
hyperuricemia
diabet
evalu
associ
clinic
paramet
pulmonari
dysfunct
result
preoper
al
observ
among
patient
wherea
subject
symptom
diagnos
copd
predict
vc
significantli
lower
patient
cardiovascular
disord
other
differ
frequenc
al
among
patient
cardiovascular
breast
lung
colorect
gastric
disord
age
male
gender
independ
associ
presenc
al
among
comorbid
hypertens
patient
al
without
al
significantli
associ
al
independ
age
sex
addit
significantli
longer
hospit
day
observ
patient
al
day
patient
without
al
day
p
conclus
preoper
al
frequent
observ
mostli
present
subclin
dysfunct
preoper
al
significantli
associ
hypertens
prolong
hospit
day
asuka
nagai
rurika
hamanaka
akinori
ebihara
tokuzen
iwamoto
ichiro
kuwahira
depart
pulmonari
medicin
tokai
univers
tokyo
hospit
background
aim
studi
cardiovascular
event
acut
myocardi
infarct
stroke
major
comorbid
lead
caus
death
patient
copd
atherosclerot
chang
larg
respons
event
present
studi
evalu
cardiovascular
risk
copd
patient
detect
platelet
hyperaggreg
measur
highsensit
creactiv
protein
hscrp
marker
system
inflamm
carotid
max
intimamedia
thick
maximt
method
studi
includ
stabl
copd
patient
healthi
control
measur
carotid
arteri
maximt
use
ultrasound
imag
hscrp
venou
blood
sampl
regard
hyperaggreg
analyz
frequenc
occurr
natur
platelet
aggreg
venou
blood
use
abbot
celldyn
sapphir
hematolog
analyz
result
platelet
aggreg
posit
copd
patient
healthi
control
averag
valu
hscrp
sd
mgdl
copd
patient
mgdl
control
averag
valu
maximt
mm
copd
patient
mm
control
tendenc
thicken
copd
group
plaqu
detect
copd
group
healthi
control
result
present
studi
indic
patient
stage
copd
signific
risk
thrombosi
due
atherosclerot
chang
suggest
earli
detect
platelet
hyperaggreg
present
method
use
prevent
cardiovascular
event
background
patient
chronic
obstruct
pulmonari
diseas
copd
pulmonari
hypertens
ph
advers
affect
surviv
perform
systemat
review
metaanalysi
assess
whether
phspecif
therapi
effect
patient
stabl
copd
method
data
sourc
medlin
octob
embas
novemb
cochran
central
regist
control
trial
koream
refer
relev
public
random
prospect
trial
compar
ph
specif
therapi
copd
week
placebo
includ
two
review
independ
extract
data
outcom
exercis
capac
minut
walk
advers
event
treatment
result
four
random
control
trial
involv
subject
includ
analysi
among
four
trial
two
involv
bosentan
one
involv
sildenafil
one
involv
beraprost
studi
vari
durat
treatment
month
month
pool
analysi
four
trial
exercisecapac
significantli
improv
phspecif
treatment
copd
risk
ratio
ci
copd
patient
overt
ph
significantli
improv
exercis
capac
mean
differ
ci
copd
patient
ph
unknown
mean
differ
ci
signific
differ
hypoxemia
phspecif
treatment
placebo
group
mean
differ
ci
conclus
ph
specif
treatment
signific
effect
improv
exercis
capac
copd
patient
overt
ph
background
chronic
obstruct
pulmonari
diseas
copd
one
common
caus
death
howev
limit
number
patient
properli
treat
japan
one
reason
patient
recogn
diagnos
gener
practition
gp
throughout
period
number
doctor
prescrib
inhal
longact
muscarin
antagonist
lama
recommend
firstlin
treatment
guidelin
japanes
respiratori
societi
significantli
increas
p
howev
signific
chang
rate
spiromet
possess
recognit
guidelin
focus
survey
result
doctor
special
intern
medicin
recognit
guidelin
significantli
increas
p
despit
chang
rate
spiromet
possess
furthermor
multivari
analysi
survey
result
reveal
doctor
special
intern
medicin
examin
mani
patient
copd
recogn
guidelin
prescrib
lama
significantli
hand
doctor
special
intern
medicin
examin
patient
copd
even
know
guidelin
conclus
educ
campaign
also
comprehens
region
medic
liaison
hospit
clinic
would
need
educ
campaign
would
benefici
gp
background
taken
consider
background
earli
initi
inhal
corticosteroid
therapi
use
certain
copd
patient
associ
copd
sign
atop
factor
clearli
defin
method
sixtyeight
copd
patient
receiv
medic
care
hospit
classifi
follow
group
bacopd
patient
diagnos
asthma
complic
copd
basi
smoke
histori
laboratori
find
copdba
patient
diagnos
copd
complic
asthma
basi
respons
treatment
copd
patient
diagnos
copd
alon
lung
capac
inhal
peripher
blood
eosinophil
count
serum
total
ige
antigenspecif
ige
antibodi
level
well
presenc
emphysemat
lesion
analyz
result
signific
age
differ
among
group
serum
total
ige
level
bacopd
group
significantli
higher
copd
group
percentag
patient
posit
specif
ige
antibodi
one
antigen
bacopd
copdba
copd
group
respect
posit
rate
higher
bacopd
copd
group
hous
dust
tick
cockroach
midg
moth
higher
copdba
copd
group
hous
dust
posit
rate
candida
aspergillu
similar
among
group
approxim
conclus
asthmat
patient
dyspnea
may
diagnos
copd
suggest
environment
antigen
sensit
may
occur
atop
factorposit
copd
patient
age
possibl
complic
asthma
must
consid
method
crosssect
studi
conduct
pilgrim
season
hajj
year
result
ninetyseven
copd
patient
identifi
subsequ
recruit
studi
proport
aecopd
hajj
n
gener
characterist
subject
follow
elderli
current
smoker
comorbid
suffer
acut
respiratori
tract
infect
moder
copd
sever
bivari
multivari
analyz
found
signific
relationship
acut
respiratori
tract
infect
comorbid
factor
incid
aecopd
conclus
studi
found
high
proport
aecopd
jakarta
embark
pilgrim
found
signific
relationship
acut
respiratori
tract
infect
comorbid
factor
incid
aecopd
key
word
acut
exacerb
copd
pilgrim
jakarta
embark
morihiro
tajiri
tomotaka
kawayama
takashi
background
aim
studi
acut
exacerb
ae
idiopath
pulmonari
fibrosi
ipf
consid
nearli
fatal
condit
clinic
cours
ipf
unrespons
convent
therapi
aim
studi
evalu
efficaci
recombin
human
solubl
thrombomodulin
rhstm
ae
ipf
conduct
retrospect
studi
ipf
case
develop
ae
treat
corticosteroid
cs
combin
rhstm
subject
rhstmtreat
group
compris
patient
mean
age
year
clinic
featur
prognosi
rhstmtreat
group
compar
control
group
consist
ipf
patient
develop
ae
receiv
rhstm
result
cs
puls
therapi
follow
cs
mainten
treatment
conduct
case
onset
ae
patient
rhstmtreat
group
receiv
combin
therapi
cs
rhstm
iukg
min
iv
daili
day
twomonth
surviv
onset
ae
rhstmtreat
group
nonrhstmtreat
group
p
median
surviv
first
onset
ae
day
rhstmtreat
group
day
nonrhstmtreat
group
therefor
prognosi
rhstmtreat
group
therefor
significantli
better
nonrhstmtreat
group
conclus
studi
indic
rhstm
combin
cs
therapi
may
benefici
effect
patiant
ae
ipf
rational
idiopath
pulmonari
fibrosi
ipf
chronic
progress
fibrot
fatal
lung
diseas
without
proven
benefici
therapi
recent
pirfenidon
pyridon
antiinflammatori
antioxid
antifibrot
agent
demonstr
improv
clinic
cours
ipf
sever
clinic
trial
howev
time
begin
pirfenidon
therapi
still
unclear
controversi
thu
object
studi
investig
clinic
featur
patient
ipf
treat
pirfenidon
month
method
studi
done
retrospect
investig
patient
ipf
usual
interstiti
pneumonia
uip
connect
tissu
diseas
ctd
except
case
acut
exacerb
patient
requir
definit
probabl
uip
pattern
highresolut
comput
tomographi
accord
intern
consensu
statement
ten
patient
ipf
patient
ctd
treat
pirfenidon
mgday
compar
sever
indic
follow
sever
pulmonari
function
test
pft
oxygen
satur
puls
oximetri
serum
level
baselin
treatment
month
result
baselin
age
restrict
disord
pft
patient
older
sever
respect
previou
studi
month
treatment
alter
vital
capac
vc
ml
ml
vc
sever
level
uml
uml
baselin
howev
compar
alter
indic
term
month
month
baselin
pirfenidon
attenu
progress
restrict
disord
pft
elev
level
one
patient
improv
sever
seriou
advers
event
seen
conclus
treatment
pirfenidon
may
stabil
improv
clinic
cours
ipf
introduct
done
earlier
littl
data
effect
interv
exercis
patient
interstiti
lung
diseas
ild
aim
studi
evalu
feasibl
effect
interv
exercis
ie
exercis
capac
patient
ild
method
patient
ild
complet
four
week
inpati
pulmonari
rehabilit
pr
tosei
gener
hospit
januari
decemb
recruit
patient
first
recommend
enrol
constant
load
exercis
cle
group
patient
could
perform
cle
protocol
particip
ie
group
ie
protocol
second
work
period
interspers
second
rest
period
minday
patient
carri
cle
cle
group
exercis
minday
target
intens
baselin
peak
work
rate
ie
group
cle
groupal
patient
evalu
pulmonari
function
test
minut
walk
distanc
constant
work
rate
test
quadricep
forc
baselin
dyspnoea
index
bdi
baselin
pr
program
result
twentyseven
ild
patient
cle
ie
studi
pr
program
increas
significantli
compar
baselin
valu
ie
group
inpati
pr
program
recommend
could
perform
outpati
pr
program
four
week
inpati
pr
program
consist
high
intens
exercis
train
peak
work
rate
use
cycl
ergomet
addit
also
perform
resist
train
dyspnea
baselin
dyspnea
index
bdi
quadricep
forc
exercis
capac
walk
distanc
health
relat
qol
sgrq
measur
baselin
four
week
pr
result
twentyeight
ipf
patient
male
year
age
fvc
predict
dlco
predict
studi
follow
pr
signific
improv
observ
bdi
p
quadricep
forc
nm
nm
nm
nm
p
p
sgrq
total
p
conclus
inpati
pr
program
improv
dyspnea
quadricep
forc
exercis
capac
hrqol
patient
advanc
stage
ipf
background
aim
studi
although
chair
stand
test
use
measur
test
assess
strength
lower
extrem
adult
use
interstiti
lung
diseas
ild
unknown
aim
studi
elucid
use
mildtomoder
ild
method
nineteen
consecut
patient
ild
underw
walk
test
evalu
clinic
practic
includ
idiopath
pulmonari
fibrosi
connect
tissu
diseas
relat
ild
data
review
retrospect
comparison
made
result
patient
male
age
year
old
modifi
medic
research
council
mrc
dyspnoea
score
torr
percent
predict
fvc
tlc
dlco
respect
data
follow
walk
distanc
maximum
heart
rate
hrmax
bpm
maximum
respiratori
rate
rrmax
bpm
minimum
min
maximum
modifi
borg
dyspnoea
score
mbsmax
contrast
data
follow
number
time
hrmax
bpm
rrmax
bpm
min
mbsmax
comparison
paramet
two
test
significantli
correl
p
howev
hrmax
rrmax
mbsmax
significantli
lower
p
p
p
respect
min
significantli
higher
p
number
patient
desatur
sever
min
significantli
smaller
vs
p
decreas
test
significantli
smaller
vs
p
conclus
use
test
evalu
exercis
capac
patient
mildtomoder
ild
allevi
desatur
background
forc
oscillometri
noninvas
method
measur
respiratori
resist
reactanc
studi
investig
characterist
resist
reactanc
obtain
impuls
oscil
system
io
patient
idiopath
pulmonari
fibrosi
ipf
method
io
spirometri
perform
ipf
patient
chronic
obstruct
pulmonari
diseas
copd
patient
healthi
volunt
respiratori
resist
reactanc
assess
measur
averag
sever
tidal
breath
wholebreath
analysi
measur
separ
averag
inspir
expir
inspiratoryexpiratori
analysi
result
wholebreath
io
analys
ipf
patient
show
increas
resist
hz
decreas
reactanc
hz
compar
control
although
featur
also
found
copd
group
howev
chang
inspir
expir
found
vari
ipf
copd
group
expiratori
neg
inspiratori
copd
patient
contrast
inspiratori
found
neg
expiratori
ipf
patient
ipf
patient
withinbreath
chang
defin
expiratori
minu
inspiratori
significantli
higher
group
furthermor
invers
correl
vital
capac
diffus
capac
carbon
monoxid
composit
physiolog
index
cpi
ipf
patient
conclus
studi
suggest
increas
magnitud
inspir
compar
expir
characterist
featur
io
measur
ipf
patient
clearli
differ
copd
patient
withinbreath
chang
ipf
might
associ
sever
physiolog
abnorm
although
studi
need
investig
caus
aim
aim
studi
investig
clinic
feasibl
quantif
lung
perfus
blood
volum
pbv
xenon
ventil
dualenergi
ct
differenti
patient
combin
pulmonari
fibrosi
emphysema
cpfe
associ
idiopath
pulmonari
fibrosi
ipf
ipf
alon
subject
method
seventeen
cpfe
patient
male
femal
mean
age
year
ipf
alon
patient
male
femal
mean
age
year
underw
dualenergi
ct
somatom
definit
siemen
healthcar
forccheim
germani
april
march
subject
inhal
stabl
nonradioact
xenon
take
singl
deep
breath
perform
xenon
ventil
ct
intraven
inject
contrast
materi
administ
xenonenhanc
pulmonari
ct
angiograph
imag
deriv
use
threemateri
decomposit
techniqu
furthermor
percentag
area
enhanc
xenon
adjust
pbv
ct
valu
calcul
upper
middl
lower
lung
field
rel
follow
formula
volum
enhanc
xenon
ga
volum
lung
field
x
pbv
ct
valueenhanc
ct
valu
pulmonari
arteri
x
result
percentag
area
enhanc
xenon
lung
calcul
cpfeipf
rel
particular
percentag
area
enhanc
xenon
upper
predomin
defect
pattern
cpfe
significantli
higher
diffus
defect
pattern
cpfe
honeycomb
lesion
ipf
alon
show
significantli
increas
percentag
area
enhanc
xenonadjust
pbv
ct
valu
ratio
compar
cpfe
addit
ratio
lung
field
diffus
defect
pattern
cpfe
decreas
ipf
alon
conclus
quantif
lung
perfus
blood
volum
xenon
ventil
dualenergi
ct
feasibl
differenti
patient
cpfe
ipf
alon
background
lymphangioleiomyomatosi
lam
progress
rare
lung
diseas
exclus
affect
women
childbear
age
recent
studi
reveal
measur
serum
vascular
endotheli
growth
factor
vegf
level
use
diagnosi
lam
serum
vegfd
level
may
serv
biomark
diseas
sever
diseas
progress
treatment
respons
lam
studi
analyz
patient
lam
retrospect
analyz
sporad
lam
year
old
tsclam
patient
year
old
retrospect
studi
patient
underw
lung
transplant
patient
pass
away
one
patient
overlap
lung
transplant
group
pass
away
group
serum
protein
level
evalu
clinic
data
use
multivari
analysi
result
seven
patient
pass
away
respiratori
failur
one
patient
sever
seizur
attack
patient
complic
pneumothorax
chylothorax
angiomyolipoma
lymphat
diseas
patient
histori
treatment
gonadotrophinreleas
hormon
analogu
n
andor
sirolimu
n
includ
patient
median
age
onset
first
medic
examin
year
old
respect
age
death
case
lung
transplant
pass
away
year
old
life
expect
diagnosi
year
year
surviv
rate
visit
hospit
among
biomark
serum
vegfd
sensit
biomark
monitor
prognosi
compar
spd
spa
ace
furthermor
serum
vegfd
level
decreas
immedi
sirolimu
treatment
conclus
lam
system
diseas
poor
prognos
serum
vegfd
level
use
biomark
clinic
diagnosi
enough
prognosi
factor
lam
howev
serum
vegfd
level
good
indic
mtor
treatment
background
patholog
find
chronic
hypersensit
pneumon
chp
mani
varieti
pattern
often
present
uip
pattern
therefor
distinct
chp
present
uip
pattern
chpuip
idiopath
pulmonari
fibrosi
ipf
often
difficult
purpos
studi
clarifi
highresolut
ct
hrct
find
use
differenti
chpuip
ipf
method
studi
includ
patient
chpuip
patient
ipf
two
group
observ
independ
assess
hrct
find
evalu
extent
abnorm
ct
find
made
firstchoic
diagnosi
diagnosi
chpuip
note
inconsist
ipf
result
correct
diagnos
made
chpuip
ipf
differ
extent
groundglass
opac
consolid
honeycomb
emphysema
group
featur
best
differenti
chpuip
ipf
excess
micronodul
hazard
ratio
ci
p
conclus
although
hrct
find
chpuip
close
resembl
ipf
excess
micronodul
hrct
use
find
differenti
chpuip
ipf
goal
studi
clarifi
characterist
pulmonari
manifest
patient
ss
method
review
patient
ss
admit
hospit
retrospect
analysi
perform
result
patient
ss
includ
primari
pss
secondari
syndrom
sss
patient
mucou
membran
dri
symptom
antissa
ssb
antibodi
serum
posit
patient
respect
thirti
three
patient
consist
find
fluoresc
dye
examin
andor
lip
biopsi
ss
interstiti
pneumonia
ip
main
pulmonari
manifest
ip
patient
unknown
etiolog
admiss
diagnos
ss
care
clinic
evalu
histopatholog
analysi
reveal
varieti
histolog
find
nonspecif
ip
cellular
bronchiol
grand
glass
attenu
major
hrct
pattern
lower
peripher
predomin
distribut
analysi
bronchoalveolar
lavag
fluid
show
increas
number
lymphocyt
neutrophil
fiveyear
surviv
rate
prognosi
patient
pss
seem
better
compar
sss
patient
conclus
ip
major
pulmonari
manifest
ss
prognosi
ss
patient
pulmonari
diseas
poor
howev
understand
diseas
care
clinic
evalu
includ
lip
biopsi
necessari
even
patient
without
sicca
symptom
underdiagnosi
ss
riluzol
recent
becom
first
drug
proven
effect
treatment
amyotroph
later
sclerosi
al
report
two
rare
case
lung
injuri
caus
riluzol
therapi
patient
al
chest
radiograph
show
bilater
lower
lobe
dorsaldomin
ground
glass
opac
andor
consolid
drug
lymphocyt
stimul
test
dlst
peripher
blood
bronchoalveolar
lavag
cell
posit
riluzol
histopatholog
examin
lung
biopsi
specimen
reveal
lung
injuri
without
fungoid
granuloma
vascul
diffus
alveolar
damag
best
knowledg
first
report
riluzoleinduc
lung
injuri
posit
dlst
result
sarcoidosi
crohn
diseas
granulomat
disord
case
thought
differ
spectra
diseas
crohn
pulmonari
manifest
mostli
drug
induc
eosinophil
pneumonia
fibrosi
subclin
pulmonari
function
abnorm
case
report
indic
antitnf
therapi
paradox
caus
sarcoidosislik
reaction
case
yearold
white
man
suffer
crohn
diseas
year
need
tumour
necrosi
factoralpha
treatment
perian
pericec
fistula
routin
control
antitnf
treatment
thorax
ct
scan
show
central
ground
glass
pulmonari
infiltr
nodul
left
apicoposterior
segment
bronchoalveolar
lavag
mycobacteri
bacteri
cultur
negatif
start
isoniazid
prophylaxi
infliximab
therapi
three
month
control
torax
ct
scan
show
regress
infiltr
patient
respiratori
complaint
followup
plan
two
year
due
new
infiltr
xray
new
ct
show
bilater
treeinbud
pulmonari
infilitr
mediastin
lymph
node
mm
tracheal
aspir
cultur
neg
tuberculosi
nonspecif
antibiotherapi
infliximab
treatment
continu
control
ct
scan
show
regress
left
lung
field
new
infiltr
right
lung
field
neither
eosinophilia
specif
antibodi
found
peripher
blood
alveol
lavag
reveal
ratio
case
diagnost
confus
pulmonari
infiltr
mediastin
lymph
node
alveol
lavag
result
crohn
diseas
alon
immit
sarcoidosi
bronkoalveol
lavag
concomin
sarcoidosi
addit
antitnf
therapi
paradox
caus
sarcoidlik
granulomatosi
clinic
discuss
whether
withdraw
infilximab
therapi
continu
followup
patient
asemptomat
pulmonari
function
loss
background
object
effect
treatment
establish
rapidli
progress
interstiti
pneumonia
rpip
outcom
poor
furthermor
predict
factor
prognosi
unkown
aim
present
studi
assess
clinic
radiolog
characterist
prognost
predictor
surviv
rpip
defin
rpip
interstiti
lung
diseas
present
acut
respiratori
failur
bilater
infiltr
shadow
chest
highresolut
ct
hrct
unrel
chronic
respiratori
diseas
altern
caus
interstiti
pneumonia
due
underli
diseas
studi
subject
method
fifteen
rpip
patient
mean
age
year
studi
retrospect
patient
treat
institut
period
august
septemb
compar
clinic
featur
hrct
find
survivor
nonsurvivor
addit
assess
prognost
predictor
surviv
day
onset
rpip
result
signific
differ
survivor
nonsurvivor
age
sex
pf
ratio
vs
serum
serum
spd
apach
score
vs
lung
injuri
score
vs
therapeut
regimen
groundglass
attenu
consolid
honeycomb
hrct
hrct
find
architectu
distort
traction
bronchiolectasi
extens
nonsurvivor
survivor
ten
patient
die
due
progress
rpip
hospit
median
surviv
period
day
survivor
day
nonsurvivor
conclus
lthough
mortal
patient
rpip
high
longterm
surviv
expect
patient
recov
statu
refractori
respiratori
failur
hrct
find
potenti
help
predict
prognosi
rpip
rapidli
progress
interstiti
pneumonia
rpip
resist
therapi
poor
prognosi
occasion
accompani
clinic
amyopath
dermatomyos
cadm
effect
treatment
rpip
associ
cadm
yet
determin
antibodi
frequent
detect
rpip
associ
cadm
thought
use
serolog
marker
addit
serum
ferritin
level
thought
predict
diseas
activ
prognosi
encount
two
japanes
patient
rpip
accompani
antibodi
posit
cadm
patient
complain
fever
rapidli
progress
dyspnea
characterist
cutan
manifest
gottron
sign
heliotrop
rash
mechan
hand
mild
muscl
weak
chest
high
resolut
comput
tomograph
scan
hrct
reveal
reticular
opac
airspac
consolid
lung
basilar
predomin
serum
ferritin
level
elev
patient
diagnosi
rpip
accompani
cadm
made
clinic
intens
therapi
initi
puls
methylprednisolon
follow
highdos
oral
administr
prednisolon
puls
cyclophosphamid
cyclosporin
immedi
earli
time
point
highdos
intraven
immunoglobulin
ivig
direct
hemoperfus
polymyxin
bimmobil
fiber
column
pmxdhp
also
administr
intens
combin
therapi
rescu
two
patient
without
respiratori
failur
chest
hrct
imag
pulmonari
function
test
gradual
improv
titer
serum
ferritin
level
decreas
parallel
earli
intens
therapi
includ
ivig
pmxdhp
could
effect
therapi
lifethreaten
rpip
associ
cadm
background
inflammatori
cytokin
report
play
import
role
pathogenesi
interstiti
lung
diseas
howev
individu
role
idiopath
interstiti
pneumon
iip
type
interstiti
pneumon
ip
includ
collagen
vascular
diseas
associ
interstiti
pneumon
cvdip
remain
unknown
studi
measur
bronchoalveolar
lavag
bal
fluid
level
sever
cytokin
patient
iip
cvdip
method
cell
subpopul
bal
fluid
count
bal
fluid
level
ifngamma
tnfalpha
measur
use
bead
suspens
array
enzymelink
immunosorb
assay
elisa
kit
patient
men
women
idiopath
nonspecif
interstiti
pneumon
nsip
patient
men
women
idiopath
usual
interstiti
pneumon
uip
patient
men
woman
rheumatoid
arthriti
cvdip
ra
patient
man
women
dermatomyos
cvdip
dm
patient
men
women
sarcoidosi
result
bal
cell
subpopul
high
amount
lymphocyt
nsip
sarcoidosi
neutrophil
ra
level
significantli
higher
dm
ra
dm
significantli
correl
lymphocyt
level
tnfalpha
highest
ra
compar
ip
sarcoidosi
addit
level
highli
detect
ra
nsip
uip
sarcoidosi
conclus
differ
cell
type
bal
fluid
level
cytokin
patient
iip
cvdip
might
reflect
pathogenesi
use
diagnosi
introduct
leukostasi
fatal
complic
leukemia
brain
lung
commonli
involv
organ
leukostasi
lung
clinic
present
similar
acut
respiratori
distress
syndrom
ard
medic
emerg
earli
recognit
leukostasi
initi
therapi
prevent
mortal
result
patient
articl
disscuss
diagnos
chronic
myelocyt
leukemia
cml
came
hospit
emerg
depart
dyspneu
blood
count
patient
got
hyperleukocystosi
leukocyt
count
mm
respect
expertis
xray
radiologist
result
lung
infiltr
blood
gase
analysi
first
patient
mmhg
mmhg
second
patient
mmhg
mmhg
third
patient
mmhg
mmhg
assses
lung
leukostasi
first
patient
underw
fine
needl
aspir
histolog
result
leukem
cell
myeloblast
mylocyt
infiltr
lung
gotten
cytoreduct
leukapheresi
hydroxyurea
clinic
labolatori
got
better
conclus
although
hydroxyurea
leukapheresi
propos
rapidli
reduc
leukocyt
count
possibl
relat
symptom
data
support
true
valu
decreas
earli
mortal
absenc
specif
guidelin
manag
symptomat
hyperleukocytosi
lung
lekostasi
leukapheresi
feasibl
consid
daytointroduct
mainli
use
monopolar
electr
scalpel
though
heat
diffus
instrument
might
possibl
mistakenli
damag
surround
tissu
vessel
addit
oper
thoracoscop
thymectomi
difficult
choos
devic
use
narrow
work
space
introduct
bipolar
tissu
seal
system
made
great
progress
solv
problem
mainli
use
enseal
trio
control
heat
diffus
later
tissu
enabl
safe
manipul
area
neighbor
blood
vessel
nerv
appropri
seal
tissu
even
high
compress
entir
length
jaw
seal
cut
tissu
one
motion
give
better
visual
manipul
narrow
oper
field
curv
jaw
shape
result
enseal
trio
experi
thoracoscop
thymectomi
demonstr
high
feasibl
without
oper
method
chang
intraop
side
injuri
postop
complic
introduct
lymphangioleiomyomatosi
rare
pulmonari
disord
character
prolifer
smooth
muscl
diffus
throughout
lung
parenchyma
patient
present
reproduct
year
surviv
gener
less
year
pulmonari
lymphangioleiomyomatosi
plam
elderli
patient
rare
case
sporad
report
pathophysiolog
mechan
epidemiolog
plam
elderli
patient
still
unknown
present
case
review
previous
report
case
plam
elderli
patient
publish
sinc
three
case
report
one
review
articl
total
elderli
patient
plam
demonstr
includ
case
report
case
reporta
old
woman
complain
dyspnea
exert
cough
previou
year
spirometri
reveal
restrict
ventilatori
impair
l
forc
vital
capac
l
predict
chest
comput
tomographi
ct
show
diffus
thinwal
cystic
air
space
throughout
lung
videoassist
thorac
surgeri
vat
perform
microscop
find
thinwal
cyst
show
prolifer
smooth
muscl
cell
immunohistochem
stain
reveal
asmaantigen
posit
although
hmb
antigen
neg
diagnos
plam
result
total
patient
includ
review
previous
publish
case
age
patient
year
patient
femal
common
symptom
initi
visit
dyspnea
exert
term
treatment
none
receiv
hormon
therapi
two
patient
surviv
conclus
plam
could
occur
elderli
patient
menopaus
even
rare
physician
consid
plam
women
present
dyspnea
exert
despit
postmenopaus
state
sever
plam
elderli
women
might
better
one
menopaus
women
background
thymic
carcinoma
rare
malign
tumor
definit
chemotherapeut
regimen
establish
advanc
diseas
especi
second
line
set
thu
prognosi
still
disappoint
thymidyl
synthas
ts
express
level
thymic
carcinoma
lower
compar
lung
squamou
cell
cancer
suggest
potenti
sensit
thymic
carcinoma
method
evalu
efficaci
toxic
monotherapi
salvag
three
patient
relaps
thymic
carcinoma
april
juli
initi
dose
determin
base
bodi
surfac
area
bsa
drug
taken
oral
twice
daili
two
week
result
one
patient
achiev
partial
respons
whilst
two
patient
stabl
diseas
median
progressionfre
surviv
time
month
three
patient
one
obtain
diseas
control
month
hematolog
toxic
mild
wherea
gastrointestin
toxic
gener
fatigu
observ
conclus
oral
monotherapi
seem
effect
safe
salvag
set
patient
advanc
thymic
carcinoma
multicent
phase
ii
trial
launch
man
indic
health
check
serum
cea
elev
visit
hospit
seen
hospit
suspect
intestin
pneumonia
chest
ct
scan
malign
diseas
histori
colon
cancer
age
resect
endoscop
mucos
resect
suspect
recurr
colon
cancer
find
suggest
malign
obtain
total
colon
fiber
scopi
chest
ct
scan
show
groundglass
pattern
thicken
interlobular
septa
lower
lobe
blood
exam
show
elev
ldh
bronchoscop
examin
susupect
intestin
pneumonia
bronchoalveolar
lavag
show
white
turbid
like
water
use
wash
rice
antigmcsf
autoantibodi
significantli
increas
serum
bronchoalveolar
lavag
diagnos
autoimmun
pulmonari
alveolar
proteinosi
got
outpati
treatment
without
worsen
respiratori
statu
month
serum
cea
usual
use
marker
malign
diseas
report
serum
follow
cea
correl
diseas
progress
autoimmun
pulmonari
alveolar
proteinosi
case
could
diagnos
pulmonari
alveolar
proteinosi
bronchoscop
examin
serum
cea
elev
serum
marker
background
aim
studi
newli
discov
inflammatori
biomark
variou
inflammatori
condit
studi
design
measur
plasma
level
febril
neutropenia
fn
lung
cancer
patient
examin
use
method
consecut
fn
patient
chemochemoradiotherapi
enrol
onset
day
plasma
taken
treatment
fn
start
follow
guidelin
plasma
also
taken
control
subject
untreat
lung
cancer
patient
without
infect
healthi
control
enrol
plasma
also
taken
enrol
day
measur
crp
level
elisa
examin
correl
clinic
paramet
fn
lung
cancer
result
plasma
crp
level
fn
lung
cancer
patient
fnlc
significantli
increas
compar
healthi
control
hc
chemochemoradiotherapi
lung
cancer
patient
cnlc
p
howev
crp
level
cnlc
significantli
higher
compar
hc
p
contrast
plasma
level
fnlc
significantli
increas
compar
hc
cnlc
p
level
fnlc
significantli
higher
compar
hc
level
fnlc
reach
peak
immedi
howev
crp
level
fnlc
reach
peak
slowli
howev
level
crp
level
significantli
correl
fever
period
conclus
potenti
use
biomark
fn
lung
cancer
patient
background
chest
radiograph
screen
commonli
use
convent
method
detect
lung
mediastin
tumor
howev
half
tumor
detect
chest
radiographi
alreadi
progress
advanc
stage
recent
studi
shown
lowdos
spiral
comput
tomographi
ct
effect
earli
stage
detect
lung
cancer
facilit
better
resect
longterm
surviv
present
studi
perform
evalu
use
chest
radiographi
spiral
ct
diagnosi
mediastin
tumor
method
approxim
consecut
asymptomat
individu
undergon
health
checkup
institut
april
march
individu
undergon
chest
radiographi
lowdos
spiral
ct
presenc
mediastin
tumor
investig
individu
result
four
mediastin
tumor
detect
thymoma
teratoma
liposarcoma
neurofibroma
recklinghausen
diseas
one
case
detect
use
chest
radiographi
ct
wherea
detect
use
chest
ct
case
abnorm
opac
observ
chest
radiograph
tumor
case
success
resect
date
tumor
recurr
observ
conclus
thu
propos
screen
use
lowdos
spiral
ct
use
chest
radiographi
might
contribut
earli
detect
treatment
mediastin
tumor
background
malign
pleural
mesothelioma
mpm
aggress
malign
tumor
associ
asbesto
exposur
limit
respons
convent
therapi
diagnos
mpm
earli
import
previous
report
angiopoietin
ang
correl
bleomycininduc
pulmonari
fibrosi
method
investig
associ
develop
mpm
origin
mesenchym
cell
similar
lung
fibroblast
result
demonstr
stimul
cell
growth
migrat
mpm
cell
vitro
studi
also
demonstr
patient
mpm
significantli
higher
serum
level
comparison
popul
expos
asbesto
develop
mpm
patient
advanc
stage
mpm
show
higher
level
earli
stage
mpm
patient
kaplanmei
method
reveal
signific
correl
serum
level
surviv
conclus
propos
possibl
play
import
role
mpm
tumor
growth
data
suggest
serum
concentr
could
use
prognost
factor
backgroundaim
growth
factor
play
critic
role
prolifer
varieti
cancer
cell
present
studi
conduct
understand
signal
cascad
receptormedi
prolifer
mesothelioma
cell
method
cell
growthand
cell
cycl
analyz
human
nonmalign
cell
malign
mesotheliomacel
cell
result
growth
allth
cell
use
affect
pdgfd
regardless
concentr
ngml
ortreat
time
h
spontan
growth
cell
significantli
inhibit
byknockingdown
pdgfd
receptor
without
affect
cell
cycl
cell
growth
wassignificantli
inhibit
akt
inhibitor
rock
inhibitor
celltyp
inhibitor
cell
alon
inhibitor
cell
alon
kinas
inhibitor
wortmannin
effect
cellgrowth
altern
significantli
attenu
map
kinas
kinas
inhibitor
inhibitor
cell
type
conclus
result
present
studyshow
pdgfd
promot
mesothelioma
cell
prolifer
target
rock
map
kinasethrough
autocrin
activ
receptor
identifi
mortal
risk
emerg
patient
essenti
consequ
increas
number
admiss
divers
sever
diseas
rapid
emerg
medicin
score
rem
develop
predict
mortal
nonsurg
emerg
patient
help
doctor
make
clinic
decis
rapidli
base
object
data
evalu
perform
rem
predict
mortal
nonsurg
emerg
patient
cipto
mangunkusumo
hospit
cmh
tertiari
referr
center
indonesia
method
perform
prospect
cohort
studi
nonsurg
patient
attend
emerg
depart
ed
cmh
octob
decemb
age
bodi
temperatur
mean
arteri
pressur
heart
rate
respiratori
rate
peripher
oxygen
satur
glasgow
coma
scale
obtain
admiss
calcul
rem
outcom
inhospit
mortal
calibr
evalu
hosmerlemeshow
test
discrimin
evalu
area
receiv
oper
characterist
curv
auc
result
total
nonsurg
patient
attend
ed
studi
mani
patient
follow
outcom
occur
inhospit
mortal
observ
patient
hosmerlemeshow
test
show
good
calibr
p
auc
rem
ci
conclus
rapid
emerg
medicin
score
good
prognost
score
system
adult
nonsurg
emerg
patient
indonesia
key
word
rapid
emerg
medicin
score
nonsurg
mortal
object
design
prototyp
endotrach
tube
doubl
cuff
small
intercuff
hole
connect
neg
pressur
port
hypothesi
studi
neg
pressur
doubl
cuff
prevent
fluid
leakag
past
doubl
cuff
method
obtain
two
cuff
standard
endotrach
tube
attach
tube
mm
intern
diamet
id
made
mmsize
hole
cuff
connect
extern
port
appli
neg
pressur
intercuff
space
pvc
trachea
mmsize
intern
diamet
intub
ett
spill
continu
bluedi
water
upper
cuff
appli
neg
pressur
intercuff
space
though
port
minut
measur
volum
drip
water
lower
cuff
leakag
test
background
streamlin
liner
pharynx
airway
slipa
dispos
supraglott
airway
two
strategi
select
size
slipa
studi
compar
util
two
strategi
select
optim
size
method
one
hundr
fortytwo
patient
randomli
divid
two
group
size
select
height
h
maxim
width
thyroid
cartilag
investig
lift
jaw
push
devic
heel
lodg
nasopharynx
investig
made
note
oropharyng
leakag
pressur
olp
degre
insert
difficulti
case
olp
investig
manipul
apparatu
tri
properli
posit
air
still
leak
anoth
attempt
made
use
slipa
one
size
larger
olp
achiev
three
attempt
insert
investig
measur
inspiratori
expiratori
tidal
volum
tvinsp
tvexp
respect
postop
presenc
blood
regurgit
fluid
devic
evalu
result
olp
group
higher
group
h
p
need
manipul
leak
fraction
tvinsptvexp
tvinsp
higher
group
h
group
p
respect
degre
insert
difficulti
number
trial
incid
blood
regurgit
fluid
devic
similar
two
group
conclus
width
thyroid
cartilag
appropri
strategi
patient
height
select
optim
slipa
size
howev
strategi
clinic
applic
background
aim
studi
util
tracheostomi
expedit
wean
prevent
complic
patient
mechan
ventil
suggest
optim
time
tracheostomi
debat
usual
strong
option
patient
famili
taiwan
cultur
lowtracheostomyr
countri
aim
studi
build
structur
famili
meet
determin
efficaci
tracheostomi
rate
ventil
wean
hospit
length
mortal
rate
patient
prolong
mechan
ventil
pmv
method
retrospect
observ
studi
implement
januari
march
structur
famili
meet
built
held
fulfil
follow
criteria
patient
admit
respiratori
care
center
rcc
subacut
ventil
depend
set
patient
endotrach
tube
intub
unwil
receiv
tracheostomi
intens
care
unit
icu
result
total
patient
enrol
patient
male
patient
femal
patient
underw
tracheostomi
implement
structur
famili
meet
patient
came
medic
icu
predictor
tracheostomi
odd
ratio
p
patient
underw
tracheostomi
longer
rcc
length
hospit
length
patient
unwil
receiv
tracheostomi
vs
p
vs
p
respect
rate
ventil
wean
mortal
rate
within
onemonth
discharg
patient
underw
tracheostomi
similar
patient
unwil
receiv
tracheostomi
vs
p
vs
p
respect
conclus
structur
famili
meet
increas
tracheostomi
patient
pmv
cultur
lowtracheostomyr
countri
background
aim
studi
discuss
analys
correl
posit
rate
common
food
allergenspecif
immunoglobulin
e
sige
suspect
food
allergi
patient
hospit
method
use
fluoresc
enzymelink
immunosorb
assay
detect
serum
sige
antibodi
patient
includ
kind
food
allergen
milk
egg
white
egg
yolk
peanut
soy
shrimp
crab
juli
januari
result
patient
detect
milk
egg
white
sige
posit
rate
milk
sige
posit
rate
egg
white
posit
r
p
patient
detect
egg
white
egg
yolk
sige
posit
rate
egg
white
sige
much
higher
yolk
sige
posit
rate
milk
egg
white
sige
decreas
age
degre
level
milk
egg
white
sige
posit
patient
detect
serum
sige
shrimp
crab
patient
case
posit
shrimp
case
crab
posit
posit
case
r
p
simultan
detect
patient
serum
sige
peanut
soybean
peanut
posit
case
soybean
posit
case
posit
case
r
p
conclus
egg
white
major
allergen
egg
allergi
relev
shrimp
crab
peanut
soybean
extrem
high
probabl
homolog
egg
white
milk
homolog
food
posit
rate
signific
correl
indic
synergist
reaction
background
tracheal
web
rare
congenit
abnorm
trachea
often
misdiagnos
refractori
asthma
mounierkuhn
syndrom
mk
also
rare
disord
character
mark
dilat
trachea
main
bronchi
sometim
diverticulosi
tracheobronchomalacia
howev
etiolog
uncertain
case
report
woman
refer
hospit
persist
cough
wheez
diagnos
asthma
year
ago
episod
pneumonia
packyear
smoke
histori
year
ago
pulmonari
function
test
show
flat
pattern
flow
volum
curv
mark
limit
peak
flow
chest
ct
scan
reveal
trachobronchomegali
diamet
mm
weblik
tracheal
stenosi
tracheal
web
obstruct
almost
insid
diamet
trachea
cm
vocal
cord
although
collaps
trachea
expir
unclear
accord
evid
patient
diagnos
mk
tracheal
web
discuss
despit
congenit
tracheal
web
asthmat
symptom
infanc
congenit
dilat
trachea
present
birth
tracheobronchomegali
case
due
congenit
abnorm
rather
atrophi
connect
tissu
trachea
also
gave
birth
safe
two
children
year
ago
asymptomat
asthmat
symptom
appear
year
ago
consid
weblik
tracheal
stenosi
progress
resect
web
might
consid
reason
treatment
lack
signific
tracheal
collaps
expir
one
main
featur
mk
might
suggest
prevent
tracheal
collaps
tracheal
web
case
thu
choic
futur
treatment
made
deliber
smoke
associ
increas
risk
variou
diseas
hand
dementia
becom
social
burden
elderli
popul
increas
present
studi
aim
clarifi
relationship
smoke
statu
cognit
function
communitydwel
elderli
men
method
comprehens
geriatr
health
survey
resid
age
year
villag
along
sea
japan
carri
august
septemb
selfadminist
questionnair
distribut
mail
subsequ
respons
valid
homevisit
facetofac
interview
train
interview
simultan
perform
miniment
statu
examin
mmse
analysi
subject
divid
group
current
smoker
former
smoker
nonsmok
mmse
score
compar
accord
smoke
statu
age
result
subject
particip
survey
particip
rate
male
subject
analyz
subject
current
smoker
former
smoker
nonsmok
group
respect
current
smoker
age
year
fewest
p
mmse
score
signific
differ
among
smoke
statu
age
group
mmse
averag
score
howev
tendenc
found
current
smoker
age
year
lowest
compar
former
never
smoker
wherea
age
year
highest
conclus
studi
could
find
associ
mmse
score
smoke
statu
background
videoassist
thoracoscop
surgeri
vat
requir
gener
anesthesia
onelung
ventil
accord
previou
studi
thoracoscop
bleb
resect
tbr
could
perform
low
tidal
volum
vt
twolung
ventil
without
technic
problem
usual
low
vt
requir
higher
respir
rate
rr
meet
patent
metabol
need
produc
fastmov
oper
field
unfavor
evalu
feasibl
ventil
set
tbr
low
vt
respect
ga
exchang
method
patient
receiv
schedul
tbr
includ
accord
inclus
exclus
criteria
gener
anesthesia
provid
tbr
perform
twolung
ventil
low
vt
set
mlkg
rr
vari
cyclesmin
accord
protocol
surgeri
perform
without
ga
insuffl
anesthesia
period
vital
sign
arteri
blood
ga
analysi
abga
valu
associ
mechan
ventil
monitor
record
result
total
patient
final
includ
statist
analysi
oper
anesthet
time
number
use
endopl
significantli
differ
group
patient
present
hypoxemia
hypercarpnia
minut
ventil
significantli
lower
rr
group
p
result
abga
physiolog
rang
conclus
towlung
ventil
low
vt
cyclesmin
rr
accept
tbr
even
though
decreas
minut
ventil
ventil
set
optim
surgic
field
guarante
arteri
blood
gase
remain
within
normal
rang
asthma
chronic
diseas
number
asthmat
patient
increas
continu
thailand
asthmat
patient
four
million
mortal
rate
asthmat
patient
year
public
health
ministri
polici
servic
depart
patient
buriram
hospit
improv
care
teamwork
one
stop
servic
adult
asthmat
clinic
everi
servic
hear
altogeth
teamwork
develop
activ
studi
descript
research
studi
result
care
asthmat
patient
consist
admit
adult
asthmat
clinic
januari
decemb
use
statist
analysi
pair
ttest
percentag
mean
result
show
admitt
decreas
ervisit
decreas
peak
flow
expiratori
rate
increas
form
signific
statist
p
one
stop
servic
implement
averag
time
spent
adult
asthmat
clinic
decreas
hour
payment
care
decreas
bath
satisfact
rate
enlarg
hospit
network
take
care
asthma
patient
care
asthma
control
servic
conveni
quickli
high
satisfact
decreas
payment
care
servic
cover
asthmat
patient
nt
admit
asthmat
clinic
especi
old
patient
nt
care
giver
servic
cover
chronic
diseas
exampl
hypertens
stroke
background
assess
patient
pulmonari
ill
requir
object
measur
howev
area
standard
spirometri
portabl
electron
spiromet
develop
need
evalu
object
studi
evalu
handheld
spiromet
diagnost
tool
comparison
standard
pulmonari
function
test
methodolog
crosssect
studi
conduct
philippin
heart
center
patient
year
old
underw
standard
pulmonari
function
test
request
undergo
handheld
spirometri
upon
return
result
interpret
independ
result
total
subject
includ
signific
differ
valu
fvc
handheld
spiromet
standard
pft
p
howev
good
agreement
two
devic
diagnosi
normal
obstruct
restrict
lung
diseas
kappa
p
also
good
agreement
two
devic
classif
mild
moder
sever
obstruct
kappa
restrict
lung
diseas
kappa
handheld
spiromet
note
accur
diagnos
obstruct
lung
diseas
kappa
sensit
specif
ppv
npv
slightli
less
accur
diagnos
restrict
lung
diseas
sensit
specif
ppv
npv
conclus
valu
fvc
obtain
use
handheld
spiromet
may
vari
significantli
standard
pft
handheld
spiromet
diagnos
normal
restrict
obstruct
lung
diseas
classifi
diseas
sever
mild
moder
sever
good
agreement
standard
pft
handheld
spiromet
found
accur
diagnos
obstruct
lung
diseas
slightli
less
accur
diagnos
restrict
lung
diseas
may
substitut
use
standard
spirometri
area
lack
standard
pft
patient
difficulti
ambul
radic
cure
treatment
lung
cancer
surgic
oper
evalu
postop
pulmonari
function
import
estim
risk
complic
longterm
disabl
pulmonari
resect
especi
elderli
patient
number
segment
method
often
use
estim
predict
postop
pulmonari
function
howev
method
consid
actual
volum
resect
lobe
current
divid
calcul
lung
volum
everi
lobe
aim
studi
reveal
differenti
actual
valu
examin
lobectomi
estim
postop
valu
calcul
tradit
number
segment
method
estim
postop
valu
calcul
resect
lobular
volum
obtain
po
eposeg
epoct
predict
po
eposeg
epoct
predict
dlco
po
dlco
eposeg
dlco
epoct
dlco
respect
method
calcul
lobar
volum
emphysemat
lobar
volum
hu
lobe
use
slicebyslic
method
softwar
program
result
patient
enrol
studi
mean
age
year
patient
classifi
diagnos
adenocarcinoma
patient
squamou
cell
carcinoma
nonsmal
cell
lung
cancer
po
epoct
significantli
larger
eposeg
statist
signific
po
epoct
significantli
differ
eposeg
epoct
significantli
smaller
po
significantli
differ
eposeg
dlco
epoct
dlco
significantli
smaller
po
dlco
conclus
copd
patient
moder
air
flow
limit
predict
postop
pulmonari
function
calcul
number
segment
method
might
underestim
compar
actual
measur
conclus
studi
lower
bmi
presenc
svc
syndrom
presenc
anemia
poor
prognost
factor
surviv
background
report
egfr
mutat
frequent
non
small
cell
lung
cancer
nsclc
patient
present
miliari
intrapulmonari
carcinomatosi
often
encount
dissemin
carcinomatosi
well
intrapulmonari
carcinomatosi
studi
aim
investig
clinic
characterist
patient
miliari
intrapulmonari
dissemin
carcinomatosi
method
patient
advanc
nsclc
harbor
egfr
mutat
present
miliari
intrapulmonari
dissemin
carcinomatosi
enrol
respect
septemb
januari
egfr
mutat
exon
confirm
pyroseqeunc
method
genom
dna
extract
paraffinembed
tissu
specimen
clinic
characterist
respons
treatment
outcom
collect
medic
record
result
frequent
mutat
infram
delet
exon
detect
patient
respect
patient
miliari
intrapulmonari
dissemin
carcinomatosi
common
femal
vs
non
smoker
vs
delet
mutat
vs
howev
signific
differ
statist
show
rel
shorter
pf
egfr
tki
median
vs
month
poorer
overal
surviv
median
vs
month
compar
patient
without
miliari
metastasi
multivari
analysi
higher
metabol
tumor
volum
mtv
petct
confirm
independ
predictor
shorter
os
consid
togeth
stage
gender
smoke
statu
conclus
data
indic
nsclc
present
miliari
intrapulmonari
dissemin
carcinomatosi
common
femal
adenocarcinoma
nonsmok
delet
mutat
compar
frequent
detect
howev
statist
signific
differ
pf
egfr
tyrosin
kinas
inhibitor
overal
surviv
less
patient
miliari
intrapulmonari
dissemin
carcinomatosi
compar
patient
without
miliari
metastasi
poor
clinic
cours
might
associ
high
tumor
burden
repres
mtv
total
lesion
glycolysi
introduct
aim
studi
evalu
recent
epidemiolog
lung
cancer
tertiari
referr
hospit
south
korea
method
consecut
patient
newli
diagnos
lung
cancer
june
decemb
seoul
nation
univers
hospit
includ
retrospect
studi
clinic
patholog
characterist
review
result
newli
diagnos
lung
cancer
patient
includ
mean
age
diagnosi
year
old
male
among
patient
neversmok
nonsmal
cell
lung
cancer
group
n
stage
iv
common
adenocarcinoma
major
patholog
diagnosi
compar
data
previou
nation
survey
proport
adenocarcinoma
increas
clinic
characterist
patient
adenocarcinoma
show
younger
age
vs
p
predomin
femal
p
never
smoker
p
better
perform
statu
p
earli
stage
p
conclus
proport
lung
adenocarcinoma
increas
introduct
lung
cancer
one
common
caus
cancer
death
end
life
care
advanc
cancer
patient
would
need
admiss
intens
care
unit
icu
patient
cancer
would
make
distress
emot
qualiti
life
decis
make
difficult
admit
icu
lung
cancer
patient
predict
factor
outcom
need
review
clinic
outcom
characterist
patient
lung
cancer
admit
icu
retrospect
method
retrospect
collect
clinic
data
patient
lung
cancer
admit
icu
januari
novemb
caus
admiss
use
mechan
ventil
presenc
donotresuscit
mortal
includ
postsurg
care
exclud
analysi
result
one
hundr
thirti
one
patient
admit
icu
postop
care
nineti
three
patient
admit
surgic
icu
exclud
analyz
thirti
eight
patient
lung
cancer
nsclc
patient
sclc
patient
patient
inoper
stage
stage
iiib
iv
caus
admiss
acut
respiratori
failur
cardiovascular
diseas
gastrointestin
bleed
neurolog
diseas
mortal
icu
seventeen
patient
famili
notic
code
donotresuscit
icu
admiss
twenti
nine
patient
receiv
mechan
ventil
patient
dead
icu
care
conclus
advanc
lung
cancer
patient
icu
care
would
need
condit
model
icu
mortal
lung
cancer
establish
purpos
welldi
care
introduct
incid
lung
malign
rise
due
preval
smoke
adenocarcinoma
common
histolog
subtyp
worldwid
malaysia
treatment
evolv
convent
chemotherapi
target
therapi
egfr
mutat
establish
predict
factor
use
tyrosin
kinas
inhibitor
tki
egfr
mutat
commonli
associ
asian
preval
among
differ
ethnic
group
among
asian
establish
method
retrospect
studi
patient
seen
respiratori
unit
nov
feb
suffer
lung
malign
includ
characterist
obtain
clinic
card
result
total
patient
includ
analysi
adenocarcinoma
found
n
case
squamou
cell
carcinoma
n
case
overal
lung
carcinoma
suffer
like
male
n
smoker
n
howev
subtyp
adenocarcinoma
femal
p
nonsmok
p
common
patient
egfr
statu
avail
analysi
detect
n
nonsmok
p
egfr
mutat
chines
higher
incid
egfr
mutat
compar
race
p
femal
p
common
mutat
delet
exon
conclus
adenocarcinoma
common
histolog
subtyp
lung
carcinoma
seen
kuch
popul
incid
lung
carcinoma
higher
smoker
nonsmok
analysi
show
nonsmok
chines
significantli
common
patient
egfr
mutat
background
amrubicin
hydrochlorid
amr
key
agent
lung
cancer
nadph
quinon
oxidoreductas
metabol
quinon
structur
contain
amrubicin
amr
amrubicinol
amroh
hypothes
polymorph
may
affect
amrrel
pharmacokinet
clinic
outcom
method
patient
lung
cancer
receiv
amr
dose
mgm
day
day
osaka
citi
univers
hospit
enrol
plasma
sampl
perform
time
point
h
third
amr
inject
concentr
amr
amroh
determin
hplc
method
polymorph
assay
use
realtim
polymeras
chain
reaction
method
result
total
patient
enrol
cc
ct
tt
observ
patient
respect
dose
mgm
administ
patient
mgm
administ
patient
mean
plasma
concentr
amroh
day
dose
mgm
mgm
ngml
respect
p
patient
amr
dose
mgm
plasma
concentr
amroh
day
exhibit
tendenc
toward
relationship
genotyp
valu
cc
ct
tt
ngml
p
cc
relat
decreas
chang
wbc
hemoglobin
platelet
count
p
p
p
respect
signific
correl
observ
genotyp
clinic
outcom
dose
mgm
conclus
polymorph
tendenc
correl
plasma
concentr
amroh
therebi
signific
correl
hematolog
toxic
genotyp
appear
candid
biomark
hematolog
toxic
amr
treatment
dose
mgm
although
nonsmal
cell
lung
cancer
nsclc
tumor
activ
mutat
egfr
highli
respons
egfr
tyrosin
kinas
inhibitor
tki
gefitinib
develop
acquir
resist
almost
inevit
statin
report
antitumor
activ
unknown
whether
simvastatin
revers
gefitinib
resist
nsclc
mutat
egfr
studi
design
investig
overcom
gefitinib
resist
mechanismbas
approach
use
simvastatin
method
effect
simvastatin
apoptosi
signal
examin
annexin
v
bind
assay
immunoblot
analysi
test
effect
sirna
overexpress
akt
simvastatin
treat
gefitinibresist
nsclc
cell
also
evalu
role
survivin
simvastatininduc
apoptosi
gefitinibresist
nsclc
result
addit
simvastatin
gefitinib
enhanc
caspasedepend
apoptosi
nsclc
cell
mutat
simvastatin
also
exert
inhibitori
effect
activ
akt
lead
suppress
activ
express
target
survivin
cyclin
insulin
treatment
akt
overexpress
markedli
increas
surivivn
level
even
presenc
gefitinib
simvastatin
hand
inhibit
akt
sirna
treatment
caus
inhibit
survivin
determin
role
survivin
simvastatininduc
apoptosi
show
proport
apoptot
cell
induc
survivinsirna
combin
gefitinib
simvastatin
greater
theoret
addict
effect
wherea
survivin
upregul
could
confer
protect
apoptosi
induc
gefitinib
simvastatin
conclus
survivin
key
molecul
render
nsclc
cell
mutat
resist
apoptosi
induc
gefitinib
simvastatin
taken
togeth
simvastatin
may
overcom
gefitinib
resist
nsclc
mutat
via
signal
depend
downregul
survivin
induc
apoptosi
lung
cancer
among
common
cancer
world
search
effect
safe
drug
chemoprevent
therapi
lung
cancer
becom
import
studi
bovin
lactoferrin
blf
use
vitro
vivo
approach
investig
activ
lung
cancer
human
lung
cancer
cell
line
express
high
level
vascular
endotheli
growth
factor
vegf
hypoxia
use
vitro
system
blf
treatment
strain
transgen
mice
carri
human
gene
induc
pulmonari
tumor
use
vivo
lung
cancer
therapi
model
found
blf
significantli
decreas
prolifer
cell
decreas
express
vegf
protein
dosedepend
manner
furthermor
oral
administr
blf
mgkg
bodi
weight
time
week
mo
transgen
mice
overexpress
significantli
elimin
express
suppress
format
tumor
addit
treatment
blf
significantli
decreas
level
proinflammatori
cytokin
tumor
necrosi
antiinflammatori
cytokin
level
proinflammatori
antiinflammatori
cytokin
also
reduc
treatment
blf
decreas
level
tumor
necrosi
cytokin
result
limit
inflamm
restrict
growth
lung
cancer
result
reveal
blf
inhibitor
angiogenesi
block
lung
cell
inflamm
consider
potenti
therapeut
use
treatment
lung
cancer
background
signal
transduc
activ
transcript
activ
frequent
found
human
lung
cancer
associ
increas
metastasi
reduc
surviv
molecular
mechan
enhanc
cancer
invas
well
character
method
express
microrna
target
gene
measur
realtim
rtpcr
protein
level
studi
western
blot
luciferas
report
assay
use
confirm
direct
target
microrna
gelatin
zymographi
use
studi
matrix
metalloproteinas
mmp
activ
transwel
assay
use
investig
cell
migrat
invas
result
find
express
neg
associ
express
endogen
mmp
inhibitor
reversioninduc
cysteinerich
protein
kazal
motif
reck
set
lung
cancer
cell
line
enforc
express
decreas
endogen
mmp
inhibitor
reck
protein
mrna
level
cell
convers
inhibitor
increas
reck
protein
cell
demonstr
upregul
repress
reck
via
posttranscript
inhibit
reck
report
activ
assay
suggest
reck
direct
repress
target
deliveri
reduc
reck
protein
level
transfect
restor
downregul
reck
attenu
mmp
activ
migrat
invas
cell
cell
suggest
critic
invas
conclus
demonstr
upregul
one
mechan
promot
cancer
invas
addit
show
reck
import
mediat
cell
invas
target
axi
may
help
treatment
lung
cancer
cxc
chemokin
angiogen
growth
factor
overexpress
variou
human
cancer
includ
nonsmal
cell
lung
cancer
nsclc
recent
shown
activ
kra
mutat
induc
overexpress
promot
cell
prolifer
migrat
nsclc
cell
current
studi
evalu
clinicopatholog
prognost
signific
express
lung
adenocarcinoma
relationship
mutat
kra
egfr
mrna
express
examin
quantit
rtpcr
use
surgic
specimen
obtain
lung
adenocarcinoma
patient
evalu
associ
express
clinicopatholog
featur
kra
egfr
mutat
statu
surviv
express
predominantli
express
lung
adenocarcinoma
elderli
patient
pleural
involv
vascular
invas
differenti
express
age
promin
nonsmok
smoker
nonsmok
subgroup
posit
correl
level
age
predominantli
express
lung
adenocarcinoma
kra
mutat
compar
egfr
mutat
wildtyp
egfrkra
posit
correl
level
age
subgroup
krasmut
egfrmut
diseasefre
surviv
df
overal
surviv
os
significantli
shorter
lung
adenocarcinoma
patient
high
express
low
express
furthermor
lung
adenocarcinoma
patient
krasmutanthigh
significantli
shorter
pf
os
compar
wildtyp
kraslow
cox
regress
analysi
reveal
express
independ
prognost
marker
lung
adenocarcinoma
find
suggest
express
associ
certain
clinicopatholog
featur
includ
age
unfavor
prognost
marker
oncogen
krasdriven
lung
adenocarcinoma
background
aim
studi
aminopeptidas
n
apn
report
play
import
role
tumor
cell
invas
tumor
angiogenesi
express
associ
poor
prognosi
patient
colon
pancreat
lung
cancer
aim
studi
evalu
antitumor
effect
human
antiapn
antibodi
mous
tumor
model
method
subcutan
tumor
tail
vein
metastasi
model
establish
immun
defici
mice
use
melanoma
cell
stabli
transfect
apn
cell
highli
express
apn
tumorbear
mice
intraperiton
administ
human
antibodi
apn
size
subcutan
tumor
measur
number
tumor
nodul
lung
surfac
count
tumor
section
immunostain
antibodi
assess
microvessel
densiti
result
administr
antiapn
antibodi
reduc
size
subcutan
tumor
number
lung
surfac
nodul
mice
bear
microvessel
densiti
tumor
also
reduc
conclus
human
antiapn
antibodi
suppress
growth
tumor
highli
express
apn
probabl
inhibit
angiogenesi
background
lymph
node
metastasi
one
major
factor
prognosi
facilit
lymphangiogenesi
howev
precis
mechan
well
understood
present
studi
investig
role
prostaglandin
prostaglandin
e
receptor
format
premetastat
nich
facilit
lymph
node
metastasi
lung
cancer
method
lewi
lung
carcinoma
llc
x
cell
suspens
orthotop
introduc
lung
parenchyma
wild
type
mice
wt
receptor
knock
mice
via
limit
skin
incis
without
thoracotomi
follow
direct
punctur
intercost
space
result
mediastin
lymph
node
metastasi
format
significantli
suppress
inhibitor
celecoxib
mgkgday
treat
mice
express
significantli
suppress
celecoxib
treat
mice
p
antagonist
amd
decreas
lymph
node
metastasi
format
furthermor
accumul
suppress
inhibitor
treat
mice
vitro
agonist
stimul
concentr
immatur
dc
significantli
enhanc
agonist
compar
wt
transplant
significantli
suppress
mediastin
lymph
node
metastasi
format
compar
wt
transplant
wt
mice
conclus
result
suggest
premetastat
nich
format
mediastin
lymph
node
induc
bone
marrow
deriv
immatur
dendrit
cell
via
signal
induct
thu
inhibitor
antagonist
andor
antagonist
may
becom
one
option
suppress
lymph
node
metastasi
method
express
nestin
achaetescut
homolog
studi
lung
cancer
cell
line
assess
function
nestin
short
hairpin
rna
shrna
target
nestin
transfect
two
sclc
cell
line
clone
cell
show
appar
downregul
nestin
obtain
nestin
express
also
studi
immunohistochem
surgic
resect
sclc
primari
tumor
metastat
sclc
tumor
obtain
autopsi
case
result
nestin
express
nine
sclc
cell
line
nestin
express
level
significantli
higher
sclc
cell
line
nonsmallcel
lung
cancer
cell
line
p
statist
signific
posit
correl
express
level
nestin
sclc
cell
line
nestin
knockdown
cell
creat
transfect
shrna
exhibit
decreas
invas
cell
prolifer
capabl
furthermor
nestin
detect
sclc
tumor
cell
tumor
vessel
clinic
tumor
specimen
conclus
nestin
express
sclc
associ
neuroendocrin
featur
particip
malign
phenotyp
includ
cell
growth
therefor
nestin
may
promis
therapeut
target
sclc
object
previou
studi
report
common
chronic
condit
found
among
hospit
patient
due
novel
influenza
asthma
howev
studi
includ
concurr
control
group
thu
investig
associ
asthma
statu
sever
influenza
method
studi
design
multisit
casecontrol
studi
case
patient
posit
pcr
influenza
admit
icu
gener
ward
diagnosi
influenza
januari
decemb
control
patient
posit
pcr
influenza
admit
hospit
result
case
includ
icu
patient
inpati
control
met
match
criteria
avail
case
mean
age
year
femal
case
comorbid
condit
case
asthma
stratifi
analysi
comorbid
condit
asthma
show
among
without
comorbid
condit
case
control
asthma
ci
p
wherea
among
subject
one
comorbid
condit
one
control
asthma
case
asthma
p
conclus
asthma
may
associ
sever
influenza
among
without
nonasthma
comorbid
condit
howev
limit
sampl
size
allow
studi
fulli
establish
statist
signific
still
recommend
asthmat
prioriti
group
influenza
vaccin
treatment
chi
ching
gan
nora
said
wai
mun
wong
jaleelahbeevi
mohd
noor
shu
yi
lee
salimah
maidin
tow
keang
lim
nation
univers
hospit
singapor
nation
healthcar
group
singapor
studi
examin
impact
onsit
nurs
review
educ
postemerg
room
er
outcom
patient
acut
asthma
exacerb
method
report
versu
studi
day
er
readmiss
outpati
asthma
clinic
attend
adult
patient
discharg
er
success
treatment
acut
asthma
exacerb
compar
result
year
versu
introduct
onsit
asthma
educ
servic
er
discharg
er
asthma
nurs
educ
taught
asthma
control
medic
inhal
techniqu
asthma
first
aid
acut
attack
give
asthma
clinic
review
date
compar
result
patient
receiv
facetofac
versu
telephon
versu
educ
chang
asthma
manag
protocol
er
year
result
follow
intervent
significantli
increas
rate
er
readmiss
versu
p
outpati
asthma
clinic
attend
versu
p
versu
respect
er
readmiss
rate
versu
versu
p
outpati
asthma
clinic
attend
rate
versu
versu
p
patient
receiv
facetofac
versu
telephon
versu
educ
respect
signific
differ
sex
age
ethnic
composit
conclus
onsit
nurs
educ
improv
patient
safeti
follow
discharg
er
onsit
nurs
educ
associ
er
revisit
poor
asthma
control
better
asthma
clinic
attend
intens
asthma
educ
significantli
relat
safer
patient
behavior
background
aim
studi
asthma
chronic
inflammatori
disord
airway
mani
cell
cellular
element
play
role
pathogenesi
chronic
inflamm
associ
airway
hyperrespons
lead
recurr
episod
wheez
breathless
chest
tight
cough
caus
widespread
variabl
often
revers
airflow
limit
aim
studi
show
frequenc
season
distribut
outpati
asthma
patient
appli
pulmonolog
clinic
method
outpati
record
pulmonari
medicin
clinic
analyz
asthma
patient
record
taken
account
due
low
case
number
summer
time
two
summer
season
includ
studi
asthma
case
divid
followup
exacerb
group
group
season
distribut
analyz
result
patient
appli
clinic
month
period
total
patient
diagnos
asthma
appli
asthma
exacerb
asthma
followup
asthma
total
case
number
spring
march
april
may
summer
june
juli
august
fall
septemb
octob
novemb
winter
decemb
januari
februari
season
asthma
exacerb
rate
spring
summer
fall
winter
conclus
patient
asthma
diagnosi
asthma
followup
rate
close
asthma
exacerb
famili
practition
activ
particip
asthma
treatment
followup
might
reason
low
case
number
followup
group
asthma
acut
exacerb
lowest
summer
highest
winter
moder
springfal
high
asthma
exacerb
rate
winter
might
caus
cold
weather
condit
increas
infecti
diseas
allergen
airpollut
lower
acut
exacerb
asthma
achiev
collabor
work
patient
respiratori
specialist
also
famili
practition
object
serum
eosinophil
cation
protein
level
asthma
bronchial
patient
compar
healthi
control
relat
serum
eosinophil
cation
protein
level
serum
total
ige
level
serum
total
eosinophil
count
evalu
patient
method
serum
eosinophil
cation
protein
ecp
level
serum
total
ige
level
serum
total
eosinophil
count
total
patient
asthma
asthma
allerg
rhiniti
age
femal
male
femal
male
healthi
subject
compar
result
mean
serum
ecp
level
patient
asthma
bronchial
significantli
higher
control
group
p
level
serum
ecp
serum
total
ige
serum
total
eosinophil
count
patient
significantli
higher
control
group
serum
ecp
level
high
control
group
asthma
bronchial
group
signific
eosinophilia
conclus
asthma
bronchial
chronic
inflammatori
airway
diseas
eosinophil
play
key
role
pathogenesi
asthma
bronchial
degre
inlamm
may
associ
protein
deriv
eosinophil
ecp
etc
studi
conduct
patient
asthma
allerg
rhiniti
ecp
level
blood
bronchoalveolar
lavag
found
increas
studi
suggest
conveni
monitor
diseas
activ
serum
ecp
level
eosinophil
count
sever
studi
increas
serum
ecp
level
patient
asthma
allerg
rhiniti
correl
serum
eosinophil
count
serum
total
ige
level
studi
accord
studi
literatur
serum
ecp
serum
total
ige
level
serum
total
eosinophil
count
patient
asthma
significantli
higher
control
group
introduct
asthma
chronic
condit
signific
morbid
mortal
high
econom
burden
singapor
asthma
common
problem
preval
high
among
children
among
adult
left
uncheck
diseas
could
becom
emerg
problem
epidem
proport
children
adult
near
futur
method
asthmat
child
caregiv
attend
high
risk
asthma
clinic
kkh
march
may
agre
particip
studi
given
set
questionnair
answer
result
mother
main
caregiv
parent
father
other
caregiv
agre
counsel
reinforc
asthma
resourc
nurs
helpfulth
read
materi
isar
given
isar
benefici
adequ
care
giver
comfort
see
asthma
resourc
nurs
clinic
assess
evalu
asthma
clinic
care
giver
said
learn
best
would
like
learn
asthma
care
talk
asthma
resourc
nurs
care
giver
use
written
asthma
action
plan
waap
manag
child
mild
asthma
attack
care
giver
confid
use
waap
guid
manag
child
condit
conclus
success
asthma
manag
cooper
effort
patient
famili
health
care
profession
involv
asthma
resourc
nurs
bridg
gap
patient
doctor
provid
comprehens
educ
maintain
continu
care
background
aim
studi
nitric
oxid
report
indic
asthmat
airway
inflamm
furthermor
distal
airway
calv
use
indic
distal
airway
inflamm
product
report
varieti
resid
cell
inflammatori
cell
synthas
no
exist
three
form
nno
eno
ino
product
steroid
naiv
snba
thought
mainli
inosexpress
bec
howev
report
point
import
constitut
no
anim
model
investig
correl
no
mrna
express
calv
distal
bec
method
bronchial
brush
bal
tblb
perform
ba
patient
includ
snba
steroidtr
asthma
stba
bec
select
isol
distal
airway
use
sheath
brush
examin
stain
hansel
stain
ino
express
immunohistochemistri
ihc
total
rna
extract
bec
bal
cell
ino
mrna
measur
qrtpcr
analyz
correl
calv
no
mrna
express
bec
result
signific
inflammatorycel
infiltr
note
express
ino
protein
distal
airway
mainli
bec
also
macrophag
eosinophil
quantit
rtpcr
show
significantli
higher
ino
mrna
express
bec
bal
cell
increas
express
nno
eno
ino
snba
ino
show
signific
correl
calv
among
three
no
ino
mrna
express
highest
distal
bec
conclus
distal
airway
asthmat
bec
main
sourc
ino
thought
main
enzym
result
cough
va
residu
volum
improv
significantli
group
degre
improv
differ
among
group
andax
improv
cough
sensit
decreas
montelukast
group
feno
fell
significantli
high
dose
bud
montelukast
group
former
improv
latter
spirometri
airway
respons
indic
io
unaffect
group
cough
tend
relaps
often
montelukast
group
follow
period
conclus
cva
effect
montelukast
compar
inhal
corticosteroid
vari
dose
least
shortterm
background
treatment
guidelin
asthma
recommend
stepdown
therapi
wellcontrol
asthma
patient
howev
strategi
stepdown
therapi
well
defin
investig
whether
wellcontrol
patient
mild
persist
asthma
treat
inhal
corticosteroid
ic
accept
stepdown
therapi
reduct
dose
ic
leukotrien
receptor
antagonist
ltra
pranlukast
pl
method
recruit
adult
patient
mild
persist
asthma
well
control
least
month
low
daili
dose
fluticason
propion
fp
therapeut
equival
dose
budesonid
bud
ciclesonid
cic
randomli
assign
month
either
switch
pl
patient
pl
group
inhal
fp
daili
therapeut
equival
dose
bud
cic
patient
ic
group
studi
period
patient
monitor
peak
expiratori
flow
respiratori
resist
reactanc
forc
oscil
techniqu
fot
fraction
exhal
nitric
oxid
feno
everi
month
result
studi
period
patient
treatment
group
requir
hospit
admiss
acut
exacerb
asthma
treatment
system
corticosteroid
rate
treatment
failur
ic
group
pl
group
respect
signific
differ
group
feno
level
pl
group
significantli
increas
ic
group
howev
signific
differ
group
lung
function
fot
conclus
patient
mild
persist
asthma
well
control
low
dose
ic
switch
pl
safe
howev
pl
group
fail
maintain
well
control
month
studi
need
investig
therapeut
efficaci
ltra
mono
therapi
stepdown
therapi
use
protocol
specif
tailor
patient
mild
persist
asthma
object
pathophysiolog
cough
variant
asthma
cva
poorli
understood
previous
identifi
featur
cvaa
heighten
cough
respons
bronchoconstrict
studi
investig
whether
measur
cough
sensit
methacholin
mch
may
help
diagnosi
cough
variant
asthma
method
measur
cough
sensit
capsaicin
exhal
nitric
oxid
eno
bronchial
revers
bronchodil
bronchial
respons
mch
cough
sensit
mch
perform
patient
chronic
nonproduct
cough
n
chronic
nonproduct
cough
respond
bronchodil
therapi
without
wheez
audibl
auscult
diagnos
cva
receiv
oper
curv
roc
analysi
measur
discrimin
cva
chronic
nonproduct
cough
perform
measur
cough
sensit
mch
perform
follow
mch
induc
bronchoconstrict
detect
use
partial
full
flowvolum
curv
defin
fall
mild
bronchoconstrict
expiratori
flow
partial
flow
volum
curv
residu
volum
level
cough
count
perform
inhal
mch
area
curv
cough
sensit
mch
eno
bronchial
revers
sensit
specif
cough
sensit
mch
discrimin
cva
chronic
nonproduct
cough
respect
conclus
measur
cough
sensit
mch
cough
count
mild
bronchoconstrict
use
discrimin
cva
chronic
nonproduct
cough
background
aim
studi
determin
whether
asthma
elderli
distinct
clinic
characterist
associ
airflow
limit
afl
character
outpati
asthma
elderli
clinic
histori
pulmonari
function
test
impuls
oscillometri
blood
analysi
method
outpati
age
older
asthma
n
men
women
mean
sd
age
survey
afl
defin
postbronchodil
postbd
accord
global
initi
obstruct
lung
diseas
impuls
oscillometri
spirometri
assess
asthmat
afl
year
male
n
asthmat
without
afl
year
male
n
shortact
stimul
treatment
multipl
regress
analysi
perform
forward
stepwis
approach
variabl
significantli
relat
afl
univari
analysi
result
mean
age
asthma
afl
significantli
higher
asthma
without
afl
rate
allerg
rhiniti
ar
asthma
ar
significantli
lower
asthma
without
afl
postbd
relat
age
ar
postbd
fvc
postbd
mmf
postbd
postbd
relat
afl
age
ar
postbd
relat
age
ar
afl
postbd
valu
impuls
oscillometri
relat
ar
afl
postbd
fre
relat
age
conclus
postbd
elderli
asthmat
relat
age
although
postbd
fvc
relat
postbd
valu
impuls
oscillometri
asthmat
relat
afl
obes
known
system
inflammatori
diseas
also
well
known
risk
factor
bronchial
asthma
live
bodi
alway
affect
intern
extern
stress
redox
system
protect
live
bodi
oxid
stress
inflamm
close
relat
oxid
stress
obes
one
major
factor
intern
oxid
stress
aim
present
studi
estim
relationship
obes
oxid
stress
bronchial
asthma
patient
bronchial
asthma
recruit
outpati
clinic
depart
estim
bmi
blood
level
adipokin
leptin
adiponectin
mdaldl
sod
patient
obes
risk
factor
hospit
asthma
attack
femal
patient
present
studi
obes
patient
show
significantli
higher
level
serum
leptin
significantli
lower
level
serum
adiponectin
compar
notobes
patient
differ
serum
adipokin
signific
femal
subject
gender
differ
observ
oxid
stress
bronchial
asthma
present
studi
took
systeinyl
leukotrien
receptor
antagonist
ltra
show
higher
serum
adiponectin
level
without
ltra
therapi
ltra
may
help
adiponectin
product
reliev
airway
oxid
stress
bronchial
asthma
back
ground
asthma
control
test
act
use
quit
frequent
clinic
evalu
asthma
control
state
aim
confirm
import
act
examin
whether
question
necessari
evalu
criteria
act
patient
stabl
asthma
subject
eightytwo
patient
bronchial
asthma
whose
symptom
stabl
month
averag
year
old
method
conduct
act
subject
analyz
point
addit
compar
reevalu
point
total
control
exclud
result
patient
point
point
point
point
well
control
one
hand
patient
got
point
patient
point
reevalu
except
ratio
total
control
point
sever
indic
consider
recommend
criteria
act
exclud
effect
one
current
act
clinic
evalu
total
control
evalu
current
act
howev
becam
higher
evalu
act
exclud
evalu
act
trend
lower
lower
accord
sever
aspirin
induc
asthma
tomoyuki
minezawa
sumito
isogai
yoshikazu
niwa
sayako
morikawa
tomoko
takeyama
teppei
ymaguchi
mariko
morishita
takuya
okamura
sakurako
uozu
yuki
mieno
tami
hoshino
masamichi
hayashi
toru
nakanishi
background
although
challeng
test
use
nonsteroid
antiinflammatori
drug
nsaid
crucial
diagnosi
aspirininduc
asthma
aia
also
drawback
term
possibl
side
effect
therefor
altern
invitro
diagnost
method
aia
await
method
nineteen
stabl
nonaia
patient
male
femal
mean
age
year
aia
patient
male
femal
mean
age
year
enrol
studi
express
peripheralblood
granulocyt
administr
aspirin
differ
concentr
vitro
examin
use
flowcytometri
result
aspirin
induc
signific
increas
express
eosinophil
neg
granulocyt
aia
patient
one
nonaia
patient
increas
express
eosinophil
aspirin
administr
suppress
dosedepend
manner
conclus
measur
express
peripheralblood
eosinophil
show
high
sensit
specif
diagnos
aia
although
method
requir
laboratori
facil
flowcytometri
may
use
diagnosi
aia
without
side
effect
addit
may
involv
regul
express
eosinophil
aspirin
administr
omalizumab
success
use
supplementari
therapi
patient
poorli
control
atop
asthma
major
commerci
avail
ige
assay
measur
free
ige
omalizumabbound
ige
total
ige
measur
avail
therapeut
monitor
aim
therapeut
monitor
antiig
therapi
newli
establish
elisa
free
ige
employ
recombin
human
solubl
captur
antigen
biotinyl
polyclon
antiig
antibodi
detect
assay
technic
robust
lowest
limit
detect
spkikerecoveri
rate
serum
determin
use
newli
establish
elisa
measur
serum
free
ige
level
five
patient
everi
week
first
inject
omalizumab
omalizumab
significantli
reduc
serum
free
ige
level
prior
second
omalizumab
inject
patient
also
measur
serum
free
ige
level
patient
treat
omalizumab
month
believ
benefit
omalizumab
treatment
sever
asthma
need
keep
serum
free
ige
concentr
patient
longterm
use
omalizumab
serum
free
ige
concentr
higher
free
ige
elisa
allow
us
easili
quantifi
free
ige
thu
monitor
patient
treat
omalizumab
data
suggest
reevalu
inject
dose
would
requir
longterm
use
omalizumab
masamitsu
tatewaki
hirokuni
hirata
mineaki
watanab
naruo
yoshida
tatsuya
yokoyama
takuya
background
inflammatori
cytokin
chemokin
report
play
import
role
pathogenesi
bronchial
asthma
howev
criteria
classif
smoker
atop
bronchial
asthma
defin
studi
compar
level
sever
cytokin
found
bronchoalveolar
lavag
bal
fluid
patient
classifi
bronchial
asthma
method
cell
subpopul
bal
fluid
count
bal
fluid
level
regul
normal
cell
express
secret
rant
measur
use
bead
suspens
array
asthma
patient
male
femal
mean
age
year
never
smoke
asthma
patient
male
femal
mean
age
year
ex
current
smoker
brinkman
index
bi
asthma
patient
male
femal
mean
age
year
current
heavi
smoker
bi
relationship
assess
spearman
rank
correl
analysi
result
number
lymphocyt
bal
cell
subpopul
never
smoker
significantli
higher
heavi
smoker
number
neutrophil
significantli
higher
heavi
smoker
never
smoker
level
rant
significantli
higher
never
smoker
heavi
smoker
addit
level
rant
never
smoker
significantli
higher
atop
asthma
patient
nonatop
asthma
patient
good
correl
note
rant
lymphocyt
atop
asthma
patient
never
smoker
conclus
differ
cell
type
bal
fluid
well
level
rant
asthma
patient
without
smoke
might
reflect
pathogenesi
background
aim
studi
ffvi
combin
inhal
corticosteroidlongact
agonist
develop
oncedaili
asthma
therapi
analysi
evalu
ethnic
sensit
ffvi
ff
alon
asthma
patient
japan
korea
method
pool
analysi
randomis
doubleblind
multicentr
phase
iibiiia
trial
efficaci
data
three
studi
compar
patient
japan
n
notjapan
countri
n
chang
baselin
trough
week
ffvi
mcg
ff
mcg
placebo
analys
two
studi
use
ancova
model
term
baselin
region
gender
age
treatment
group
studi
region
treatment
interact
ffvi
mcg
ff
mcg
data
one
studi
safeti
data
six
studi
compar
patient
japankorea
n
notjapankorea
n
pharmacokinet
pharmacodynam
data
collect
background
allerg
sensit
import
step
pathogenesi
asthma
howev
littl
known
molecul
critic
regul
establish
allerg
sensit
airway
thu
investig
global
gene
express
analysi
identifi
candid
gene
signal
pathway
involv
hous
dust
mite
extract
hdm
induc
allerg
airway
sensit
mice
method
sensit
challeng
mice
hdm
salin
control
airway
hdmsensit
challeng
mice
got
asthmalik
respons
includ
eosinophil
airway
inflamm
airway
hyperrespons
day
day
first
sensit
day
second
sensit
day
challeng
extract
total
rna
lung
tissu
perform
mrna
microarray
analysi
data
analysi
perform
use
genespr
ingenu
pathway
analysi
result
repeat
hdm
instil
airway
induc
stepwis
upregul
myeloid
lipopolysaccharidebind
compon
tolllik
receptor
signal
complex
conclus
data
suggest
innat
immunerel
gene
includ
might
regul
establish
allerg
airway
sensit
hdm
mice
background
microrna
mirna
report
use
therapeut
diagnost
target
patient
asthma
exosom
mirna
serum
stabl
might
use
biomark
howev
littl
known
regard
exosom
mirna
serum
suitabl
realtim
monitor
allerg
inflamm
airway
therefor
investig
mirna
microarray
analysi
identifi
candid
exosom
mirna
serum
involv
allerg
inflamm
airway
mice
method
sensit
challeng
mice
hous
dust
mite
extract
hdm
salin
control
day
collect
lung
tissu
serum
extract
total
rna
lung
tissu
exosom
serum
perform
mirna
microarray
analysi
use
extract
rna
data
analysi
perform
use
genespr
softwar
gene
network
analysi
perform
use
ingenu
pathway
analysi
result
identifi
hdminduc
mirna
lung
exosom
serum
conclus
data
suggest
exosom
mirna
serum
identifi
might
new
diagnost
biomark
therapeut
target
allerg
inflamm
airway
yasuhiro
gon
shuichiro
maruoka
yoshitaka
shintani
daisuk
koyama
tadataka
sekiyama
hisato
hiranuma
toshio
inou
ikuko
takeshita
exosom
cellular
secretori
vesicl
contain
microrna
mirna
secret
exosom
abl
transfer
mirna
recipi
cell
consequ
transfer
microrna
potenti
modul
function
cell
hypothes
airway
secret
exosom
deriv
mirna
profil
allerg
airway
inflamm
might
differ
normal
condit
studi
exosom
mirna
profil
mice
hous
dust
mite
hdm
induc
allerg
airway
inflamm
exosom
obtain
bronchial
alveolar
lavag
fluid
balf
mice
day
last
allergen
exposur
number
purifi
exosom
increas
time
hdmexpos
mice
compar
sham
mice
exosom
mirna
balf
analyz
mirna
array
microrna
probe
profil
exosom
mirna
hdm
expos
mice
significantli
differ
sham
mice
interestingli
increas
exosom
mirna
hdm
exposur
p
decreas
invers
lung
tissu
allerg
inflamm
contrast
decreas
exosom
mirna
hdm
exposur
less
p
increas
invers
lung
tissu
observ
suggest
possibl
exosom
mirna
select
secret
airway
fluid
allerg
inflammatori
condit
regul
cellular
transcriptom
select
secret
exosom
mirna
might
involv
pathogenesi
allerg
inflamm
airway
eosinophil
specif
accumul
site
inflamm
hypothes
ua
act
activ
eosinophil
method
eosinophil
isol
peripher
blood
normal
individu
incub
presenc
absenc
monosodium
urat
msu
uric
acid
crystal
releas
atp
cytokin
evalu
result
eosinophil
expos
msu
crystal
rapidli
ie
within
min
exposur
releas
atp
extracellular
milieu
eosinophil
incub
msu
crystal
incub
uric
acid
solut
produc
cytokin
chemokin
also
produc
eosinophil
incub
msu
crystal
conclus
ua
stimul
eosinophil
releas
atp
product
cytokin
thu
human
eosinophil
may
respond
particul
damageassoci
endogen
danger
signal
respons
eosinophil
tissu
damag
may
explain
selfperpetu
natur
chronic
inflamm
certain
human
diseas
asthma
background
aim
studi
pirfenidon
antifibrot
drug
antiinflammatori
antioxid
effect
delay
fibrosi
idiopath
pulmonari
fibrosi
ipf
patient
ipf
greater
cough
reflex
sensit
inhal
capsaicin
healthi
peopl
cough
independ
predictor
ipf
diseas
progress
howev
effect
pirfenidon
cough
reflex
sensit
unknown
method
challeng
aerosol
antigen
activ
sensit
guinea
pig
pirfenidon
administ
intraperiton
cough
reflex
sensit
measur
h
challeng
bronchoalveolar
lavag
bal
perform
tracheal
tissu
collect
result
pirfenidon
suppress
capsaicininduc
increas
cough
reflex
sensit
dosedepend
manner
addit
increas
level
prostaglandin
substanc
p
leukotrien
histamin
bal
fluid
dose
depend
suppress
pirfenidon
decreas
neutral
endopeptidas
activ
tracheal
tissu
also
allevi
pirfenidon
treatment
total
number
cell
compon
bal
fluid
influenc
conclus
result
suggest
pirfenidon
amelior
isol
cough
base
increas
cough
reflex
sensit
associ
allerg
airway
diseas
potenti
reliev
chronic
cough
ipf
patient
often
increas
cough
reflex
sensit
prospect
studi
coughreliev
effect
pirfenidon
patient
ipf
therefor
warrant
background
aim
studi
well
known
women
suffer
sever
asthma
frequent
men
interleukin
il
cell
cell
axi
may
play
import
role
develop
chronic
inflammatori
diseas
includ
asthma
aim
studi
investig
whether
differ
asthma
sever
sex
associ
product
experiment
model
allerg
asthma
method
eosinophil
count
cytokin
profil
bronchoalveolar
lavag
bal
fluid
assess
ovalbumin
ova
sensit
challeng
male
femal
mice
wildtyp
mice
result
aerosol
ova
challeng
caus
mark
eosinophilia
bal
fluid
number
eosinophil
bal
fluid
significantli
higher
male
mice
male
wt
mice
hand
signific
differ
number
eosinophil
bal
fluid
femal
mice
femal
wt
mice
level
bal
fluid
tend
lower
male
mice
male
wt
mice
signific
differ
level
femal
mice
femal
wt
mice
conclus
differ
sever
eosinophil
airway
inflamm
sex
may
associ
differ
product
experienc
two
case
femor
neck
fractur
extrem
elderli
patient
develop
pulmonari
complic
rightsid
pleuriti
one
bilater
aspir
pneumonia
first
case
old
woman
case
left
femor
neck
fractur
complic
rightsid
recurr
pleuriti
perform
sever
pleural
punctur
administ
antibiot
pleuriti
partli
due
parapneumon
effus
surgeri
fractur
subsequ
perform
pleural
effus
recur
patient
discharg
second
case
old
man
whose
right
femor
fractur
complic
aspir
pneumonia
bilater
lung
famili
wish
oper
patient
extrem
age
perform
ivh
administr
antibiot
tazpipc
pipc
conserv
patient
improv
gradual
oral
feed
becam
possibl
rehabilit
leg
gradual
increas
adl
accord
spontan
heal
femor
neck
fractur
sinc
supin
posit
requir
femor
fractur
protect
decubitu
skin
care
also
need
case
treat
elderli
femor
fractur
earli
stage
pulmonari
complic
pneumonia
etc
might
prevent
report
also
sever
refer
background
nurs
healthcareassoci
pneumonia
nhcap
common
elderli
patient
also
associ
aspir
drug
resist
antibiot
moxifloxacin
mflx
respiratori
quinolon
effect
anaerob
addit
unnecessari
reduc
amount
mflx
even
patient
renal
dysfunct
therefor
assess
efficaci
safeti
mflx
patient
nhcap
patient
method
nhcap
patient
mild
moder
sever
adrop
system
jr
communityacquir
pneumonia
guidelin
visit
hospit
septemb
march
clinic
symptom
chest
xray
andor
ct
peripher
white
red
blood
cell
platelet
count
serum
crp
ast
alt
bun
creatinin
evalu
clinic
efficaci
mflx
categor
effect
ineffect
undetermin
patient
age
year
old
consid
age
patient
side
effect
also
evalu
mflx
treatment
collect
sputum
sampl
also
bacteriolog
evalu
result
forti
patient
evalu
averag
age
yea
old
malefemal
one
comorbid
median
durat
administr
day
day
efficaci
patient
efficaci
age
group
age
year
old
age
year
old
pneumonia
sever
group
adrop
system
mild
moder
diarrhea
observ
one
patient
start
mflx
administr
sputum
sampl
investig
patient
gramposit
cocci
sampl
gramneg
rod
sampl
candida
one
sampl
detect
sampl
sampl
show
aureu
pneumonia
alphastreptococcu
k
pneumonia
h
influenza
catarrhali
p
aeruginosa
conclus
mflx
effect
safe
patient
nhcap
femal
diagnos
system
sclerosi
collagen
vascular
diseas
associ
interstiti
pneumonia
administr
prednisolon
mgday
mizoribin
mgday
initi
sinc
cavitari
mass
lesion
recogn
right
lower
lobe
lung
august
becam
larger
size
undergon
bronchoscopi
examin
cultur
bronchial
wash
fluid
cavitari
lesion
result
posit
mycobacterium
avium
intracellular
aspergillu
fumigatu
terreu
time
cultur
result
aspergillu
spp
consid
colon
diagnos
pulmonari
nontuberculosi
mycobacteriosi
administ
clarithromycin
mgday
rifampicin
mgday
ethambutol
mgday
februari
develop
right
hydropneumothorax
microbi
examin
reveal
gaffki
number
right
pleural
effus
avium
cultur
right
pneumothorax
empyema
refractori
drainag
therapi
patient
receiv
right
lower
lobectomi
five
month
surgeri
infiltr
right
middl
lobe
gradual
deterior
develop
fistula
dead
space
right
thorax
pleural
effus
also
increas
fumigatu
isol
right
pleural
effus
patient
diagnos
aspergillu
empyema
intraven
micafungin
mcfg
start
howev
diseas
state
unrespons
conserv
medic
manag
perform
open
window
thoracostomi
debrid
focu
pariet
pleura
addit
local
antifung
treatment
daili
dress
amphotericin
b
immers
gauz
start
combin
system
mcfg
administr
antifung
treatment
continu
month
patient
gradual
improv
although
aspergillu
empyema
rare
lifethreaten
infecti
diseas
standard
therapeut
strategi
exist
report
aspergillu
empyema
case
success
treat
open
window
thoracostomi
system
local
antimicrobi
administrationand
review
literatur
background
aim
studi
human
metapneumoviru
hmpv
discov
member
paramyxovirida
famili
accumul
data
show
hmpv
one
common
caus
agent
human
respiratori
tract
infect
although
lot
studi
reveal
clinic
characterist
hmpv
infect
children
report
focus
adult
outbreak
hmpv
infect
occur
longterm
care
facil
mental
handicap
patient
okinawa
locat
subtrop
region
japan
evalu
clinic
radiolog
find
patient
hmpv
infect
method
rna
extract
nasopharyng
swab
use
dnarna
elut
kit
analyz
multiplex
pcr
kit
seeplex
onestep
ace
detect
seegen
inc
seoul
retrospect
evalu
medic
nurs
record
patient
facil
outbreak
period
chest
xray
ct
scan
analyz
three
physician
special
pulmonari
diseas
result
outbreak
occur
march
april
patient
symptom
fever
run
nose
sore
throat
cough
hmpvrna
detect
patient
symptomat
patient
total
pneumonia
chest
xray
bilater
shadow
spread
radial
bilater
hili
bronchial
wall
thicken
observ
patient
pneumonia
ct
scan
perform
patient
segment
distribut
parenchym
abnorm
commonli
observ
bacteri
coinfect
detect
patient
streptococcu
pneumonia
isol
patient
compar
patient
without
pneumonia
patient
pneumonia
older
abnorm
laboratori
examin
conclus
hmpv
caus
pneumonia
high
rate
bilater
bronchopneumonia
pattern
characterist
find
background
aim
studi
respiratori
system
constantli
attack
multipl
infecti
agent
attack
lead
infect
nose
paranas
sinus
ear
pharynx
nasopharynx
call
upper
respiratori
tract
infect
urti
cough
promin
symptom
patient
urti
appli
pulmonari
medicin
outpati
clinic
aim
studi
express
outpati
urti
rate
pulmonari
medicin
clinic
method
outpati
record
pulmonari
medicin
clinic
analyz
urti
patient
record
taken
account
due
low
case
number
summer
time
two
summer
season
includ
studi
result
patient
admit
clinic
month
period
total
patient
diagnos
urti
urti
case
number
spring
march
april
may
summer
june
juli
august
fall
septemb
octob
novemb
winter
decemb
januari
februari
discuss
patient
admit
depart
diagnos
upper
respiratori
tract
infect
treatment
given
cough
major
symptom
respiratori
diseas
patient
urti
appli
pulmonari
medicin
outpati
clinic
patient
urti
cough
also
sore
throat
postnas
drip
nasal
congest
appli
pulmonari
medicin
clinic
instead
ent
clinic
reason
might
patient
fear
lower
respiratori
tract
infect
pneumonia
risk
gramposit
pathogen
streptococcu
pneumonia
spn
intens
studi
almost
hundr
year
studi
found
autophagi
protect
mechan
human
lung
epitheli
cell
infect
spn
studi
design
investig
express
microtubuleassoci
protein
light
chain
human
alveolar
epitheli
cell
effect
streptococcu
pneumonia
lay
foundat
studi
role
autophagosom
process
streptococcu
pneumonia
infect
method
human
pulmonari
epitheli
cell
cultur
vitro
stimul
streptococcu
pneumonia
extract
ribonucl
acid
rna
cell
hour
detect
mrna
express
revers
transcriptionpolymeras
chain
reaction
rtpcr
necrosi
cell
control
group
group
spn
group
spn
ad
group
detect
necrosi
kit
hour
nonradioact
cytotox
assay
respect
result
express
mrna
stimul
detec
rtpcr
differ
necrosi
test
show
blank
group
group
significantli
differ
spn
group
spn
ad
group
significantli
differ
express
mrna
alveolar
epitheli
cell
stimul
streptococcu
pneumonia
significantli
differ
necrosi
number
alveolar
epitheli
cell
ad
increas
conclus
result
indic
autophagi
signal
pathway
prevent
apoptosi
type
ii
alveolar
epitheli
cell
infect
streptococcu
pneumonia
may
repres
molecular
target
promot
cell
surviv
infect
respiratori
pathogen
background
bronchial
carcinoma
current
rank
lead
caus
cancer
relat
death
men
women
time
diagnos
major
lung
cancer
progress
advanc
state
earli
diagnosi
essenti
fibr
optic
bronchoscopi
fob
exert
role
regard
observ
studi
carri
nidch
mohakhali
dhaka
bangladesh
januari
decemb
period
total
patient
underw
fob
fulfil
inclus
exclus
criteria
biopsi
brush
bronchoalveolar
lavag
bal
obtain
suspect
case
confirm
bronchial
carcinoma
result
patient
includ
studi
malefemal
ratio
patient
age
year
mitot
lesion
detect
case
inflammatori
lesion
detect
case
remain
patient
normal
rare
find
histopatholog
bronchial
biopsi
mitot
lesion
case
reveal
patient
squamou
cell
carcinoma
patient
adenocarcinoma
histopatholog
bronchial
brush
reveal
patient
squamou
cell
carcinoma
patient
adenocarcinoma
conclus
bronchoscopi
use
investig
bronchial
carcinoma
provid
histolog
confirm
extent
diseas
evid
inoper
endobronchi
site
tumour
newer
techniqu
like
endobronchi
ultrasound
ebu
transbronchi
needl
aspir
tbna
simultan
autofluoresc
endoscopi
safe
introduc
increas
diagnost
yield
alreadi
start
bangladesh
technic
develop
last
two
decad
made
possibl
pulmonologist
endobronchi
ultrasound
ebu
ebu
miniprob
multilay
structur
tracheobronchi
wall
analyz
better
imag
modal
instead
fluoroscop
guid
biopsi
ebu
use
biopsi
peripher
lesion
ebustransbronchi
needl
aspir
prove
valuabl
subcarin
hilar
mediastin
lymph
node
nation
institut
diseas
chest
hospit
nidch
dhaka
introduc
ebu
first
time
bangladesh
far
done
ebu
patient
result
follow
adenocarcinoma
squamou
cell
carcinoma
small
cell
carcinoma
tuberculosi
lymphoma
inconclus
much
conclus
comparison
convent
modal
diagnost
procedur
use
previous
eg
convent
bropnchoscopi
ctguid
fnac
etc
studi
shown
ebu
costeffect
reduc
need
morbid
costli
invas
procedur
like
mediastinoscopi
thoracotomi
prospect
studi
need
bangladesh
see
ebu
help
popul
lymphadenopathi
chest
xray
procedur
give
conclus
diagnosi
background
selfexpand
metal
stent
use
success
overcom
larg
airway
obstruct
due
malign
pulmonari
diseas
techniqu
modifi
place
stent
direct
vision
use
fibreopt
bronchoscop
effect
procedur
lung
function
patient
well
investig
three
patient
nidch
dhaka
bangladesh
stent
insert
uncompl
method
three
patient
malign
tracheobronchi
tumour
treat
symptom
life
threaten
airway
obstruct
collaps
lung
insert
expand
metal
stent
local
anaesthet
use
fibreopt
bronchoscop
inoper
cancer
histopatholog
diagnosi
conclus
patient
stent
insert
one
sit
one
patient
need
debulk
tumour
measur
perform
patient
stent
includ
object
measur
pulmonari
function
test
arteri
blood
ga
tension
nonobject
measur
patient
well
perform
statu
result
overal
patient
show
symptomat
improv
patient
measur
perform
patient
show
improv
forc
expiratori
volum
one
second
forc
vital
capac
fvc
peak
expiratori
flow
rate
pefr
arteri
oxygen
tension
periop
complic
conclus
suitabl
patient
either
extralumin
intralumin
tumour
insert
expand
metal
stent
use
fibreopt
bronchoscop
local
anaesthet
valuabl
addit
palli
therapi
treatment
lung
cancer
background
topic
anesthet
affect
procedur
implement
fiberopt
bronchoscopi
fob
way
done
local
anesthesia
studi
compar
spray
nebul
topic
anesthet
patient
undergo
fob
method
studi
conduct
adam
malik
hospit
involv
patient
men
age
year
done
bronchoscopi
randomli
sampl
spray
lignocain
sprayer
n
nebul
ml
lidocain
n
addit
patient
receiv
lignocain
bronchoscop
airway
procedur
direct
oper
patient
receiv
diazepam
mg
intramuscularli
premed
hour
procedur
amount
cough
procedur
record
procedur
patient
ask
indic
sens
discomfort
visual
analoqu
scale
result
procedur
perform
bronchoscopi
wash
brush
spray
group
wash
brush
nebul
group
lignocain
dose
use
group
signific
differ
p
averag
lignocain
spray
group
nebul
group
mg
mg
respect
mg
sd
number
cough
two
group
signific
p
averag
cough
spray
group
time
nebul
group
time
averag
va
score
spray
group
cm
cm
nebul
group
va
score
two
group
differ
significantli
p
statist
result
number
cough
va
score
group
show
differ
discomfort
p
valu
conclus
effect
spray
nebul
topic
anesthet
equal
reduc
patient
discomfort
undergo
fob
keyword
fob
spray
nebul
va
ayako
igarashi
yasutaka
kawai
mitsuru
ogri
takuya
sasaki
ryo
ota
depart
respiratori
medicin
oji
gener
hospit
tomakomai
hokkaido
japan
depart
otorhinolaryngolog
oji
gener
hospit
tomakomai
hokkaido
japan
foreign
bodi
hair
crab
shell
airway
rare
manag
type
foreign
bodi
difficult
even
thoracotomi
might
consid
experienc
case
foreign
bodi
hair
crab
shell
bronchu
retriev
tracheostomi
patient
man
aspir
piec
hair
crab
shell
accident
suck
leg
meat
mild
cough
throat
discomfort
develop
immedi
present
hospit
next
day
complain
dyspnea
supin
posit
continu
overnight
physic
examin
show
inspiratori
stridor
left
lung
although
chest
xray
normal
chest
ct
scan
reveal
foreign
bodi
hair
crab
shell
left
main
bronchu
confirm
flexibl
bronchoscopi
initi
tri
grasp
shell
allig
forcep
fail
due
slipperi
surfac
move
slightli
central
retriev
net
basket
forcep
therefor
underw
tracheostomi
gener
anesthesia
facilit
follow
procedur
sinc
spine
shell
penetr
bronchial
mucosa
imposs
retriev
shell
use
rigid
bronchoscop
forcep
final
remov
tracheostomi
nasal
forcep
rigid
endoscop
endoscop
sinu
surgeri
use
safeti
endobronchi
ultrasoundguid
transbronchi
needl
aspir
ebustbna
establish
recent
studi
evalu
whether
age
increas
risk
procedur
present
studi
aim
assess
use
safeti
ebustbna
older
patient
medic
record
databas
patient
receiv
ebustbna
nagoya
univers
hospit
nagoya
japan
review
retrospect
patient
underw
bronchoscopi
light
sedat
midazolam
total
patient
age
year
older
older
group
age
year
younger
younger
group
analyz
patient
characterist
chang
clinic
paramet
usabl
dose
midazolam
lidocain
procedur
durat
geograph
data
biopsi
lymph
node
diagnost
yield
complic
group
result
commod
older
group
four
patient
older
group
poor
perform
statu
systol
blood
pressur
baselin
significantli
higher
older
group
statist
differ
two
group
clinic
paramet
minimum
oxygen
satur
reduct
maximum
oxygen
supplement
elev
systol
blood
pressur
increas
heart
rate
procedur
diagnost
perform
older
patient
similar
found
younger
patient
differ
frequenc
complic
group
conclus
safeti
use
ebustbna
older
patient
compar
younger
patient
complic
parapneumon
effus
common
yet
optim
manag
continu
matter
debat
medic
thoracoscopi
play
increas
role
manag
complic
pleural
infect
util
remain
controversi
report
two
case
complic
parapneumon
effus
medic
thoracoscopi
may
found
nich
first
patient
year
old
male
admit
cardiolog
diagnosi
tricuspid
valv
infect
endocard
tricuspid
regurgit
complic
septic
emboli
lung
spleen
right
iliacu
right
obtur
externu
muscl
day
admiss
develop
larg
right
complic
parapneumon
pleural
effus
initi
chest
tube
drainag
unsuccess
multidisciplinari
consult
cardiothorac
surgeon
patient
refer
pulmonologist
trial
intrapleur
fibrinolysi
first
oper
risk
deem
signific
underw
medic
thoracoscopi
well
intrapleur
fibrinolysi
repeat
chest
radiograph
cxr
day
fibrinolysi
show
dramat
improv
second
patient
year
old
male
premorbidli
wheelchair
bound
multipl
comorbid
admit
left
complic
parapneumon
effus
two
consecut
chest
tube
insert
yield
poor
drainag
decis
made
proceed
medic
thoracoscopi
deem
high
risk
surgic
candid
multipl
locul
dens
adhes
note
procedur
broken
achiev
drainag
new
chest
drain
insert
repeat
cxr
one
month
later
demonstr
complet
resolut
left
pleural
effus
henc
juri
regard
optim
manag
complic
parapneumon
effus
multidisciplinari
approach
would
appropri
strongli
believ
medic
thoracoscopi
role
care
select
patient
background
transthorac
needl
biopsi
one
diagnost
procedur
peripher
lung
lesion
pleural
lesion
howev
perform
complic
procedur
vari
depend
lesion
characterist
oper
skill
retrospect
studi
patient
peripher
lung
lesion
underw
ct
guid
transthorac
biopsi
biopsi
procedur
perform
use
gaug
coaxial
needl
cut
biopsi
spiral
scan
techniqu
mm
collim
depart
radiolog
sdmc
medic
center
result
total
patient
elig
biopsi
perform
singl
experienc
intervent
radiologist
femal
case
mean
age
patient
year
common
chest
radiograph
find
intrapulmonari
mass
lesion
locat
lung
lesion
rul
rml
rll
lul
lll
two
case
extrapulmonari
pleural
lesion
one
multipl
pulmonari
nodul
result
biopsi
adenocarcinoma
biopsi
procedur
lesion
size
cm
diamet
remain
diagnost
result
tuberculosi
squamou
cell
carcinoma
small
cell
carcinoma
poorli
differenti
carcinoma
mesothelioma
chronic
fungal
infect
silicot
nodul
non
diagnost
patholog
find
chronic
interstiti
pneumon
fibrosi
inadequ
sampl
note
case
less
cm
size
lesion
pneumothorax
commonli
observ
procedur
relat
complic
biopsi
mild
degre
pleural
air
observ
imag
requir
drainag
chest
tube
thoracostomi
among
patient
develop
pneumothorax
lesion
less
cm
diamet
conclus
coaxial
needl
thorac
biopsi
provid
accept
diagnost
perform
peripher
lesion
mostli
malign
addit
minim
pneumothorax
commonli
observ
procedur
pulmonari
rehabilit
essenti
compon
manag
obstruct
lung
diseas
recommend
minimum
length
program
six
week
howev
program
institut
shorten
four
week
due
logist
practic
purpos
studi
aim
determin
program
provid
benefit
particip
regard
function
capac
exercis
toler
qualiti
life
qol
data
particip
chronic
obstruct
lung
diseas
bronchial
asthma
analyz
minut
walk
test
chronic
respiratori
questionnair
use
measur
particip
function
capac
exercis
toler
qol
paramet
measur
start
upon
complet
program
particip
copd
averag
age
year
male
femal
upon
complet
week
program
half
improv
function
capac
two
third
improv
exercis
toler
five
six
felt
improv
qol
particip
bronchial
asthma
averag
age
year
male
femal
less
half
improv
exercis
capac
threefourth
note
increas
exercis
toler
eight
five
show
improv
qol
week
program
week
pulmonari
rehabilit
program
institut
show
modest
improv
function
capac
exercis
toler
qol
particip
still
determin
shorten
durat
program
provid
signific
improv
data
need
background
expiratori
muscl
activ
revers
sniff
maneuv
akin
blow
nose
increas
stepwis
increment
revers
sniff
nasal
expiratori
pressur
rsnep
maneuv
use
assess
expiratori
muscl
strength
erj
patient
neuromuscular
diseas
rsnep
may
influenc
expiratori
also
upper
airway
muscl
activ
fact
upper
airway
muscl
significantli
contribut
sniff
nasal
inspiratori
pressur
reliabl
maneuv
measur
inspiratori
muscl
strength
erj
expiratori
upper
airway
muscl
behav
revers
sniff
sit
supin
posit
method
healthi
subject
age
year
insert
fine
wire
electrod
genioglossu
gg
transversu
abdomini
ta
muscl
use
highresolut
ultrasonographi
rsnep
measur
cathet
occlud
one
nostril
contralater
nostril
remain
open
subject
perform
short
sharp
maximum
variabl
intens
revers
sniff
begin
frc
sit
supin
posit
gg
ta
emg
activ
express
percent
maximum
emg
emgmax
result
mean
rsnep
sit
supin
posit
respect
subject
gg
ta
emg
activ
increas
stepwis
increment
rsnep
sit
supin
posit
signific
linear
relationship
rsnep
emg
activ
muscl
gg
sit
r
supin
r
ta
sit
r
supin
r
emgmaxrsnep
slope
gg
supin
significantli
higher
sit
ta
signific
differ
slope
two
posit
conclus
conclud
revers
sniff
gg
ta
contribut
produc
rsnep
gg
activ
influenc
postur
ta
activ
work
support
mext
japan
kakenhi
diaphragmat
ruptur
due
blunt
thorac
trauma
rare
entiti
spesif
symtom
patient
want
present
case
diaphragmat
ruptur
seen
rare
blunt
thorac
trauma
year
old
male
patient
histori
fall
meter
height
three
day
ago
trauma
surgic
patholog
found
given
analges
treatment
admit
clinic
reliev
pain
addit
increas
pain
physic
examin
patient
reveal
abnorm
find
except
pain
right
lumbal
region
palpat
plain
roentgenogram
patient
report
normal
suspect
diaphragmat
injuri
comput
tomographi
perform
comput
tomographi
reveal
isol
right
posterolater
diaphragmat
ruptur
surgeri
advis
patient
suspect
diaphragmat
injuri
mainstay
diagnosi
diaphragmat
ruptur
progress
herniat
occur
ruptur
diagnos
late
treat
time
strangul
abdomin
organ
ocur
lead
lifetr
statu
order
prevent
traumat
patient
complic
diaphragmat
ruptur
kept
mind
trauma
patient
pneumomediastinum
defin
presenc
free
air
mediastinum
trauma
play
import
role
etiolog
may
occur
spontan
common
syptom
swell
due
subcuthan
emphysema
chest
pain
dispn
hoars
mostli
patholog
recov
spontan
rare
requir
surgic
intervent
herein
aim
present
pneumomediastinum
case
follow
clinic
mean
age
patient
year
common
complaint
patient
neck
pain
swell
neck
upper
part
bodi
dispnea
none
patient
describ
trauma
histori
one
patient
histori
swell
neck
arm
time
four
six
patient
investig
endoscopi
fob
patholog
found
four
patient
regress
spontan
one
patient
present
pneumothorax
pneumomediastinum
statu
epilepticu
attack
treat
chest
tube
one
patient
severli
disturb
due
subcuthan
emphysema
place
intra
venou
cathet
subcuthan
infra
supra
clavicular
region
order
purg
free
air
mean
hospit
time
seven
day
day
primari
spontan
pneumomediastinum
rare
patholog
patient
regress
spontan
first
week
need
surgic
intervent
close
followup
import
think
addit
endoscop
screen
test
provid
signific
benefit
diagnosi
followup
patient
reexpans
pulmonari
edema
rare
complic
occur
reexpand
collaps
lung
factor
pneumothorax
pleural
effus
atelectasi
hour
collaps
lung
rapid
reexpand
import
risk
factor
aim
present
case
observ
clinic
male
patient
present
clinic
leftsid
chest
pain
day
onset
medic
histori
treat
two
time
spontan
pneumothorax
last
year
physic
examin
breath
sound
diminish
left
side
chest
xray
reveal
left
upper
lobe
partli
lower
lobe
total
collaps
left
tube
thoracostomi
perform
clamp
safeti
reexpans
perform
patient
complain
dyspnea
oxygen
satur
level
pressur
measur
mmhg
blood
ga
control
chest
xray
reveal
acut
pulmonari
edema
left
lung
patient
lay
right
side
patient
treat
diuret
oxygen
fluid
restrict
symptom
began
declin
hour
hour
pressur
level
measur
mmhg
blood
ga
edema
significantli
regress
hour
chest
xray
vat
perform
day
tube
thoracostomi
patient
discharg
postop
day
complic
occur
reexpans
pulmonari
edema
rare
complic
high
mortal
correctli
evalu
lung
collaps
long
time
rpe
consid
concentr
possibl
find
neurofibromatosi
von
recklinghausen
diseas
geneticallyinherit
disord
nerv
tissu
grow
tumor
neurofibroma
deseas
character
neurofibroma
cafe
au
lait
spot
lisch
nodul
aim
present
neurofibromatosi
case
massiv
chest
wall
year
old
male
patient
admit
chest
wall
deform
skin
lession
complaint
swell
pain
back
diseas
start
childhood
appear
axillari
skin
hyperpig
lesion
swell
appear
back
start
increas
size
lesion
resect
patholog
diagnosi
neurofibroma
physic
examin
asymmetr
deform
right
side
chest
wall
big
cafeu
lait
spot
multipl
spot
averag
diamet
cm
part
bodi
evalu
thorax
ct
seen
right
side
chest
wall
involv
neurofibroma
concomit
rib
massiv
deform
multipl
lisch
nodul
detect
ophtalm
examin
patholog
find
detect
brain
mri
signific
restrict
found
pulmonari
function
test
patient
followupth
patient
describ
typic
case
neurofibromatosi
multipl
systemat
symptom
may
ocur
thees
patient
case
detail
investig
requir
nf
patient
risk
gener
involv
organ
malign
potenti
patient
must
follow
close
dermatofibrosarcoma
protuberan
dfsp
rare
slow
grove
soft
tissu
tumor
origin
dermi
pulmonari
metastasi
seen
especi
fibrosarcomat
variant
dfsp
wide
surgic
resect
recommend
treatment
local
recurr
rate
high
aim
present
dermatofibrosarcoma
bilater
multipl
pulmonari
metastasi
case
rare
seen
old
male
patient
consult
clinic
bilater
pulmonari
multipl
nodul
medic
histori
tumor
resect
right
suprascapular
region
report
fibrohistiocyt
tumor
age
tumor
occur
region
resect
last
histopatholog
result
report
fibrosarcomat
variant
dermatofibrosarcoma
protuberan
fsdfsp
patient
underw
bilater
thoracotomi
differ
nodul
right
lung
nodul
left
lung
resect
report
dfsp
metastasi
patient
discharg
postop
day
complic
occur
although
dfsp
local
agress
low
grade
tumor
fibrosarcomat
variant
dfsp
high
local
recurr
distant
metastasi
rate
distant
metastasi
occur
local
recurr
case
recurr
fibrosarcomat
variant
examin
care
pulmonari
metastasi
etsuhiro
nikkuni
ritsuko
arakawa
toshiya
irokawa
hiromasa
ogawa
hajim
kurosawa
depart
occup
health
tohoku
univers
graduat
school
medicin
sendai
japan
headup
postur
deg
commonli
use
respiratori
care
rehabilit
relax
abdomin
muscl
partli
easi
breath
immobil
patient
howev
whether
ventilatori
imped
decreas
postur
well
known
studi
respiratori
system
resist
rr
reactanc
xr
evalu
postur
supin
upright
use
forc
oscil
techniqu
fot
healthi
subject
age
male
follow
tidal
quiet
breath
includ
stabl
respiratori
cycl
rr
hz
xr
hz
assess
use
commerci
fot
apparatu
chest
mi
inc
tokyo
japan
multifrequ
puls
wave
han
interv
sec
use
oscil
lung
vital
capac
vc
inspiratori
capac
ic
assess
use
convent
spirometri
chest
mi
inc
tokyo
japan
fot
spirometri
perform
postur
includ
supin
deg
headup
deg
deg
upright
deg
posit
random
order
increas
degre
headup
decreas
anova
p
increas
p
deg
significantli
lower
posit
p
although
ic
linearli
decreas
upright
supin
postur
anova
p
chang
seem
linear
specul
chang
rr
headup
reflect
lung
volum
also
mechan
upper
airway
collaps
graviti
result
subject
underw
patient
maxim
exercis
test
analys
subject
mean
work
rate
mean
max
mlkgmin
subject
normal
exercis
test
none
health
care
visit
relat
dyspnea
subject
cardiac
limit
decondit
mean
max
mlkgmin
mean
anaerob
threshold
mean
subject
cardiac
subject
cardiac
evalu
two
abnorm
find
one
ischaemia
one
heart
failur
seven
subject
decondit
mean
max
mlkgmin
mean
anaerob
threshold
one
subject
normal
cardiac
evalu
none
health
care
visit
relat
dyspnea
year
studi
among
maxim
exercis
test
subject
normal
studi
group
cardiac
evalu
cardiac
limit
group
ct
thorax
reveal
tb
decondit
group
coronari
angiogram
remain
either
target
investig
pertain
limit
undergo
investig
year
stabil
conclus
cpet
use
tool
channel
subsequ
evalu
dyspnea
focus
manner
therebi
limit
amount
investig
undergon
otherwis
outpati
set
purpos
intend
determin
clinic
effect
accuraci
infrar
thermal
imag
irti
novel
techniqu
noninvas
imag
detect
vessel
function
diagnos
lower
limb
dvt
human
method
dvt
patient
nondvt
volunt
definit
diagnos
doppler
vascular
compress
ultrasonographi
cup
angiographi
enrol
research
util
irti
sensor
detect
lower
limb
dvt
patient
irti
pictur
captur
studi
qualit
pseudocolor
analysi
quantit
temperatur
analysi
term
mean
area
temperatur
averag
tav
mean
linear
temperatur
tla
region
interest
roa
shown
irti
differ
tav
tla
dvt
nondvt
side
irti
patient
well
tdtav
tdtla
dvt
patient
nondvt
volunt
compar
result
qualit
pseudocolor
irti
analysi
reveal
bilater
infrar
present
distribut
characterist
pdc
visibl
asymmetri
abnorm
high
temperatur
district
dvt
side
assum
posit
definit
dvt
patient
posit
irti
irti
posit
case
infrar
pdc
coincid
dvt
situ
case
coincid
dvt
side
compar
result
cpu
angiographi
highli
statist
signific
differ
dvt
side
nondvt
side
dvt
group
p
dvt
group
nondvt
group
p
conclus
irti
use
detect
screen
dvt
effect
accur
hemodynam
respons
vasodil
akan
kuroki
takahiro
sato
ichizo
tsujino
ayako
igarashi
hiroshi
background
certain
subset
group
pulmonari
hypertens
ph
patient
known
exhibit
advanc
outofproport
ph
popul
vasodil
treatment
gener
recommend
lack
evid
possibl
deterior
ventilationperfus
mismatch
object
investig
efficaci
safeti
vasodil
treatment
patient
outofproport
group
ph
subject
sinc
treat
consecut
patient
progress
dyspnea
due
ph
use
sildenafil
alon
n
sildenafil
plu
beraprost
n
sildenafil
plu
bosentan
n
underli
pulmonari
diseas
earlyonset
chronic
obstruct
pulmonari
diseas
n
rheumatoid
arthritisassoci
interstiti
pneumonia
n
cystic
lung
diseas
n
combin
pulmonari
fibrosi
emphysema
n
result
treatment
patient
present
progress
dyspnea
demonstr
increas
mean
pulmonari
arteri
pressur
mpap
mmhg
pulmonari
vascular
resist
pvr
dyn
cm
vasodil
treatment
welltoler
followup
assess
month
later
patient
note
less
dyspnea
signific
reduct
mpap
mmhg
pvr
dyn
cm
pulmonari
oxygen
deterior
patient
improv
significantli
chang
remain
patient
conclus
five
patient
progress
group
outofproport
ph
respond
favor
vasodil
vasodil
therapi
particularli
use
sildenafil
may
repres
promis
option
popul
introduc
earli
phase
diseas
background
gener
recogn
narrow
diminut
small
vessel
pulmonari
angiographi
patient
chronic
thromboembol
pulmonari
hypertens
cteph
previou
studi
shown
vascular
alter
could
assess
crosssect
area
small
pulmonari
vessel
csa
highresolut
ct
hrct
patient
copd
howev
unknown
whether
correl
csa
hemodynam
patient
cteph
aim
retrospect
evalu
relationship
csa
hrct
hemodynam
measur
right
heart
catheter
rhc
materi
method
patient
yr
male
proven
cteph
underw
nonenhanc
hrct
rhc
hrct
imag
mm
section
thick
mm
space
select
ct
imag
patient
use
semiautomat
imageprocess
program
imag
j
csa
less
mm
mm
total
lung
area
measur
percentag
total
csa
less
mm
mm
lung
area
csa
respect
calcul
correl
csa
hemodynam
measur
rhc
evalu
result
mean
pulmonari
arteri
pressur
mpap
pulmonari
vascular
resist
pvr
rhc
mmhg
wood
unit
respect
csa
respect
correl
coeffici
csa
mpap
pvr
p
p
respect
correl
coeffici
mpap
pvr
p
p
respect
conclus
studi
suggest
csa
measur
hrct
invers
correl
pvr
use
evalu
hemodynam
cteph
subject
method
cross
section
studi
ph
screen
doppler
echocardiographi
patient
one
hour
follow
dialysi
done
one
independ
oper
without
know
clinic
background
patient
histori
take
physic
examin
secondari
data
medic
record
includ
laboratori
data
includ
result
pulmonari
hypertens
detect
patient
ph
brachial
av
shunt
seen
patient
diabet
nephrophati
common
etiolog
group
seen
patient
mean
pap
mmhg
cardiac
output
lmin
seen
patient
ef
seen
patient
determin
factor
studi
left
ventricular
diastol
dysfunct
p
background
aim
studi
evalu
reliabl
phase
contrast
pc
mr
imag
ct
predict
pulmonari
hypertens
ph
patient
suspect
ph
studi
protocol
approv
institut
review
board
subject
fortyseven
patient
suspect
ph
male
femal
mean
age
interstiti
pneumonia
heart
failur
diseas
includ
chronic
pulmonari
arteri
thromboembol
right
heart
catheter
rhc
cardiac
magnet
reson
mr
imag
chest
ct
perform
mean
veloc
minimum
area
maximum
area
mean
pulmonari
arteri
mpa
measur
phasecontrast
mri
pcmri
ct
imag
mpa
diamet
obtain
also
measur
volum
fibrosi
normal
lung
use
computeraid
system
paramet
correl
mean
pulmonari
arteri
pressur
mpap
measur
rhc
use
pearson
correl
analysi
area
receiv
oper
characterist
roc
curv
construct
assess
predict
valu
paramet
identif
ph
candid
may
caus
drugsassoci
pah
method
woman
took
herbal
medicin
bofutsushosan
two
week
stop
take
due
gener
malais
exert
dyspnea
caus
exert
dyspnea
seek
find
result
discontinu
bofutsushosan
dyspnea
continu
three
month
echocardiographi
reveal
tricuspid
regurgit
pressur
gradient
mmhg
suspect
exist
ph
chest
roentgenogram
show
promin
hilar
pulmonari
arteri
ctr
lowest
oxygen
satur
perfus
scan
normal
contrast
ct
scan
show
pulmonari
embol
right
heart
catheter
reveal
elev
pap
mpap
pulmonari
capillari
wedg
pressur
ci
result
calcul
pvr
treat
oxygen
diet
therapi
dyspnea
exert
gradual
disappear
discharg
month
later
need
oxygen
bnp
normal
chest
roentgenogram
reveal
improv
cardiac
enlarg
admit
hospit
revalu
month
first
catheter
right
heart
catheter
reveal
normal
pap
mmhg
ci
pvr
conclus
first
report
spontan
remit
pah
induc
herbal
medicin
report
may
provid
clinician
import
inform
earli
suspicion
recognit
pulmonari
hypertens
need
patient
exert
dyspnea
took
herbal
medicin
avoid
deterior
pulmonari
arteri
hypertens
pah
becom
import
topic
basic
clinic
research
recent
year
morpholog
research
shown
specif
pahles
locat
small
arteri
lobul
correl
hemodynam
measur
howev
still
remain
shown
patholog
chang
small
arteri
lobul
develop
pah
base
fractal
properti
pulmonari
arteri
tree
asynchron
phasic
contract
lobular
arteri
muscl
even
pulmonari
capillari
pressur
pcp
lung
construct
integr
model
pulmonari
circul
demonstr
mathemat
relationship
mean
pulmonari
arteri
pressur
mpap
cardiac
output
co
use
relationship
mpap
co
abl
explain
pathogenesi
pulmonari
hypertens
ph
term
statist
chang
region
tempor
perfus
lung
order
clinic
detect
earli
stage
ph
suggest
import
establish
pulmonari
function
imag
region
tempor
perfus
background
aim
studi
high
altitud
pulmonari
edema
hape
noncardiogen
lifethreaten
pulmonari
edema
character
exagger
hypox
pulmonari
hypertens
pathogenesi
remain
conclus
elucid
genet
polymorph
highli
propos
associ
hape
aim
studi
attempt
identifi
candid
human
gene
might
associ
develop
hape
method
case
group
includ
japanes
hape
suscept
subject
develop
hape
climb
mountain
higher
control
group
enrol
japanes
hape
resist
subject
elit
alpinist
develop
hape
histori
casecontrol
associ
studi
perform
use
polymorph
microsatellit
marker
pcr
sequenc
gene
scan
softwar
result
nine
marker
show
statist
signific
associ
suscept
hape
three
marker
show
signific
associ
resist
hape
also
evalu
associ
hape
six
singl
nucleotid
polymorph
snp
inhibitor
metalloproteinas
gene
includ
resist
microsatellit
marker
one
six
snp
gene
significantli
associ
hape
suscept
p
conclus
first
genomewid
associ
studi
hape
reveal
sever
candid
gene
associ
hape
find
also
elucid
polymorph
gene
significantli
associ
suscept
hape
studi
provid
first
evid
develop
hape
may
determin
interact
multipli
gene
may
influenc
risk
hape
report
case
previous
healthi
old
girl
treat
antitb
drug
combin
isoniazid
rifampicin
pyrazinamid
ethambutol
tb
aden
note
resolut
howev
day
drug
intak
flulik
symptom
prurit
erythemat
maculopapular
rash
eventu
dyspnea
develop
vital
sign
stabl
patient
febril
multipl
erythemat
hyperpig
macul
confluent
patch
face
trunk
extrem
dryness
slight
scale
lip
conjunct
anicter
sclera
suppl
neck
multipl
cervic
lymphadenopathi
bibas
crackl
eosinophilia
transamin
peripher
blood
smear
show
leukocytosi
without
atyp
lymphocytosi
antinuclear
antibodi
ana
neg
arteri
blood
gass
reveal
uncompens
respiratori
alkalosi
moder
hypoxemia
ratio
less
consist
ard
discuss
patient
diagnos
definit
case
final
score
dress
syndrom
base
postul
score
system
kardaun
et
al
clinic
featur
typic
fever
lymphadenopathi
eosinophila
skin
rash
suggest
dress
biopsi
suggest
dress
viscer
involv
lung
liver
signific
improv
skin
lesion
note
intraven
hydrocortison
antimicrobi
antihistamin
given
howev
fever
persist
desatur
hypotens
ensu
diffus
bilater
lung
infiltr
progress
patient
die
knowledg
rariti
incid
exposur
repres
first
report
case
dress
syndrom
due
antitb
drug
philippin
overal
mortal
dress
syndrom
conclus
gener
awar
pharmacovigil
import
due
sever
lifethreaten
potenti
type
drug
reaction
propos
algorithm
diagnosi
manag
dress
addit
tiotropium
provid
bronchodil
reduc
exacerb
patient
sever
asthma
kerstjen
et
al
nejm
subgroup
analys
perform
determin
whether
posit
effect
limit
defin
subgroup
patient
method
elig
patient
histori
asthma
experienc
exacerb
previou
year
time
first
sever
exacerb
pool
data
week
primari
end
point
secondari
end
point
includ
time
first
episod
asthma
worsen
subgroup
analys
time
first
sever
exacerb
perform
group
defin
baselin
characterist
includ
age
allerg
statu
smoke
statu
revers
result
patient
randomis
receiv
tiotropium
via
soft
mist
tm
inhal
receiv
placebo
daili
week
total
studi
group
time
first
sever
exacerb
increas
addit
tiotropium
risk
reduct
hazard
ratio
p
time
first
episod
asthma
worsen
increas
tiotropium
group
compar
placebo
risk
reduct
hazard
ratio
p
subgroup
analys
show
neither
time
first
sever
exacerb
time
first
episod
asthma
worsen
depend
baselin
characterist
signific
interact
conclus
increas
time
first
sever
exacerb
first
episod
asthma
worsen
found
addit
tiotropium
limit
specif
subgroup
patient
includ
characterist
usual
found
patient
chronic
obstruct
pulmonari
diseas
former
smoke
nonallerg
statu
minim
revers
tiotropium
seem
effect
across
broad
spectrum
patient
sever
persist
asthma
remain
symptomat
experi
exacerb
despit
combin
use
moderateto
highdos
inhal
corticosteroid
plu
longact
beta
agonist
background
chronic
eosinophil
pneumonia
cep
gener
respond
steroid
therapi
howev
relaps
frequent
occur
prolong
steroid
therapi
need
case
mast
cell
play
import
role
allerg
diseas
interstiti
lung
diseas
tryptas
releas
activ
mast
cell
associ
intract
pathogenesi
littl
known
clinic
signific
measur
mast
cell
tryptas
bronchoalveolar
lavag
fluid
balf
patient
eosinophil
pneumonia
method
balf
patient
eosinophil
pneumonia
cep
patient
acut
eosinophil
pneumonia
aep
patient
druginduc
eosiophil
pneumonia
drug
patient
analyz
monoclon
antibodybas
tryptas
immunofluoroassay
detect
monom
inact
tetram
activ
form
tryptas
relationship
clinic
characterist
tryptas
balf
analyz
retrospect
result
tryptas
balf
could
detect
patient
cep
aep
tryptaseposit
group
patient
cep
aep
drug
concentr
tryptas
tryptaseposit
group
ngml
cep
n
mean
sd
ngml
aep
n
tryptas
concentr
significantli
higher
cep
aep
drug
p
recurr
eosinophil
pneumonia
seen
patient
cep
aep
drug
six
patient
cep
asthma
histori
one
patient
allerg
bronchopulmonari
aspergillosi
anoth
one
chronic
eosinophil
sinus
conclus
tryptas
balf
detect
patient
cep
tryptaseposit
patient
cep
tend
relaps
complic
asthma
mast
cell
tryptas
may
associ
intract
pathogenesi
cep
work
support
part
grant
japanes
ministri
educ
scienc
cultur
introduct
eosinophil
granulomatosi
polyangi
egpa
also
known
churgstrauss
syndrom
rare
diseas
character
presenc
allerg
granulomatosi
necrot
vascul
often
effect
treat
corticosteroid
howev
relaps
rate
high
unknown
reason
egpa
patient
suffer
frequent
relaps
entri
initi
remiss
regulatori
treg
cell
b
cell
implic
develop
progress
egpa
explor
influenc
treg
cell
costimulatori
factor
present
b
cell
develop
cours
egpa
method
studi
egpa
patient
experienc
frequent
relaps
seldom
relaps
control
patient
gener
asthma
determin
count
percentag
wholeblood
cell
exhibit
follow
characterist
cell
among
treg
cell
cell
among
treg
cell
cell
among
b
cell
also
measur
serum
igg
concentr
result
compar
patient
asthma
seldomrelaps
egpa
frequent
relaps
egpa
patient
activ
diseas
exhibit
decreas
count
treg
cell
increas
percentag
b
cell
score
patient
frequent
relaps
egpahad
increas
percentag
b
cell
fewer
b
cell
patient
two
group
lower
b
cell
count
associ
reduc
treg
cell
count
lower
serum
igg
concentr
conclus
patient
frequent
relaps
egpa
decreas
treg
cell
number
increas
percentag
activ
b
cell
may
induc
apoptosi
b
cell
nitrogen
singlebreath
washout
sbw
test
measur
ventil
distribut
inhomogen
also
small
airway
function
offer
complementari
inform
spirometri
howev
relev
forc
oscil
techniqu
fot
pulmonari
emphysema
copd
fulli
understood
hypothes
pulmonari
function
forc
oscillatori
paramet
emphysema
extent
would
contribut
independ
result
sbw
test
crosssect
studi
assess
relationship
phase
iii
slope
delta
deriv
sbw
paramet
method
spirometri
lung
volum
sbw
broadband
frequenc
fot
use
perform
patient
stabl
copd
use
respiratori
system
resist
hz
reson
frequenc
differ
inspiratori
expiratori
respiratori
system
reactanc
hz
expiratori
flow
limit
efl
index
emphysema
extent
measur
highresolut
comput
tomographi
score
median
rang
valu
predict
forc
vital
capac
predict
delta
respiratori
resist
hz
ls
reson
frequenc
hz
efl
index
emphysema
score
multipl
regress
analys
delta
independ
predict
forc
vital
capac
reson
frequenc
emphysema
score
p
conclus
degre
ventil
inhomogen
deriv
sbw
independ
predict
spirometri
lung
mechan
degre
emphysema
akinori
ebihara
asuka
nagai
rurika
hamanaka
tokuzen
iwamoto
ichiro
kuwahira
pulmonari
medicin
tokai
univers
tokyo
hospit
gener
thorac
surgeri
tokai
univers
tokyo
hospit
japan
background
cardiovascular
event
import
part
comorbid
complic
copd
patient
analyz
data
ratio
serum
eicosapentaeno
acid
arachidon
acid
epaaa
ankl
brachial
pressur
index
abi
use
indic
arteriosclerosi
examin
correl
studi
method
total
subject
male
femal
enrol
studi
inform
consent
obtain
januari
may
erimo
town
clinic
hokkaido
divid
potenti
subject
three
group
group
histori
copd
sever
exposur
tobacco
smoke
brinkman
index
group
histori
copd
exposur
histori
brinkman
index
less
group
histori
diseas
without
copd
diabet
hypertens
hyperlipidemia
result
subject
male
femal
subject
male
femal
subject
male
femal
respect
abi
epaaa
demonstr
signific
declin
abi
epaaa
compar
howev
signific
differ
data
conclus
copd
patient
sever
exposur
smoke
signific
declin
abi
epaaa
observ
result
indic
patient
increas
risk
smokerel
cardiovascular
diseas
acut
myocardi
infarct
stroke
introduct
chronic
obstruct
pulmonari
diseas
copd
inflammatori
lung
diseas
caus
smoke
pathogenesi
remain
unclear
although
chronic
inflammatori
respons
copd
affect
lung
signific
system
consequ
studi
correl
clinic
use
inflammatori
biomark
exercis
capac
studi
design
find
relationship
amongst
pulmonari
function
test
inflammatori
biomark
lactat
dehydrogenas
ldh
blood
urea
nitrogen
bun
patient
exercis
capac
subject
method
march
decemb
patient
copd
record
daili
number
step
week
pedomet
patient
record
daili
number
step
week
enrol
data
patient
exclud
due
inadequ
record
obtain
data
analyz
divid
date
averag
weekday
weekend
correl
number
step
serum
ldh
bun
level
evalu
result
correl
exercis
capac
patient
copd
serum
ldh
bun
level
correl
found
serum
ldh
level
averag
number
step
day
p
averag
number
step
weekday
p
averag
number
step
weekend
p
also
correl
serum
bun
level
averag
number
step
day
p
averag
number
step
weekday
p
averag
number
step
weekend
p
correl
found
exercis
capac
measur
pedomet
either
conclus
correl
amongst
preexist
pulmonari
function
test
marker
inflammatori
biomark
ldh
bun
exercis
capac
copd
patient
background
morpholog
chang
relat
chronic
obstruct
pulmonari
diseas
copd
occur
mild
stage
copd
although
overinfl
lung
copd
known
relat
morpholog
tracheal
deform
relationship
morpholog
chang
trachea
lung
volum
paramet
mildtomoder
stage
copd
yet
determin
thu
aim
investig
associ
tracheal
index
ti
lung
function
paramet
includ
relat
lung
volum
copd
patient
mildtomoder
airflow
limit
materi
method
retrospect
studi
conduct
mildtomoder
airflow
limit
patient
subject
normal
lung
function
control
group
two
independ
observ
measur
ti
three
differ
anatom
level
chest
radiograph
ct
result
compar
control
group
ti
significantli
reduc
sabersheath
trachea
frequent
observ
copd
patient
mildtomoder
airflow
limit
three
differ
trachea
level
ti
appar
invers
correl
total
lung
capac
function
residu
capac
residu
volum
particularli
notabl
ti
measur
upper
margin
aortic
arch
chest
ct
even
adjust
covari
associ
persist
conclus
ti
reduc
even
mildtomoder
copd
patient
ti
measur
chest
ct
show
signific
invers
relationship
lung
volum
paramet
suggest
tracheal
morpholog
might
chang
earli
stage
copd
background
airflow
obstruct
copd
caus
chronic
inflamm
perman
structur
chang
smaller
airway
lung
parenchyma
current
studi
antiinflammatori
treatment
copd
focus
target
inhibit
phosphodiesteras
major
enzym
camp
inflammatori
cell
roflumilast
target
inhibitor
phosphodiesteras
reduc
inflammatori
product
leukotrien
b
tnfa
inflammatori
cell
method
patient
consid
year
old
diagnosi
moder
sever
copd
confirm
postbronchodil
fvc
ratio
postbronchodil
predict
valu
patient
current
former
smoker
minimum
smoke
histori
least
pack
year
histori
chronic
product
cough
intervent
test
roflumilast
combin
laba
search
strategi
focus
rct
experiment
group
includ
roflumilast
laba
vs
laba
placebo
primari
efficaci
endpoint
observ
chang
prebronchodil
baselin
post
randomis
visit
secondari
endpoint
includ
postbronchodil
preand
postbronchodil
fvc
transit
dyspnea
index
statist
analys
perform
use
revman
comput
softwar
result
three
thousand
nine
hundr
five
patient
includ
three
trial
report
chang
mean
prebronchodil
baselin
post
randomis
visit
laba
roflumilast
note
signific
differ
compar
laba
placebo
improv
prebronchodil
p
secondari
outcom
test
also
show
signific
differ
compar
laba
roflumilast
vs
laba
placebo
p
conclus
roflumilast
improv
lung
function
patient
moderatetosever
copd
alreadi
treat
laba
use
oral
daili
antiinflammatori
agent
instead
inhal
corticosteroid
concomit
therapi
laba
advantag
increas
complianc
demonstr
increas
risk
pneumonia
plasma
level
inflammatori
protein
cathepsin
b
natur
inhibitori
protein
cystatin
c
examin
chronic
obstruct
pulmonari
diseas
copd
patient
two
week
well
week
acut
exacerb
ae
chang
plasma
level
protein
evalu
specul
whether
well
correl
inflammatori
status
copd
exacerb
copd
patient
includ
male
femal
includ
studi
plasma
collect
three
differ
time
ie
week
well
week
ae
healthi
subject
includ
male
femal
studi
control
enzymelink
immunosorb
assay
elisa
wad
use
measur
plasma
level
studi
protein
plasma
level
cathepsin
b
significantli
higher
copd
patient
week
week
ae
compar
healthi
subject
copd
patient
plasma
level
cathepsin
b
significantli
higher
week
ae
time
ae
plasma
level
cystatin
c
show
significantli
higher
plasma
level
healthi
subject
time
ae
also
week
week
ae
howev
signific
differ
time
ae
week
ae
conclus
persist
signific
higher
plasma
level
cystatin
c
copd
patient
ae
also
week
ae
healthi
subject
might
repres
chronic
inflammatori
statu
copd
moreov
plasma
level
cathepsin
b
significantli
increas
week
ae
return
nonsignific
week
ae
copd
patient
aim
tai
chi
ancient
chines
martial
art
involv
seri
slow
control
movement
practis
increasingli
west
mean
exercis
aim
studi
determin
accept
tai
chi
caucasian
peopl
copd
complet
tai
chi
train
program
method
particip
copd
finish
twice
weekli
shortform
sunstyl
tai
chi
train
program
complet
survey
eight
question
question
answer
put
stroke
cm
visual
analogu
scale
higher
score
indic
better
experi
number
supervis
train
session
attend
period
number
unsupervis
home
practis
day
also
report
result
twentythre
particip
caucasian
previou
experi
tai
chi
complet
survey
mean
sd
age
year
mean
predict
particip
attend
supervis
train
session
possibl
session
practis
day
per
week
unsupervis
home
train
result
four
eight
survey
question
enjoy
tai
chi
program
mean
sd
score
cm
help
tai
chi
program
improv
physic
fit
cm
balanc
cm
short
breath
cm
hard
rememb
tai
chi
movement
cm
would
continu
tai
chi
train
regular
exercis
regimen
cm
conclus
particip
report
shortform
sunstyl
tai
chi
highli
enjoy
exercis
improv
physic
fit
balanc
short
breath
particip
also
adher
supervis
unsupervis
train
session
importantli
particip
indic
would
continu
tai
chi
regular
exercis
regimen
result
patient
n
mean
age
year
gold
grade
iii
diseas
randomis
budform
ibtsr
n
full
analysi
set
fa
n
ibtsr
n
fa
n
differ
baselin
characterist
group
improv
predos
baselin
significantli
greater
budform
ibtsr
ibtsr
alon
increas
cl
p
reduct
exacerb
rate
rate
ratio
p
point
improv
sgrqc
vs
p
addit
budform
patient
experienc
advers
event
ae
relat
treatment
budform
ibtsr
ibtsr
discontinu
due
ae
budform
ibtsr
ibtsr
conclus
addit
budform
ibtsr
well
toler
associ
clinic
signific
benefit
lung
function
exacerb
rate
healthrel
qualiti
life
chines
patient
sever
copd
studi
demonstr
benefit
budform
use
combin
wide
use
local
regimen
fund
astrazeneca
background
master
effect
breath
sputum
clearanc
techniqu
essenti
patient
copd
moreov
enhanc
patient
selfmanag
skill
could
contribut
reduc
hospit
readmiss
order
facilit
bedsid
educ
physiotherapi
depart
north
district
hospit
develop
patient
educ
packag
evalu
effect
learn
process
assess
chart
known
breath
control
bronchial
hygien
bcbh
score
devis
patient
perform
use
correl
hospit
readmiss
method
copd
patient
refer
respiratori
collabor
care
team
servic
receiv
assess
daili
bedsid
coach
educ
aid
review
made
patient
discharg
chart
evalu
manag
exacerb
point
techniqu
breath
control
point
sputum
clearanc
point
give
total
score
result
novemb
novemb
patient
assess
major
elderli
age
mean
total
score
increas
baselin
discharg
baselin
mean
score
lower
elderli
age
discharg
score
improv
elderli
age
hospit
readmiss
rate
within
day
respect
conclus
studi
show
bcbh
score
could
use
object
measur
patient
learn
patient
age
higher
score
lower
hospit
readmiss
rate
educ
elderli
patient
challeng
although
visual
aid
incorpor
patient
booklet
certain
level
literaci
necessari
engag
caregiv
patient
educ
may
help
reinforc
techniqu
learnt
although
studi
need
determin
minim
clinic
import
improv
bcbh
score
result
younger
group
suggest
score
would
necessari
demonstr
compet
background
aim
studi
chronic
obstruct
pulmonari
diseas
major
burden
mani
healthcar
system
worldwid
includ
hong
kong
hospit
copd
inpati
reach
fifth
lead
caus
death
hong
kong
monitor
assess
larg
patient
group
hot
debat
medic
field
year
rather
simpl
tool
came
late
copd
assess
test
cat
score
questionnair
aim
reflect
health
statu
patient
thu
hope
role
assist
patient
physician
quantifi
impact
copd
patient
health
statu
accord
cat
develop
steer
group
expert
believ
differ
chang
unit
suggest
clinic
signific
differ
health
statu
aim
studi
see
mean
applic
unit
chang
elderli
chines
copd
patient
method
copd
patient
come
medic
consult
request
cat
questionnair
literaci
among
patient
rather
low
unifi
protocol
rehabilit
nurs
read
question
get
score
patient
ask
nurs
medic
consult
ie
minut
later
without
prior
awar
result
interview
consecut
patient
patient
chang
score
equal
unit
analysi
found
signific
chang
correl
older
age
lower
educ
level
frequent
hospit
past
year
conclus
cat
score
may
applic
group
old
chines
copd
patient
low
educ
level
million
yet
undiagnos
therefor
urgent
need
find
undiagnos
patient
treat
earlier
copd
assess
test
cat
develop
simpl
patientcomplet
tool
assess
monitor
impact
copd
health
statu
easi
implement
routin
use
within
primari
care
hypothes
cat
may
util
casefind
patient
need
spirometri
diagnos
copd
primari
care
method
two
multicent
nonintervent
prospect
studi
studi
conduct
center
across
japan
subject
studi
age
year
older
smoke
histori
subject
studi
diagnos
copd
experienc
repeat
respiratori
tract
infect
subject
studi
routin
visit
cardiovascular
diseas
subject
complet
cat
prior
lung
function
test
handheld
spirometri
haicheck
investig
relationship
cat
score
airflow
limit
result
cat
score
avail
total
subject
studi
studi
male
age
year
mean
sd
airflow
limit
found
subject
studi
studi
cat
score
subject
airflow
limit
higher
subject
without
airflow
limit
studi
confid
interv
ci
vs
ci
studi
ci
vs
ci
studi
conclus
suggest
cat
potenti
identifi
subject
need
spirometri
diagnos
copd
particularli
histori
frequent
exacerb
comorbid
cardiovascular
diseas
background
aim
studi
combin
longact
muscarin
antagonist
lama
longact
laba
demonstr
superior
bronchodil
compar
lama
laba
monotherapi
patient
copd
indacaterol
oncedaili
inhal
ultralaba
shown
effect
moder
sever
copd
howev
efficaci
combin
lama
indacaterol
unclear
patient
sever
copd
aim
studi
estim
efficaci
combin
two
oncedaili
inhal
bronchodil
indacaterol
tiotropium
patient
sever
copd
method
ix
japanes
patient
sever
copd
accord
global
initi
chronic
obstruct
lung
diseas
criteria
enrol
patient
alreadi
administ
tiotropium
daili
receiv
indacaterol
addit
daili
concurr
efficaci
outcom
evalu
spirometri
data
health
statu
assess
copd
assess
test
cat
baselin
tiotropium
alon
week
tiotropium
indacaterol
result
week
tiotropium
plu
indacaterol
increas
comparison
tiotropium
alon
four
six
patient
although
one
patient
drop
week
improv
other
kept
increas
week
howev
statist
signific
differ
inspiratori
capac
cat
score
combin
therapi
show
subject
symptom
remark
improv
two
patient
signific
differ
three
get
wors
one
conclus
combin
therapi
indacaterol
tiotropium
increas
part
patient
sever
copd
although
seem
correl
degre
improv
cat
score
patient
felt
remark
efficaci
subject
symptom
combin
background
aim
studi
forc
expiratori
volum
second
chronic
obstruct
pulmonari
diseas
copd
known
annual
decreas
obvious
normal
subject
howev
airflow
limit
copd
partli
revers
sever
drug
copd
newli
develop
aim
studi
evalu
chang
pulmonari
function
copd
ad
medic
treatment
identifi
predictor
chang
pulmonari
function
method
studi
patient
visit
kumamoto
univers
hospit
gener
hospit
kumamoto
citi
less
diagnos
copd
treat
medic
respiratori
physician
year
clinic
background
pulmonari
function
test
lung
imag
studi
first
visit
treatment
latest
pulmonari
function
test
collect
retrospect
medic
record
signific
predictor
chang
first
latest
pulmonari
function
test
evalu
use
multipl
regress
analysi
result
first
visit
ml
predict
ml
increas
latest
visit
mlyear
signific
predictor
favor
cours
less
smoke
histori
higher
revers
inhal
short
act
inhal
agonist
saba
first
visit
use
long
act
inhal
agonist
laba
conclus
confirm
copd
patient
higher
revers
inhal
saba
less
smoke
histori
maintain
pulmonari
function
medic
therapi
global
initi
chronic
obstruct
lung
diseas
gold
propos
copd
assess
framework
focuss
symptom
exacerb
risk
studi
conduct
japanes
subject
moderatetosever
copd
mmrc
score
greater
assess
whether
gold
strategi
effect
medic
practic
real
world
set
japan
purpos
studi
assess
control
copd
use
symptom
exacerb
risk
treatment
strategi
base
gold
abstract
summar
methodolog
studi
advanc
public
result
method
studi
multicentr
randomis
doubleblind
doubledummi
parallel
group
trial
patient
recruit
randomis
receiv
treatment
either
salmeterolfluticason
propion
sfc
mcg
twice
daili
tiotropium
bromid
mcg
daili
copd
manag
patient
assess
interv
patient
remain
high
level
symptomat
impact
daili
health
life
measur
cat
score
experi
exacerb
option
discuss
doctor
patient
step
treatment
medic
ie
sfc
tiotropium
tripl
therapi
primari
endpoint
number
patient
abl
remain
randomis
therapi
patient
still
well
control
tripl
option
add
treatment
possibl
stepdown
tripl
base
lack
respons
also
incorpor
result
studi
help
physician
understand
tripl
therapi
effect
manag
symptom
exacerb
patient
moder
sever
copd
studi
also
clarifi
proport
type
patient
manag
singl
therapi
tripl
therapi
background
pulmonari
rehabilit
chronic
obstruct
pulmonari
diseas
copd
patient
intend
improv
lung
function
exercis
function
activ
daili
live
adl
produc
pulmonari
rehabilit
program
necessari
know
life
style
detail
howev
report
lifestyl
method
thirtynin
sever
copd
patient
year
old
particip
studi
divid
two
group
group
group
b
group
consist
patient
sever
copd
stage
iii
group
b
consist
patient
sever
copd
stage
iv
investig
lung
function
nourish
state
exercis
function
adl
level
life
style
perform
inform
consent
member
investig
result
lung
function
exercis
function
b
group
significantli
lower
group
adl
level
group
lower
especi
b
group
daili
role
home
seldom
particip
commun
activ
mani
variou
anxieti
daili
activ
social
particip
go
trip
conclus
improv
qol
sever
copd
patient
necessari
improv
basic
adl
also
daili
social
activ
background
aim
studi
airflow
limit
may
common
among
patient
need
thorac
surgeri
may
influenc
periop
statu
postop
outcom
object
studi
investig
preval
airflow
limit
among
patient
thorac
surgeri
hospit
analyz
impact
postop
complic
outcom
surgeri
method
retrospect
review
clinic
record
patient
underw
thorac
surgeri
juntendo
univers
hospit
patient
lack
data
pulmonari
function
surgeri
exclud
patient
classifi
two
group
group
airflow
limit
surgeri
group
b
without
airflow
limit
analyz
preval
comorbid
frequenc
postop
complic
result
patient
underw
thorac
surgeri
case
preoper
pulmonari
function
data
analyz
mean
age
year
old
male
current
exsmok
comorbidi
preval
group
includ
hypertens
diabet
mellitu
cardiovascular
diseas
copd
bronchial
asthma
neurolog
diseas
collagen
vascular
diseas
p
signific
differ
preval
note
hyperlipidemia
interstiti
lung
diseas
postop
complic
includ
respiratori
failur
requir
oxygen
supplement
atelectasi
delirium
reoper
arrhythmia
prolong
air
leakag
significantli
preval
group
p
period
postop
hospit
stay
show
signific
differ
group
b
conclus
patient
airflow
limit
comorbid
postop
complic
thorac
surgeri
without
airflow
limit
background
inflammatori
cell
mediat
may
lead
destruct
chang
airway
lung
hyperinfl
sever
chronic
obstruct
pulmonari
diseas
copd
aim
test
hypothesi
neutrophil
venou
blood
relationship
ratio
forc
expiratori
forc
inspiratori
volum
first
second
measur
hyperinfl
sever
copd
method
five
male
outpati
copd
age
forc
expiratori
volum
second
predict
exsmok
undergo
longterm
oxygen
therapi
includ
measur
obtain
four
time
ratio
circul
neutrophil
count
peripher
white
blood
cell
count
neutrophil
predict
creactiv
protein
crp
juli
juli
result
neutrophil
significantli
correl
rs
p
l
rs
p
predict
rs
p
crp
mgdl
significantli
correl
conclus
report
suggest
circul
chronic
increas
neutrophil
might
abl
progress
lung
hyperinfl
sever
copd
naoki
ijiri
yoshihiro
tochino
kazuhiro
yamada
naoko
yoshii
gakuya
tamagaki
fumihiro
nagayasu
kazuhiro
asai
hiroshi
kamoi
method
studi
patient
copd
hospit
august
juli
classifi
group
accord
compar
cat
score
clinic
indic
six
minut
walk
test
pulmonari
function
test
pft
group
mild
low
cat
score
versu
b
mild
high
cat
score
c
sever
low
cat
score
versu
sever
high
cat
score
ac
low
cat
group
versu
bd
high
cat
group
clinic
indic
includ
six
minut
walk
distanc
desatur
area
da
pft
includ
dlco
maxim
midexpiratori
flow
mmf
copd
patient
examin
year
old
male
classifi
gold
group
group
b
group
c
group
dlco
group
significantli
lower
group
c
dlco
mmf
group
bd
significantli
lower
group
ac
da
group
bd
higher
group
c
ac
respect
differ
clinic
indic
group
b
conclus
result
suggest
exercis
intoler
desatur
exert
small
airway
obstruct
might
correl
high
cat
score
copd
patient
low
pulmonari
function
katsuya
onishi
daisuk
yoshimoto
gerri
hagan
paul
w
jone
onisi
heart
clinic
mie
japan
medic
affair
respiratori
glaxosmithklin
kk
tokyo
japan
background
aim
studi
although
cardiovascular
diseas
chronic
obstruct
pulmonari
diseas
copd
share
common
risk
factor
copd
patient
frequent
comorbid
cardiovascular
diseas
preval
copd
outpati
cardiovascular
diseas
japan
unknown
method
multicent
nonintervent
prospect
studi
conduct
center
across
japan
investig
preval
airflow
limit
compat
copd
defin
handheld
spirometri
haicheck
outpati
routin
visit
cardiovascular
diseas
age
year
older
smoke
histori
subject
complet
copd
assess
test
cat
prior
handheld
spiromet
test
result
total
subject
particip
spirometri
data
subject
avail
subject
male
age
mean
sd
year
old
preval
airflow
limit
compat
copd
n
subject
n
diagnos
copd
subject
cat
score
preval
airflow
limit
higher
subject
score
sensit
specif
conclus
preval
airflow
limit
studi
indic
quarter
outpati
cardiovascular
diseas
copd
although
almost
undiagnos
suggest
import
look
routin
copd
cardiovascular
diseas
outpati
use
cat
cardiolog
clinic
patient
year
old
smoke
histori
may
simpl
way
assess
patient
need
spirometri
diagnos
copd
aim
studi
evalu
clinic
benefit
daili
longact
agonist
indacaterol
addon
therapi
stabl
copd
patient
muscarin
antagonist
tiotropium
treatment
method
japanes
patient
femal
mean
sever
stageii
copd
treat
tiotropium
month
copd
symptom
ad
indacaterol
daili
respiratori
function
io
cat
questionnair
usabl
breez
heller
assess
week
addon
therapi
result
three
question
cat
activ
breathless
confid
ic
improv
significantli
week
addon
therapi
three
question
cat
chest
tight
sleep
energi
fvc
io
ax
fre
signific
differ
subject
show
signific
improv
questionnair
survey
usabl
breez
heller
show
easi
use
conclus
result
suggest
respiratori
function
air
trap
symptom
qol
physic
activ
exercis
toler
improv
combin
differ
mechan
bronchodil
lama
block
receptor
laba
stimul
receptor
background
cat
eightitem
questionnair
design
assess
quantifi
impact
copd
symptom
health
statu
wide
use
mani
countri
nutrit
impair
import
system
manifest
associ
poor
prognosi
deterior
qualiti
life
howev
relationship
nutrit
statu
cat
score
unknown
aim
determin
relationship
cat
score
nutrit
statu
assess
mnasf
compar
abil
cat
predict
exacerb
mnasf
method
pulmonari
function
modifi
mrc
scale
mmrc
bodi
mass
index
bmi
evalu
stabl
patient
copd
mean
yr
mean
fev
cat
mnasf
also
complet
initi
assess
exacerb
record
prospect
one
year
result
mean
cat
score
low
medium
high
high
mean
mnasf
score
well
cat
score
significantli
correl
mmrc
fev
correl
bmi
mnasf
score
mnasf
score
correl
exacerb
frequenc
wherea
cat
score
associ
exacerb
frequenc
conclus
cat
appear
assess
health
statu
copd
independ
nutrit
statu
mnasf
well
cat
clinic
import
predict
copd
exacerb
background
aim
nutrit
state
import
determin
symptom
disabl
prognosi
chronic
obstruct
pulmonari
diseas
copd
anxieti
depress
major
comorbid
copd
mini
nutrit
mna
questionnair
simpl
valid
questionnair
wide
use
identifi
elderli
risk
malnutrit
mna
explor
compon
affect
malnutrit
examin
whether
impair
nutrit
statu
use
mna
associ
anxieti
depress
copd
method
total
clinic
stabl
copd
patient
mean
age
year
global
initi
chronic
obstruct
lung
diseas
stage
ii
iii
iv
male
previous
investig
associ
studi
malnutrit
assess
mna
decreas
exercis
intoler
present
at
includ
studi
pulmonari
function
exercis
intoler
walk
distanc
test
anxieti
depress
hospit
anxieti
depress
scale
had
nutrit
statu
mna
addit
bodi
composit
evalu
calcul
total
score
score
nutrit
statu
domain
mna
anthropometr
function
dietari
selfpercept
assess
result
depress
anxieti
score
had
significantli
correl
mna
total
score
high
score
indic
good
nutrit
statu
p
respect
rho
respect
depress
score
also
significantli
correl
mna
selfpercept
score
p
rho
conclus
malnutrit
assess
mna
associ
depress
anxieti
patient
copd
especi
depress
associ
selfpercept
affect
malnutrit
copd
treat
depress
may
improv
nutrit
statu
copd
patient
background
although
smoke
strongest
risk
factor
copd
develop
patient
histori
smoke
nonsmok
copd
present
anoth
characterist
risk
factor
compar
smoker
copd
method
domin
characterist
neversmok
copd
compar
eversmok
copd
use
data
korean
nation
health
nutrit
examin
survey
knhane
evalu
copd
defin
patient
known
asthma
patient
restrict
lung
function
exclud
neversmok
defin
subject
never
smoke
smoke
past
less
packyear
result
among
total
subject
enrol
period
perform
pulmonari
function
test
pft
subject
show
accept
pft
sinc
exclus
criteria
final
subject
evalu
proport
smoker
incid
copd
preval
copd
eversmok
much
higher
neversmok
vs
p
histori
tuberculosi
neversmok
ci
vs
eversmok
ci
presenc
bronchiectasi
neversmok
ci
vs
eversmok
ci
close
relat
exist
copd
neversmok
compar
eversmok
besid
risk
factor
age
educ
level
live
partner
famili
incom
also
signific
risk
factor
copd
group
conclus
nonsmok
known
asthma
present
pft
obstruct
pattern
histori
tuberculosi
presenc
bronchiectasi
consid
object
contrast
effect
ningpai
main
compon
eucalyptol
chronic
cigarett
smokeexpos
rat
explor
mechan
airway
mcc
function
method
model
establish
continu
expos
cigarett
smoke
week
ningpai
eucalyptol
interven
begin
smoke
expos
compar
intervent
treatment
differ
group
rat
gener
morpholog
airway
bacteri
load
airway
scaveng
activ
exogen
h
influenza
microstructur
chang
tem
abpa
stain
airway
mucin
product
express
result
compar
smoke
expos
group
patholog
structur
rel
improv
ningpai
intervent
group
though
obviou
structur
chang
still
exit
compar
normal
control
group
bacteri
load
reduc
rat
airway
ningpai
intervent
group
scaveng
activ
exogen
h
influenza
acceler
tem
result
show
airway
epitheli
cilia
structur
rel
intact
prompt
medic
intervent
cilia
play
protect
role
damag
cell
structur
organel
improv
obviou
effect
ningpai
mucou
secret
manifest
regul
acid
mucopolysaccharid
proport
secret
airway
epithelium
goblet
cell
affect
properti
mucu
reduc
airway
express
level
therapeut
effect
eucalyptol
intervent
group
similar
ningpai
intervent
group
signific
statist
differ
show
glycerol
drug
control
influenc
detect
index
conclus
ningpai
effect
reduc
airway
bacteri
load
rat
expos
cigarett
smoke
increas
bactiria
scaveng
activ
improv
airway
mucociliari
clearanc
function
effect
mainli
perform
protect
airway
epitheli
cilia
structur
regul
acid
mucopolysaccharid
ratio
mucin
level
secret
goblet
cell
key
word
ningpai
eucalyptol
copd
rat
expos
cigarett
smoke
mucociliari
clearanc
h
influenza
rational
although
textbook
tell
expiratori
airflow
limit
emphysema
occur
peripher
airway
wheez
gener
wheez
often
heard
without
stethoscop
realli
gener
peripheri
lung
recent
reveal
imag
expiratori
airflow
limit
emphysema
occur
intramediastin
airway
intrathorac
trachea
main
bronchi
right
lobar
bronchi
due
dynam
compress
enhanc
surround
overinfl
lung
membran
part
cartilag
highli
deform
perform
expiratori
airflow
simul
use
comput
fluid
dynam
cfd
investig
relationship
tracheal
shape
pressur
fluctuat
gener
airflow
method
finit
element
model
node
displac
accord
breath
motion
construct
cylindr
trachea
open
atmospher
posit
subglott
caviti
posterior
wall
trachea
deform
mimick
imag
airflow
expir
comput
solv
numer
incompress
navierstok
equat
move
boundari
condit
solver
acusolv
altair
engineerng
usa
time
step
assign
sec
dynam
le
larg
eddi
simul
model
appli
turbul
result
slight
pressur
fluctuat
beyond
hz
caus
turbul
observ
airflow
simul
nondeform
trachea
howev
deform
trachea
period
vortex
releas
hz
end
protrus
membran
part
found
rang
flow
rate
ls
ls
airflow
simul
peripher
airway
perform
use
model
scale
appar
pressur
fluctuat
observ
within
airway
conclus
present
simul
studi
strongli
suggest
wheez
gener
peripher
intramediastin
airway
masuo
nakamura
hiroo
wada
kojiro
honda
keitaro
nakamoto
haruyuki
ishii
shinichi
inou
fumi
kobayashi
hiroshi
kamma
hajim
takizawa
hajim
goto
depart
respiratori
medicin
kyorin
univers
school
medicin
tokyo
japan
depart
infecti
diseas
kyorin
univers
school
medicin
tokyo
japan
background
even
shortterm
exposur
cigarett
smoke
caus
airway
inflammatori
respons
similar
characterist
neutrophil
inflamm
seen
copd
steroidresist
asthma
proinflammatori
cytokin
provok
neutrophil
inflamm
role
airway
inflamm
induc
cigarett
smoke
investig
use
murin
model
method
defici
mice
wildtyp
mice
expos
tobacco
smoke
day
use
tobacco
smoke
exposur
system
mice
anaesthet
sacrif
bronchoalveolar
lavag
bal
fluid
collect
prior
obtain
lung
tissu
cellular
respons
bal
fluid
determin
protein
level
proinflammatori
protein
bal
fluid
measur
use
enzymelink
immunosorb
assay
well
mrna
level
lung
tissu
use
quantit
rtpcr
section
mu
paraffinembed
lung
tissu
stain
hematoxylin
eosin
result
number
neutrophil
bal
fluid
reach
maximum
day
decreas
number
neutrophil
bal
fluid
mrna
level
kc
gmcsf
lung
tissu
lower
defici
mice
wildtyp
mice
p
signific
differ
mrna
level
tumor
necrosi
factoralpha
detect
result
indic
play
role
neutrophil
inflamm
induc
cigarett
smoke
probabl
via
kc
gmcsf
conclus
use
murin
model
demonstr
play
role
induct
neutorphil
inflamm
evok
cigarett
smoke
exposur
amira
p
tarigan
tamsil
syafiuddin
faisal
yunu
suradi
yahwardiah
siregar
syafruddin
pulmonolog
depart
univers
north
sumatera
medan
indonesia
depart
pulmonolog
univers
indonesia
depok
indonesia
depart
pulmonolog
univers
surakarta
surakarta
indonesia
eijkman
instituut
jakarta
indonesia
background
chronic
obstruct
pulmonari
diseas
copd
highest
caus
mortal
morbid
world
data
show
copd
case
caus
smoke
chronic
heavi
smoker
develop
copd
indic
differ
suscept
damag
smoke
may
link
genet
factor
purpos
studi
analyz
occurr
chronic
obstruct
pulmonari
diseas
role
path
tnfalpha
gene
polymorph
ltalpha
gene
polymorph
smoker
method
casecontrol
studi
compar
genet
group
peopl
copd
case
group
peopl
suffer
copd
control
smoke
histori
implement
studi
start
background
aim
studi
efferocytosi
homeostat
phagocytosi
apoptot
cell
prevent
releas
toxic
intracellular
content
subsequ
tissu
damag
impair
efferocytosi
report
alveolar
macrophag
am
patient
chronic
obstruct
pulmonari
diseas
copd
common
diseas
caus
smoke
copd
histon
deacetylas
hdac
activ
reduc
am
investig
whether
reduct
hdac
activ
associ
impair
efferocytosi
method
murin
am
collect
bronchoalveolar
lavag
pretreat
am
cigarett
smoke
extract
cse
trichostatin
tsa
abil
efferocytosi
apoptot
human
polymorphonuclear
leucocyt
assess
rhoa
rac
activ
evalu
enzymelink
immunosorb
assay
colorimetr
approach
surfac
express
am
analyz
flow
cytometri
result
cse
tsa
reduc
hdac
activ
suppress
efferocytosi
tsa
inhibit
activ
rac
key
mediat
efferocytosi
tsainduc
impair
restor
treatment
am
aminophyllin
potent
activ
hdac
elucid
underli
mechan
explor
role
tsainduc
impair
efferocytosi
tetraspan
transmembran
protein
facilit
uptak
sever
pathogen
materi
tsa
profoundli
downregul
express
am
express
partli
downregul
rac
inhibitor
final
pretreat
mab
inhibit
efferocytosi
attribut
reduc
bind
am
apoptot
cell
conclus
cigarett
smoke
impair
efferocytosi
via
inhibit
hdac
pathway
aminophyllinetheophyllin
effect
restor
impair
efferocytosi
might
benefit
treatment
patient
copd
background
aim
studi
obstruct
sleep
apnea
osa
occur
lower
bodi
mass
index
bmi
asian
popul
compar
european
descent
well
known
howev
characterist
asian
patient
obes
hypoventil
syndrom
oh
yet
establish
aim
reveal
preval
oh
characterist
individu
oh
japan
clarifi
factor
relat
hypercapnia
oh
patient
method
studi
consecut
patient
hospit
examin
osa
octob
septemb
multipl
regress
analysi
perform
identifi
variabl
independ
associ
arteri
carbon
dioxid
pressur
obes
osa
bmi
kgm
apneahypopnea
index
ahi
result
preval
oh
osa
obes
osa
respect
addit
increas
ahi
patient
oh
lower
expiratori
residu
volum
even
adjust
waist
circumfer
multipl
regress
analysi
reveal
independ
age
bmi
arteri
oxygen
pressur
contribut
rate
r
oxygen
desatur
index
odi
r
carbon
monoxid
diffus
capacityalveolar
volum
dlcova
r
hemoglobin
concentr
r
well
waist
circumfer
r
independ
associ
longterm
continu
posit
airway
pressur
cpap
treatment
month
level
patient
oh
improv
conclus
preval
oh
obes
osa
japan
approxim
west
even
less
obes
bmi
kgm
factor
contribut
elev
dlcova
hemoglobin
concentr
cardiac
output
etc
consid
manag
oh
longterm
cpap
treatment
effect
attain
mmhg
oh
patient
background
object
obstruct
sleep
apnea
osa
affect
daili
function
cognit
perform
continu
posit
airway
pressur
cpap
treatment
may
improv
symptom
qualiti
life
differ
extent
studi
investig
relationship
cpap
adher
daytim
sleepi
qualiti
life
emot
adherencerel
cognit
subject
osa
year
cpap
use
method
subject
newli
diagnos
osa
cpap
therapi
navi
recruit
epworth
sleepi
scale
ess
calgari
sleep
apnea
qualiti
life
index
saqli
depress
anxieti
stress
scale
selfefficaci
measur
sleep
apnea
questionnair
semsa
assess
year
cpap
treatment
cpap
usag
data
download
complet
studi
regress
analys
perform
assess
doserespons
relationship
cpap
adher
daili
perform
subject
osa
result
subject
osa
indic
cpap
treatment
recruit
averag
age
year
bmi
kgm
ahi
eventshour
one
year
cpap
treatment
averag
cpap
daili
usag
hour
per
day
usag
index
percentag
day
use
cpap
least
hour
per
day
cpap
usag
index
found
doserespons
effect
improv
conclus
cpap
treatment
cpap
adher
shown
signific
doserel
improv
function
cognit
perform
subject
osa
background
aim
studi
patient
sleep
apnea
syndrom
sa
patient
diabet
mellitu
dm
increas
japan
sought
assess
recent
preval
dm
glucos
toler
profil
patient
sa
method
data
patient
sa
apneahypopnea
index
eventshr
male
femal
mean
age
mean
bodi
mass
index
review
gm
oral
glucos
toler
test
ogtt
perform
sa
patient
diagnos
dm
homeostasi
model
assess
insulin
resist
index
homar
insulinogen
index
ii
calcul
adopt
diagnost
criteria
japan
diabet
societi
american
diabet
associ
result
sa
patient
alreadi
diagnos
dm
sa
patient
diagnos
diabet
time
current
ogtt
sa
patient
diagnos
impair
glucos
toler
andor
impair
fast
glucos
sa
patient
normal
ogtt
found
onehour
serum
glucos
level
higher
mgdl
abnorm
homar
abnorm
ii
found
subject
respect
conclus
sa
patient
dm
sa
patient
intact
glucos
toler
background
object
sleep
disturb
patient
chronic
obstruct
pulmonari
diseas
copd
poor
sleep
qualiti
nocturn
oxygen
desatur
presenc
coexist
obstruct
sleep
apnea
osa
call
overlap
syndrom
describ
sever
report
howev
major
previou
report
sleep
assess
polysomnographi
subject
report
first
populationbas
studi
assess
sleep
qualiti
hygien
copd
patient
use
actigraphi
type
portabl
monitor
home
environ
studi
aim
determin
preval
copd
patient
patient
overlap
syndrom
urban
asian
male
subject
actigraphi
type
portabl
monitor
home
method
crosssect
epidemiolog
health
survey
male
employe
age
bodi
mass
index
kgm
mean
sd
done
sleep
qualiti
measur
epworth
sleepi
scale
ess
pittsburgh
sleep
qualiti
index
psqi
respiratori
disturb
index
rdi
indic
osa
result
nineteen
subject
copd
osa
eleven
overlap
syndrom
sleep
durat
ess
psqi
score
significantli
differ
copd
patient
normal
control
subject
howev
copd
patient
significantli
longer
sleep
latenc
p
lower
sleep
effici
p
higher
sleep
fragment
index
p
averag
activ
p
sleep
control
subject
also
significantli
higher
rdi
sever
desatur
sleep
control
subject
p
differ
remain
adjust
age
bmi
disappear
follow
adjust
rdi
conclus
populationbas
data
collect
actigraphi
type
portabl
monitor
home
environ
even
patient
mildtomoder
copd
nocturn
desatur
osarel
impair
sleep
qualiti
although
ess
psqi
reveal
signific
symptom
naoki
okamoto
tsuneto
akashiba
akihito
uematsu
kenichi
nagaoka
koumei
igei
yu
kohzu
natsuko
kiyofuzi
kazuhito
katsura
syu
hashimoto
depart
respiratori
medicin
nihon
univers
scholl
medicin
depart
sleep
medicin
nihon
univers
school
medicin
japan
background
aim
nasal
cpap
ncpap
firstlin
treatment
patient
osa
although
ncpap
complet
abolish
upper
airway
occlus
apnea
sleep
substanti
high
pressur
affect
pulmonari
system
patient
may
harm
longterm
durat
howev
longterm
effect
ncpap
pulmonari
function
arteri
blood
gase
still
unclear
therefor
investig
chang
pulmonari
function
ncpap
treatment
longterm
durat
patient
osa
method
seventyf
male
patient
osa
underw
ncpap
therapi
year
includ
studi
pulmonari
function
test
blood
ga
analysi
perform
year
treatment
pulmonari
function
test
consist
spirometri
pulmonari
volum
diffus
capac
flowvolum
curv
subject
divid
two
group
high
pressur
group
ncpap
low
pressur
group
ncpap
chang
pulmonari
function
compar
two
group
result
signific
chang
pulmonari
function
vc
tlc
frc
rv
dlco
arteri
blood
gase
ph
year
year
ncpap
treatment
signific
chang
pulmonari
function
blood
gase
low
pressur
group
high
pressur
group
conclus
longterm
ncpap
treatment
affect
pulmonari
function
arteri
blood
gase
patient
osa
even
patient
high
pressur
ncpap
safe
treatment
patient
osa
longterm
durat
background
aim
studi
obstruct
sleep
apnea
syndrom
osa
patient
concomit
chronic
obstruct
pulmonari
diseas
copd
term
overlap
syndrom
os
wors
prognosi
patient
one
diseas
aim
studi
investig
alter
system
inflammatori
mediat
patient
osa
copd
os
explor
relat
serum
level
inflammatori
mediat
polysomnographi
psg
variabl
pulmonari
function
variabl
score
health
statu
questionnair
os
patient
method
prospect
observ
studi
implement
march
may
design
three
group
follow
copd
group
includ
patient
copd
alon
osa
group
includ
patient
moderatetosever
osa
alon
os
group
includ
patient
osa
copd
venou
blood
sampl
obtain
morn
psg
result
total
patient
osa
patient
copd
patient
os
patient
enrol
highsensit
creactiv
protein
hscrp
elev
os
patient
compar
osa
patient
copd
patient
p
p
respect
tumor
necrosi
elev
os
patient
compar
osa
patient
hscrp
similar
osa
patient
copd
patient
similar
among
three
group
os
patient
neg
correl
first
second
forc
expiratori
volumeforc
vital
capac
total
lung
capac
tlc
respect
r
p
r
p
respect
test
inflammatori
mediat
show
correl
psg
variabl
apneahypopnea
index
lowest
mean
score
health
statu
questionnair
copd
assess
test
modifi
medic
research
council
dyspnea
scale
conclus
compar
osa
patient
copd
patient
os
patient
significantli
higher
system
inflammatori
mediat
neg
correl
tlc
introduct
demonstr
accept
rate
continu
posit
airway
pressur
cpap
treatment
patient
diagnos
obstruct
sleep
apnoea
osa
significantli
higher
addit
individu
consult
usual
structur
educ
talk
talk
alon
object
specialist
nurseclin
followup
would
offer
patient
agre
receiv
cpap
therapi
use
complianc
cpap
treatment
would
monitor
evalu
methodolog
retrospect
studi
evalu
cpap
complianc
rate
cpap
therapi
medic
nurs
consult
note
patient
schedul
clinic
onemonth
initi
cpap
therapi
respiratori
nurs
would
deal
problem
associ
machin
accessori
interfac
data
read
includ
averag
usag
hour
mask
leakag
residu
apnoeahypnoeaindex
record
advic
frequent
offer
enhanc
comfort
adher
overnight
oximetri
report
would
review
phone
followup
would
offer
necessari
result
patient
attend
educ
talk
individu
consult
although
patient
initi
agre
cpap
therapi
patient
attend
nurs
clinic
rest
attend
physician
clinic
patient
report
problem
relat
cpap
followup
eventu
solv
accept
complianc
defin
kribb
et
al
cpap
use
least
hday
least
night
per
week
cpap
complianc
rate
significantli
higher
patient
attend
specialist
nurseclin
physician
followup
p
conclus
specialti
nurs
clinic
cpap
therapi
improv
patient
complianc
cpap
therapi
background
panic
disord
pd
complex
condit
complic
numer
induc
includ
hypercapnia
hypoxia
sodium
lactat
caffein
cholecystokinin
seem
unlik
specif
suffoc
receptor
induc
brain
novel
hypothesi
caus
panic
disord
submit
without
brain
method
pulmonari
neuroepitheli
bodi
neb
situat
bifurc
point
small
bronchi
act
storag
cell
sensor
suffoc
suppos
pd
might
repres
hyperfunct
inflammatori
neb
bradykinin
bk
augment
airway
hyperrespons
divers
indcer
might
caus
cell
releas
along
peptid
panneuroendcrin
marker
dencecor
secretori
granul
reveal
bk
could
cross
bloodbrain
barrier
bbb
result
releas
cell
along
bk
cross
bbb
releas
axon
termin
serotonerg
neuron
brain
inhibit
autoreceptor
inhibit
axon
termin
caus
suppress
periaqueduct
gray
matter
inhibit
flight
reaction
impend
danger
pain
asphyxia
short
serotonerg
situat
might
bring
pd
conclus
accord
theori
type
induc
pd
patient
expos
unimport
long
stimul
neb
effect
bk
pd
would
revalu
lung
diseas
directli
revers
affect
brain
background
aim
studi
previou
studi
shown
high
preval
obstruct
sleep
apnea
osa
among
patient
alzheim
diseas
ad
howev
poorli
assess
whether
chronic
intermitt
hypoxia
cih
characterist
osa
affect
pathophysiolog
ad
aim
investig
direct
effect
intermitt
hypoxia
ih
pathophysiolog
ad
vivo
vitro
method
vivo
male
tripl
transgen
ad
mice
expos
either
cih
normoxia
everi
min
hday
week
amyloidbeta
abeta
profil
cognit
brain
function
brain
patholog
evalu
vitro
human
neuroblastoma
cell
stabli
express
wildtyp
amyloid
beta
precursor
protein
expos
either
ih
cycl
minut
follow
minut
normoxia
abeta
profil
condit
medium
analyz
result
cih
significantli
increas
level
brain
mice
without
increas
hypoxiainduc
factor
alpha
subunit
express
furthermor
cih
significantli
increas
intracellular
abeta
brain
cortex
signific
chang
cognit
function
ih
significantli
increas
level
medium
cell
without
increas
express
cih
directli
select
increas
level
ad
model
conclus
result
suggest
osa
would
aggrav
ad
earli
detect
intervent
osa
ad
may
help
allevi
progress
diseas
background
aim
noninvas
mechan
ventil
modal
give
ventilatori
support
without
bypass
upper
airway
use
devic
tracheal
tube
laryng
mask
tracheostomi
paper
aim
describ
practic
institut
nimv
ust
hospit
review
outcom
well
appropri
use
adher
guidelin
institut
method
review
chart
inpati
place
noninvas
mechan
ventil
juli
march
emphasi
follow
variabl
demograph
clinic
profil
clinic
cours
outcom
patient
pediatr
age
group
patient
place
cpap
manag
obstruct
sleep
apnea
exclud
result
total
patient
includ
studi
patient
fail
nimv
intub
eventu
discharg
intub
subsequ
die
die
nimv
common
indic
institut
nimv
pneumonia
success
rate
success
highest
among
patient
place
nimv
cardiac
caus
asthma
metabol
acidosi
conclus
failur
rate
nimv
institut
high
compar
previou
studi
even
exclud
patient
place
nimv
advanc
direct
mani
fail
nimv
die
therefor
import
patient
select
emphas
asid
patient
select
standard
care
taken
consider
impact
outcom
investig
futur
studi
antiar
antibodi
detect
patient
patient
patient
patient
antiej
patient
antik
patient
five
patient
antiarsantibodiesposit
group
show
erythema
suggest
myositi
mechan
hand
periungu
erythema
nail
fold
bleed
hand
patient
antiarsantibodiesneg
group
show
erythema
suggest
myositi
radiolog
find
highresolut
ct
antiarsantibodiesposit
group
show
significantli
higher
rate
cystic
format
antiarsantibodiesneg
group
show
significantli
higher
rate
consolid
thicken
bronchovascular
bundl
antiarsantibodiesposit
group
significantli
shorter
durat
diagnosi
begin
treatment
neg
group
although
signific
differ
resist
treatment
surviv
group
also
signific
differ
bronchoalveolar
lavag
fluid
result
pulmonari
function
test
conclus
detect
antiar
antibodi
ss
patient
investig
suggest
antiar
antibodi
modifi
clinic
featur
ss
therefor
measur
antiar
antibodi
patient
diagnos
ss
masaru
ando
eishi
miyazaki
akihiro
goto
taiki
masuda
mari
yamasu
takehiro
hashimoto
kohsuk
jo
yutaka
mukai
hiroki
yoshikawa
toshihiro
ishiii
ryuichi
takenaka
satoshi
toba
kazuhiko
hashinaga
hisako
kushima
kenji
umeki
shinichi
nureki
issei
tokimatsu
kazufumi
hiramatsu
junichi
kadota
depart
respiratori
medicin
infecti
diseas
oita
univers
faculti
medicin
oita
japan
center
commun
medicin
oita
univers
faculti
medicin
oita
japan
background
hypothes
increas
pulmonari
vascular
permeabl
may
play
role
pathogenesi
acut
exacerb
idiopath
interstiti
pneumonia
aeiip
promot
endotheli
activ
destabil
inflamm
examin
whether
express
would
associ
pathogenesi
aeiip
method
twentythre
patient
aeiip
patient
acut
lung
injuryacut
respiratori
distress
syndrom
aliard
patient
idiopath
pulmonari
fibrosi
ipf
healthi
volunt
hv
enrol
serum
level
measur
enzymelink
immunosolb
assay
result
serum
level
patient
aeiip
aliard
higher
ipf
hv
balf
level
also
higher
ipf
posit
correl
serum
level
crp
patient
aeiip
wherea
signific
posit
correl
found
serum
level
crp
sofa
score
patient
aliard
although
baselin
level
relat
surviv
level
significantli
declin
treatment
survivor
nonsurvivor
conclus
increas
pulmonari
vascular
permeabl
inflamm
due
may
play
role
pathogenesi
aeiip
background
aim
studi
clinic
cours
interstiti
pneumonia
often
progress
poor
prognosi
howev
group
patient
rel
stabl
clinic
cours
clinic
characterist
patient
interstiti
pneumonia
whose
respiratori
function
monitor
ten
year
retrospect
examin
method
nineteen
patient
admit
hospit
enrol
studi
clinic
background
age
sex
underli
diseas
prognosi
examin
respiratori
function
paramet
first
visit
annual
chang
also
examin
result
patient
consist
male
femal
year
old
followup
period
year
eleven
patient
collagen
vascular
diseas
among
patient
ra
idiopath
nonspecif
interstiti
pneumonia
found
patient
patient
idiopath
pulmonari
fibrosi
ipf
one
patient
idiopath
pulmonari
upper
lobe
fibrosi
one
combin
pulmonari
fibrosi
emphysema
cpfe
includ
studi
group
annual
declin
fvc
entir
followup
period
patient
ml
significantli
differ
normal
popul
conclus
patient
interstiti
pneumonia
surviv
year
stabl
ventilatori
function
patient
ipf
surviv
year
except
patient
cpfe
background
alveolar
epitheli
cell
apoptosi
involv
pathogenesi
lung
injuri
pulmonari
fibrosi
hand
epitheli
mesenchym
transit
emt
alveolar
epitheli
cell
induc
tgfbeta
report
play
promot
role
develop
lung
fibrosi
bax
proapoptot
member
famili
protein
play
central
role
mitochondriadepend
apoptosi
report
bax
express
increas
pulmonari
alveolar
epitheli
cell
patient
idiopath
pulmonari
fibrosi
ipf
howev
relat
bax
emt
still
remain
unknown
aim
purpos
studi
investig
whether
control
bax
activ
reduc
apoptosi
emt
alveolar
epitheli
cell
vitro
method
murin
pulmonari
alveolar
epitheli
cell
cell
human
pulmonari
alveolar
epitheli
cell
cell
stimul
bleomycin
blm
induct
apoptosi
emt
cell
pretreat
bax
inhibit
peptid
ad
blm
design
prevent
transloc
bax
mitochondria
bind
ntermin
bax
cytosol
apoptosi
assay
flow
cytometri
emt
analyz
western
blot
immunostain
result
cell
cell
underw
apoptot
chang
hour
stimul
blm
pretreat
decreas
apoptot
chang
significantli
cell
cell
underw
emt
chang
hour
stimul
blm
pretreat
decreas
emt
chang
significantli
conclus
control
bax
activ
antiapoptot
effect
antiemt
effect
lung
epitheli
cell
